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SUMMARY 
 
Viral respiratory infection exacerbates asthma symptoms in almost all patients with 
allergic asthma. Asthma symptoms in viral associated asthma exacerbation are often 
severe and require urgent care as well as hospitalisation. Corticosteroids are the 
mainstay treatment for asthma. However, they are less effective in treating virus 
associated asthma exacerbation. The main aim of the thesis is to determine the role of 
virus infection in airway allergic inflammation and then define the effects of 
corticosteroids in virus associated exacerbations of airway allergic inflammation.   
Mice sensitised and challenged with ovalbumin demonstrated most of the main 
features of asthma including lung cellular inflammation with eosinophilia, early phase 
asthmatic responses (EAR), late phase asthmatic responses (LAR), and airway 
hyperresponsiveness (AHR) to methacholine provocations. Treatment with either 
systemic (dexamethasone: DEX) or inhaled (fluticasone propionate: FP) corticosteroids 
in the murine ovalbumin allergic airways inflammation model attenuated inflammatory 
cells influx and eosinophilia, LAR, and the AHR. 
Influenza A (H1N1/PR8) is the most infective to mice compared to human 
parainfluenza virus type 3 (HPIV3), and a synthetic dsRNA, poly (I:C). Influenza 
infection in mice caused a significant increase of inflammatory cell influx in the airways 
with marked neutrophilia, and AHR. Ovalbumin challenge in the acute course of 
influenza infection on a murine model of allergic airways inflammation exacerbated the 
inflammatory cells influx, LAR, and AHR. Treatment with either DEX or FP attenuated 
the airway cellular inflammation, LAR, but not the AHR. Mice only infected with 
influenza were resistant to the corticosteroids (DEX and FP) treatment.  DEX but not 
FP showed antiviral activity against HPIV3 and influenza A in vitro.  
These data suggest that influenza infection in a murine model of allergic airways 
inflammation exacerbates the inflammation and alters the sensitivity toward 
corticosteroids. It is also suggested that some elements in the influenza associated 
exacerbation of murine model of allergic airways inflammation are refractory or not 
regulated by corticosteroid treatment.  
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I. RESPIRATORY VIRAL INFECTIONS 
Respiratory tract infections which are predominantly viral, are responsible for the 
majority of acute illnesses worldwide and have been established as leading causes of 
morbidity and mortality particularly at the extremes of age and in high-risk individuals. It  
is  estimated, about  5-6%  of  all  deaths and  about  60%  of respiratory disease 
related deaths are caused by respiratory viruses (Benson and Marano, 1998). 
Various respiratory viruses are known to cause acute respiratory infections in humans, 
including the common cold, bronchiolitis, and pneumonia (Tregoning and Schwarze, 
2010). The major known pathogens are respiratory syncytial virus (RSV), human 
rhinovirus (RV), human metapneumovirus (HMPV), human parainfluenza virus, 
enterovirus, influenza viruses, adenoviruses, and human bocavirus   (Fabbiani et al., 
2009). Some of the mentioned viruses produce local infection which is primarily 
restricted to the respiratory tract. However, adenovirus, coxcackie, and echoviruses 
have been identified to cause more serious respiratory and systemic disease (Welliver 
and Ogra, 1988). 
Respiratory syncytial virus, human parainfluenza virus, adenovirus, and influenza 
virus are known as the most common causes of serious lower respiratory tract 
disease in infants and children. Epidemiological studies suggest that most children are 
infected at least once with human parainfluenza virus early in life, and re-infections 
occur throughout life (Henrickson, 2003). This thesis will evaluate the nature of 
infection of human parainfluenza virus type 3 (HPIV3) and influenza A virus 
(H1N1/PR8) in vitro and in vivo (in mouse).  The nature of those virus infections on 
their susceptible cells and the possible antiviral effects of corticosteroids are presented 
in chapter 3. Chapter 4 will mainly evaluate the nature of infection of some infective 
agent candidates in mice which will then be utilised to generate exacerbation of allergic 
inflammation, in subsequent studies.  
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I.1. ANTIVIRAL IMMUNE RESPONSES 
A typical antiviral immune response of the host involves a combination of nonspecific 
(innate) and specific (adaptive) immunity.  
Innate Immunity or the nonspecific type of immunity include: phagocytes, natural killer 
(NK) cells and components of body fluids such as enzymes and complements  which 
are capable of neutralizing viral infections independently, or in combination with 
antibodies (Message and Johnston, 2001). The phagocytosis action of 
macrophages which engulf and destroy virus are triggered by pattern recognition 
receptors (PRRs) on the surface of the phagocyte and are activated by pathogen-
associated molecular patterns (PAMPs) on the surface of the virus. 
Macrophages might also play a significant role in phagocytosis of virions or debris from 
virus-infected cells (Crowe and Williams, 2003).  
Nonspecific immune mechanisms are important for early defence against the virus 
during the early stages of infection. When viruses infect the respiratory tract, 
multiplication will peak on the second day of infection when type I interferons which are 
released by the infected cells, are first detected.  The interferons reach maximum 
levels at day 3 and are undetectable by day 8. Interferons then activate NK cells, which 
destroy viral infected cells and release cytokines, including Type II interferon 
(Interferon-γ) which activates additional inflammatory cells in the airway. NK cells are 
first detected at day 3 and then peak at day 4 (Message and Johnston, 2001).  
The second type of immunity is adaptive immunity. The cells of specific immunity are 
lymphocytes, especially B and T lymphocytes. Antigens are processed and presented 
by dendritic cells to naive T-cells in the lymph node. Virus will be presented by both 
MHC class I and class II. MHC class I activates CD8+ T-cells to produce IFN-γ, which 
skews the differentiation of CD4+ T-cells into Th1 phenotype. The activated T-cells 
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may then stimulate B-cells to produce specific antibodies which will aid virus 
eradication (Message and Johnston, 2001; Openshaw and Tregoning, 2005). 
During the first few days of infection, dendritic cells process viral antigens locally in 
regional lymph nodes and then present them to T-cells. T-cell recruitment depends on 
the expression of adhesion molecules on the vascular endothelium at the site of 
inflammation and on the production of chemokines. CD4+ and CD8+ T-cells are 
detected on day 4 and day 6. CD8+cytotoxic T-cell responses peak on day 7 and are 
then undetectable by day 14, although memory CD4+ and CD8+ responses may 
remain a lifetime (Message and Johnston, 2001).   
B Cells are responsible for the production of antibodies. Mucosal Ig (Immunoglobulin) A 
– IgA is detected at day 3, becoming undetectable after 3 to 6 months, serum IgM is 
detected at day 5 to 6 and IgG is detected at day 7 to 8; these antibodies then increase 
in quantity and activity for 2 to 3 weeks. Serum IgG may remain detectable for life. 
Within 7 days after infection, the infectious virus is eradicated because the activity of 
specific immune system namely CD8+ T-cells and Immunoglobulin (Ig) (Message and 
Johnston, 2001).  
Figure 1.1. Inflammatory cells and mediators involve in viral respiratory infection immune 
response. Infection of the epithelial cells triggers the release of early inflammatory mediators 
which leads to the recruitment of inflammatory cells at the site of infection (Openshaw and 
Tregoning, 2005). 
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In the case of re-infection, adaptive immunity is important.  When the same serotype of 
virus re-infects, B- and T-cell- will be mobilised even faster. The level of T-cells and NK 
cells peak earlier on day 3–4. Antibodies, which still exist in the circulation, neutralize 
the virus. Viral replication will be slowed down or stopped by this mechanism. As a 
consequence, in secondary infection, fewer cells are infected, allowing nonspecific 
immunity to be less active (Crowe and Williams, 2003). 
 
Figure 1.2. Acquired immune response by production of IgM and IgG is directed against 
respiratory viral infection. The concentration of serum immunoglobulin varies depending on 
whether it is primary or secondary viral infection (Openshaw and Tregoning, 2005). 
II. ALLERGIC INFLAMMATION OF THE AIRWAYS 
Allergy is an inappropriate susceptibility of some individuals to certain substances, 
usually environmental proteins (antigens), which lead to the development of signs and 
symptoms of reactivity or hyperreactivity. The cornerstone of an allergic response is the 
production of allergen specific immunoglobulin E (IgE) and the response of the 
developed IgE to the future exposure of naturally harmless substances. The production 
and exaggerated response of IgE toward allergen involve activation and interactions of 
a number of leukocytes particularly T- cells populations (Ishmael, 2011). 
In allergic individuals, high levels of allergen activated T-cells are present in the 
peripheral blood circulation. These CD4+ T cells produce abnormal levels of Th2 
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specific cytokines; IL-4, IL-5, IL-9, and IL-13, which contributes to the clinical features 
of allergic inflammation pathophisiology. Manifestation of this cascade is allergic 
disorders; one of them is allergic (atopic) asthma (Galli et al., 2008).  
II.1.  ASTHMA: DEFINITION AND PREVALENCE 
Asthma, as defined by The Global Strategy for Asthma Management and Prevention 
Report (Report, 1995) is "a chronic inflammatory disease of the airways in which many 
cell types play a role, in particular mast cells, eosinophils and T lymphocytes. In 
susceptible individuals the inflammation causes recurrent episodes of wheezing, 
breathlessness, chest tightness and cough particularly at night and/or early morning. 
These symptoms are usually associated with widespread but variable airflow 
obstruction that is at least partly reversible either spontaneously or with treatment. The 
inflammation also causes an associated increase in airway responsiveness to a variety 
of stimuli. Reversibility of airflow limitation may be incomplete in some patients with 
asthma" 
Asthma is a serious worldwide problem affecting approximately 300 million people of all 
ages (GINA, 2012). There is an increasing trend of asthma prevalence, especially in 
children; in the UK alone around 20–33% of children have asthma. The financial impact 
of this condition is significant in terms of un-productivity at work or school, general 
practice consultations, hospital admissions and mortality.  
As a multi-factorial disorder, asthma expresses different phenotypes but shares similar 
symptoms: difficulties in breathing and airways hyperresponsiveness with underlying 
cascade of inflammation. At the moment, asthma has been classified based on the 
objective phenotypes (Wenzel, 2006)  according to different observable components of 
asthmatics such as clinical features, immunological mechanism, and response to 
treatment (Lotvall et al., 2011).  
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One categorisation which receives a particular interest is atopic and non-atopic 
asthma. This classification, in convention, is based on the response to common 
allergen and supported by the presence of allergen specific IgE. Atopic asthma usually 
begins before the age of 6 and is associated with atopy with a higher level of serum 
total IgE concentration compared to normal individuals which persists into adulthood. 
While the non-atopic or instrinsic variant of asthma shows normal serum total IgE 
concentration with no evidence of specific IgE antibody towards a certain allergen. Non 
atopic asthma usually begins later in life with more severe clinical consequence 
compared to the atopic asthma. Non atopic asthma comprised only a third of total 
asthmatics (Humbert et al., 1999). 
Atopic asthmatics express significantly increased number and activity of eosinophils 
compared to non-atopic (Amin et al., 2000). While in the non atopic airways, neutrophil 
infiltration seems to be more elevated, even though neutrophils tend to be elevated in 
all type of more severe asthmatics. The level of IL-4 and IL-5 are also significantly 
higher in atopic asthmatics, whereas in non-atopic asthmatics, IL-8 expression is 
higher (van Aalderen, 2012). 
II.2. PATHOGENESIS OF ASTHMA 
II.2.1. ALLERGEN SENSITISATION 
The underlying features of asthma are closely associated with interaction between 
genes and the environment, between genetically susceptible individuals and an 
exaggerated immune response to environmental allergens. Allergen sensitisation is a 
central element in allergic asthma. In allergic sensitisation, the airway is capable of 
recognising usual allergens to develop Th2 cytokines responses, which also involves a 
cascade of inflammation caused by the interaction of respiratory epithelium, innate and 
adaptive immune system, which drives a chronic inflammatory response (Ishmael, 
2011). 
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Inhaled allergens, which are typically common environmentally proteins such as pollen, 
house-dust mites, and mould are processed by one of the antigen presenting cells 
(APCs) commonly, dendritic cells. Processed allergens are then loaded into to the 
major histocompatibility complex II (MHC II), a cell surface molecule which presents the 
allergens on the surface of cells and enables APC to interact with CD4+ T-cells. The 
MHC II – allergen combination interacts with naive T-cells, which initiates sensitisation 
and triggers the subsequent immune response to the allergen. Dendritic cells also 
contribute to the differentiation of the nature of the immune response (Th1/Th2) by 
producing inflammatory mediators such as IL-12 and type I interferons which stimulate 
naive T cells differentiation into Th1 cells.  The production of IL-4 by eosinophils and 
mast cells inhibits the expression of IL-12 and subsequently Th1 development, 
therefore directing the immune response to the production of Th2 effector cells. 
Expression of IL-4, OX40L and the CD86 (cluster of differentiation (CD) marker) 
polarises T -cells differentiation in favour of Th2 responses which is the hallmark of 
allergic response (Lambrecht and Hammad, 2010). 
Activated and sensitised T-cells then produce a range of cytokines fundamental to 
allergy; IL-3, IL-4, IL-5, IL-6, IL-9, IL-13 and granulocyte–macrophage colony 
stimulating factor (GM-CSF). IL-4 and IL-13 produced by T-cells, drive B-cells to 
proliferate and produce allergen-specific antibodies (IgE) which is the main pathway of 
allergen sensitisation. The sensitisation results in the formation of IgE memory B-cells 
and allergen specific memory T-cells which are responsible for future allergic 
responses (Levine and Wenzel, 2010).  
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II.2.2. ANTIGEN CHALLENGE 
Allergen challenge in sensitised asthmatics can provoke two phases of temporal airway 
responses, namely early-phase reaction and late-phase reaction. 
Early-phase reaction occurs immediately (within minutes) after allergen encounter. The 
early phase reaction is often also named as immediate hypersensitivity reactions. In 
allergic patients, inhaled allergen challenge initiates an early allergic inflammatory 
reaction and this may be followed sometime later with a late-phase reaction (Bousquet 
et al., 2000).   The early phase reaction mainly portrays the cascade of responses as a 
result of mediator secretion by mast cells. Mast cells in allergic individuals bear high 
affinity IgE receptors (FcεRI) on their surfaces. Allergen specific IgE produced by B 
cells binds to high affinity allergen-specific IgE receptors (FcεRI) on the surface of mast 
cells.  When the sensitised individual is exposed to inhaled allergen, the antigen will 
bind to the allergen specific IgE on the surface of mast cells, which leads to the 
activation of mast cells. The activated mast cells subsequently release their granules, 
which contain inflammatory mediators such as histamine, leukotrienes,  reactive 
oxygen species, and lipid mediators (Jarjour et al., 1997). Degranulation, the process 
when the mast cells cytoplasmic granules membrane fuses with the plasma 
membrane, is responsible for the release of the mediators. The outcome of the 
mediators release includes bronchoconstriction, vasodilatation, increased vascular 
permeability and increased mucus production, and enhanced airway responsiveness. 
Mast cells activation also induces slower expression of other cytokines and 
chemokines (TNF (tumour necrosis factor) -α, IL-4 and IL-5) up to 72 hours after 
allergen challenge (Okayama et al., 2003), which contributes to the inflammatory 
cascade of allergen-induced late phase reaction (Holgate, 2008). 
Late-phase reaction peaks at six to nine hours after allergen provocation. The 
orchestration of the late phase reaction is thought to be the result of long term 
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outcomes of mast cells activation during the early phase reaction and allergen 
activated T-cells. The release of Th2 cytokines, which is initiated by the activation of T 
cells after allergen challenge, is an important mechanism of the late-phase response 
(Kay, 1991). However, the release of cytokines by mast cells has been thought to 
initiate the early recruitment of inflammatory cells (Bradding et al., 1994). The nature of 
the late phase reaction represents the increasing number and activity of resident cells 
and recruited leucocytes to the airways such as  eosinophils (De Monchy et al., 1985), 
neutrophils (Montefort et al., 1994), basophils (Guo et al., 1994), macrophages 
(Calhoun et al., 1992) and CD4+ T cells (Robinson et al., 1993). Airway 
hyperresponsiveness is usually observed after the late phase reaction but not after the 
early phase reaction (Bousquet et al., 2000).  
II.2.3. RECRUITMENT OF INFLAMMATORY CELLS INTO THE AIRWAYS  
One of the hallmarks of asthma is infiltration of the airways by inflammatory cells 
including T cells, mast cells, basophils, macrophages, and eosinophils. Upregulation of 
the production of proinflammatory cytokines, chemokines, mediators, and cell surface 
adhesion molecules are responsible for the recruitment of the inflammatory cells into 
the site (Bousquet et al., 2000). The inflammatory response, tissue damage and 
remodelling in asthma is orchestrated by the interactions of all these effector cells and 
their pro inflammatory products (Hamid et al., 2003). 
A. EOSINOPHILS 
Although not specific to asthma, airway eosinophilia is a characteristic of asthma. In 
fact, activated eosinophils and T cells are the hallmarks of asthma. There is 
a significant correlation between eosinophil activation and asthma severity and 
bronchial hyperresponsiveness (Bradley et al., 1991).   Eosinophil priming, activation, 
and survival are known to be regulated by IL-3, IL-5, and GMCSF cytokines, which are 
released from Th2 cells. Eosinophils are recruited into airways through  the release of 
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TNF-α by degranulated mast cells and the release of IL-5 by activated T cells (Barnes, 
2002). Eosinophils are also involved in airways remodelling because they release 
growth factors, elastase, and metalloproteases, which contribute in the process of 
tissue remodeling and fibrosis (Bousquet et al., 2000).  
B. T-LYMPHOCYTES 
T lymphocytes also play an important effector role in asthma. T cells are activated and 
produce high levels of cytokines during acute asthma exacerbations in response to 
antigen stimulation. According to their cell surface markers and distinct functions, T 
lymphocytes are grouped into two types: the CD4+ (T helper) and the CD8+ (T 
cytotoxic) cells. Based on the type of cytokines they produce, CD4+ cells are 
subdivided into Th1, Th2, Th17, Th9, T follicular helper, and regulatory T cells. Th2 
cells, which are more prominent in asthmatics release IL-4, IL-5, and IL-13. IL-4 is 
important in allergic sensitisation, IL-5 is essential in esoinophil survival, while  IL-13 
leads the induction of bronchial hyperresponsiveness, airway smooth muscle 
proliferation, subepithelial fibrosis, and goblet cell hyperplasia (Lloyd and Hessel, 
2010). IL-13 also increases eosinophil numbers and activation via up regulation of 
multiple chemokines including CCL11  (Robinson et al., 1993).  Th-9 cells express IL-9 
which plays a role in mast cell proliferation, activation, recruitment, and survival 
(Kearley et al., 2011). Th17 cells produce IL-17 which is thought to contribute to the 
severity of the disease in cortisteroid-resistant asthma. T regulatory (Treg) cells inhibit 
the development of allergic airway inflammation. Treg control inflammation by 
preventing the activation of dendritic cells by allergen (Lloyd and Hessel, 2010). T 
follicular helper cells are thought to have a role in a B cells isotype switching (Kemeny, 
2012). 
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C. MAST CELLS 
Within the airway tissue, mast cells make up approximately 20% of inflammatory cells, 
although they only make up a small portion (0.02% to 0.48%) of total cells recovered in 
broncholaveolar lavage (BAL) fluids. In atopic or non-atopic asthma, there is an 
increase of normal mast cell numbers by 2- to 6-fold. Mast cells seem to be an 
important contributor during episodes of acute asthma, which leads to acute 
bronchoconstriction,
 
oedema, and mucus secretion (Hamid et al., 2003). On allergen 
challenge of the airways, mast cells respond immediately (within minutes) by 
degranulation, which then release histamine and other
 
vasoactive and bronchoactive 
mediators such as Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (Broide et al., 
1991). Other stimuli such as exercise, aspirin, and chemicals are also known to trigger 
mast cell degranulation, causing bronchoconstriction and vascular changes. Mast cells 
are also involved in the production of cytokines including IL-3, IL-4, IL-5, IL-13, IL-6, 
and TNF-α (Hamid, 2003). Mast cell products may also be involved in airways 
remodeling by stimulating the migration and proliferation of fibroblasts (Bousquet et al., 
2000).   
D. MACROPHAGES 
In both non-asthmatics and asthmatics, the most prominent cells found in BAL fluid are 
macrophages. Increased activation of macrophages has been linked to the severity of 
asthma. Airway macrophages may participate in airway inflammation through several 
mechanisms. Macrophage is one of professional antigen presenting cells (Sprent, 
1995). Macrophages may also be involved in the development of airways 
inflammation
 
and the airways obstruction via release of enzymes, eicosanoids, platelet-
activating
 
factor (PAF), oxygen free radicals and cytokines, and mucus secretagogues.  
They also produce pro-inflammatory cytokines such as IL-1, TNF-α, IL-6 and GM-CSF, 
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which may induce endothelial cell activation, cellular recruitment, and prolonged 
eosinophil survival (Poulter et al., 1990).  
Macrophages may be involved in mast cell activation during the late-phase reaction in 
asthma by releasing histamine-releasing factors which act on basophils and mast cells 
by binding to surface IgE (Liu et al., 1986). Macrophages may also play a role in the 
regulation of the airway remodeling via the secretion of growth-promoting factors for 
fibroblasts, cytokines, and growth factors such as platelet-derived growth factor 
(PDGF), basic fibroblast growth factor (bFGF), or TGF-β (Kovacs and DiPietro, 1994). 
E. NEUTROPHILS 
Neutrophil number is higher in some patients with severe asthma, which has been 
linked with the high dose corticosteroid treatment on severe asthmatics (Lacoste et al., 
1993).  Elevated numbers of neutrophils in lavage fluids have also been found in fatal 
asthma. Some studies showed that there is an association between the number of 
neutrophil found in sputum and the degree of airway obstruction (Woodruff and Fahy, 
2002). Neutrophils also seem to have a role in corticosteroid insensitivity (Green et al., 
2002). 
F. DENDRITIC CELLS 
There are two main subsets of dendritic cells: plasmacytoid dendritic cells and 
conventional dendritic cells. Plasmacytoid dendritic cells are the main producers of type 
I interferons while conventional dendritic cells act mainly as antigen presenting cells 
(Manh et al., 2013). As an antigen presenting cell (APC), the role of the dendritic cell 
network within the human airways is to express major histocompatibility complex 
(MHC). Dendritic cells are specialized in antigen processing and presentation, so they 
play an important role in the induction of immune responses in the airways (Hance, 
1993).  
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Figure 1.3. Schematic figures of pathophysiology of asthma. In atopic individual, exposure to 
allergen will activate Th2 lymphocytes and stimulate IgE production. Future exposure to the 
same allergen will cause immediate release of pro-inflammatory mediators via mast cells 
degranulation as well as eosinophil activation and airway hyperresponsiveness  (Taher et al., 
2010).  
 
II.2.4. AIRWAY HYPERRESPONSIVENESS 
Measurements of airway responsiveness to inhaled bronchoconstrictor mediators 
(most often histamine or methacholine) are important in asthma studies.  In most 
asthma studies, exposure to a single allergen, repetition of low dose allergen, and 
exacerbations of asthma may increase methacholine or histamine responsiveness in 
the range of 1–2 doubling doses from a stable baseline in average (Zosky et al., 2004). 
This is airways hyperresponsiveness (AHR). 
The term AHR takes both airway hyperreactivity and airway hypersensitivity into 
account. Airway hyperreactivity is a greater degree of closure in the airways to a variety 
of stimuli and the maximum bronchoconstriction to methacholine is elevated (Fig. 1.4). 
While airway sensitivity is a decrease in the threshold of the airways to react to stimuli, 
therefore sensitive airways respond to a dose of stimuli that would have no effect on 
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normal airways (O'Connor et al., 1999). The term of stimuli can be classified into 2 
types; direct acting stimuli which include histamine and methacholine, and indirect 
acting stimuli such as exercise, hyperventilation, cold and dry air which induce AHR by 
releasing bronchococstrictor mediators from cells  (O'Byrne and Inman, 2003). Non 
asthmatics need more than 16 mg/ml of methacholine to reduce the FEV1 (the volume 
of air exhaled in 1 second of the forced expiratory manoeuvre) by 20%, whereas 
asthmatics would only need less than 3 mg/ml to achieve the same PC20 (provocative 
concentration of a substance causing a 20% fall in FEV1) (Cockcroft and Davis, 2006) 
(Fig. 1.4). 
There is an established relationship between the level of AHR and the severity of 
airway inflammation. In asthmatic subjects, exposure to inhaled allergen induces a 
cascade that increase airway inflammation and enhances reactivity (Meurs et al., 
2008). Many different factors have been suggested to be involved in the AHR seen in 
asthma. Sterk and Bel  suggested that change in airway smooth muscle contractility, 
thickening of the airway wall, and decreased elastic loads may increase the airway 
reactivity, while epithelial damage, alteration in neural control, inflammatory cells, and 
their mediators contribute to the hyper sensitivity of the airways (Sterk and Bel, 1989). 
Eosinophilia is one airway inflammation process thought to play a role in AHR (O'Byrne 
and Inman, 2003). Eosinophila in asthmatic airways is suggested to contribute to 
epithelial damage, thickening of the basement membrane, and the release of mediators 
which cause bronchial smooth muscle contraction and exudation of plasma. All of 
these processes result in thickening of the airway wall which causes change in airway 
geometry. The airway will be narrower as a result of the swelling and smooth muscle 
shortening which are associated with AHR (Cockcroft and Davis, 2006). 
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Figure 1.4. The change of FEV1 compared to baseline provoked by the exposure of 
methacholine (bronchocostrictor) in normal and asthmatic individuals. An increase in slope 
indicating increased sensitivity while increasing maximal response indicating increased 
reactivity of the airways (O'Byrne and Inman, 2003).  
 
II.3. ASTHMA EXACERBATIONS 
For most asthmatics, the disease would be stable with some episodes of disease 
exacerbations. Asthma exacerbations are “acute or sub-acute episodes of 
progressively worsening shortness of breath, cough, wheezing, and chest tightness, or 
some combination of these symptoms, characterized by decreases in expiratory airflow 
and objective measures of lung function (spirometry and peak flow) (Busse and 
Lemanske Jr., 2007). Asthma exacerbations are classified into moderate and severe 
exacerbations. Moderate asthma exacerbation features include deterioration in asthma 
symptoms and lung functions, increase use of bronchodilator, but not severe enough to 
require hospital care. Severe asthma exacerbations warrant increasing dose of 
corticosteroids for 3 days and usually need hospitalization (Reddel et al., 2009).  
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Asthma exacerbation triggers are multifactorial, including viral infections, allergens 
(pollen, animal danders, dust mite), exercise, airborne irritants (cigarette smoke, strong 
odors, dust), occupational irritants, hormones, and drugs (aspirin and other non-
steroidal anti-inflammatory drugs (NSAIDs)). These diverse triggers can produce 
symptoms that range from mild brief to life-threatening episodes of respiratory distress 
(Maddox and Schwartz, 2002). 
There is a common pattern of asthma exacerbations. Phase 0 is the baseline of stable 
maintenance asthma. Phase 1 is where the stable baseline of lung functions abruptly 
and progressively decline with variation in onset, the rate of decline and the extent of 
decline, and phase 2 when the exacerbations progress to death or recovery 
(Tattersfield et al., 1999). 
III. VIRUS INFECTION AND ASTHMA  
Respiratory viruses are closely associated with acute exacerbations 
of asthma. Evidence shows that they are responsible for 80–85% of acute asthma 
exacerbations (Johnston, 1995). In almost all studies of asthmatics, the predominant 
viruses are RVs (rhinoviruses), RSVs (respiratory syncytial viruses), influenza and 
parainfluenza viruses. Of the common respiratory viruses, RV is the most frequent 
causative agent. Adenoviruses, enteroviruses, coronaviruses, and 
metapneumoviruses, may also be associated with exacerbations of asthma but less 
frequently. A study in the UK estimated the cost of asthma exacerbations to be 3.5-
times higher per patient compared to asthma patients who did not experience 
exacerbation (Hoskins et al., 2000). Although asthmatics have the same probability of  
encountering viral infection as normal people do, they have more severe, as well as 
longer duration of, lower airway symptoms and also increased reduction in lung 
function compared to normal healthy people. Hence, respiratory tract viral infections 
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cause a higher level of morbidity in patients with asthma than in the healthy population 
(Corne, 2002). The more severe consequences of viral infection in asthmatics is a 
result of both pre-existing asthmatic pathology and the toxic effect of viral pathology. 
The underlying asthmatic Th2 type immune response may interfere with effective 
antiviral responses, equally, virus infection may amplify the hypersensitivity of 
asthmatic airways to allergen exposure (Message and Johnston, 2001).  
Respiratory viruses infect the bronchial epithelium and upregulate a range of pro-
inflammatory cytokines, chemokines, adhesion molecules, mucins and growth factors, 
all of which contribute to loss of lung function and causing airway inflammation. In 
virus-induced asthma exacerbations neutrophils seem to play a more significant role, 
while in allergen-induced asthma exacerbations eosinophils seem to be more 
prominent. T lymphocytes appear to be important to both (Pizzichini et al., 1998).  
Most respiratory viruses enter and replicate within airway epithelial cells and damage 
both ciliated and non-ciliated respiratory epithelial cells, leading to necrosis of the 
epithelium, ciliostasis, loss of cilia, and impairment of mucociliary clearance (van der 
Schans, 2007; Thornton et al., 2008). Damaged epithelial cells increase epithelial 
permeability, which in turn increases penetration of allergen, including penetration into 
respiratory tract smooth muscle cells which causing an increase in airway 
hyperresponsiveness. The clinical manifestations of viral infection on top of pre-existing 
asthma are also likely to be a result of pro-inflammatory mediators released by 
damaged epithelial cells, as well as a direct cytotoxic effect of the virus (Message and 
Johnston, 2001).  
Asthma is characterized by type 2 T-cell (Th-2) infiltration with production of their 
specific cytokines  (Jackson et al., 2008). On the other hand, viral infection is 
characterized by type 1 T-cell (Th-1) responses leading to production of interferons 
(Message and Johnston, 2001). Therefore, the balance between Th-1 and Th-2 
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cytokine production can be important to viral clearance. Studies have shown that within 
a pre-existing type 2 cytokine allergic asthmatic environments, the normally effective 
type 1 antiviral immune response might be inhibited, the immune response would be 
skewed toward type 2 responses, or both (Gern et al., 2000). 
 
Figure 1.5. The immune response of respiratory viral infection with underlying asthma. The Th2 
immune response in pre-existing asthma might alter the Th1 antiviral immune response skewing 
towards Th2 or mixed response which leads to increased immunopathology and tissue damage 
due to delay in viral clearance and prolonged viral induced inflammation (Message and 
Johnston, 2001).  
 
IV. CURRENT THERAPIES FOR ASTHMA 
Asthma is a chronic respiratory disease which is characterised by variable episodes of 
impaired breathing attacks.  The hallmarks of asthma include bronchoconstriction, 
airway hyperresponsiveness with underlying airway inflammation, and some symptoms 
such as shorthness of breath, wheezing, chest tightness and cough due to narrowing of 
small airways (Taylor et al., 2008). Based on the pathophisiology of asthma, the two 
most important classes of medications for asthma are controllers and relievers.  
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1. Controllers basically keep asthma under control to achieve target management of 
asthma which is defined as: asthma without any daytime or night symptoms, no 
needs of relievers, no exacerbations, and preserve a normal lung function 
(BTS/SIGN Asthma Guidelines (British Thoracic Society/Scottish Intercollegiate 
Guidelines Network, 05/08), 2012). Controllers available in the market and clinical 
practice include corticosteroid, cromones (i.e. sodium cromoglycates and 
necrodomil sodium), leukotrienes modifiers (i.e. montelukast, pranlukast, and 
zafilukast), and sustained release theophylline (GINA, 2012). Although these 
controllers have anti-inflammatory properties, at the moment, inhaled corticosteroids 
remain the cornerstone of asthma therapy because they are proven to be the most 
effective agents in this category of asthmatic medications (GINA, 2012). In patients 
with mild to moderately persistent asthma, inhaled corticosteroids significantly 
reduce exacerbations and asthma death (Suissa et al., 2000)  Another study shows 
corticosteroids improved pathological signs of airway inflammation, pulmonary 
function, and reduced airway hyperresponsiveness (Djukanovic et al., 1992). 
Asthma exacerbations can also be treated to a lesser extent by cromones (Holgate, 
1996) and theophylline (Bousquet et al., 2000).   
2. Reliever function is mainly to quickly reverse bronchocostriction and relieve its 
symptoms. Relievers are mainly bronchodilators such as short-acting inhaled or oral 
β2-agonists, inhaled anticholinergics, and short acting theophylline (GINA Report, 
2012). The relievers are the first line therapy of acute asthmatic exacerbations to 
reverse airway obstruction because this class of medicines relax airway smooth 
muscle and also increase mucociliary clearance. In most asthma treatment 
guidelines, short acting β2-adrenergic agonists are regarded as the most effective 
and widely used bronchodilator (GINA Report, 2012). 
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IV.1. ASTHMA TREATMENT LADDER 
Most asthma guidelines classify asthmatics based on the frequency of attack and 
severity of symptoms i.e: mild intermittent, mild persistent, moderate persistent and 
severe persistent asthma. Evidence based management of asthma also recommends 
gradual steps of treatments based on the disease classification with aims to improve or 
achieve asthma control (GINA Report, 2012).  
In mild intermittent asthmatics whose symptoms occur less than once a week and night 
symptoms less than twice a month, with small (<20%) variability of their PEF (peak 
expiratory flow rate), inhaled short acting ß2 –agonists are the main therapy. The short 
acting ß2 –agonists should only be used when needed because their regular use could 
be harmful and have no additional benefit (Walters and Walters, 2000). When the 
patient uses more than 1 canister of Inhaled short acting ß2 –agonists per month, the 
disease is regarded as poorly controlled therefore there is a need to step up on the 
treatment ladder with the addition of regular controller or anti inflammatory treatment. 
Inhaled corticosteroids are also given to this group of patients who experience severe 
exacerbation 
Controller treatment is started at any level of non-well controlled (persistent) asthma. 
The mild persistent asthmatic has one or more symptom a week but less than once a 
day and more than twice per month night symptoms.  They also have 20 – 30% 
variability of PEF value. This group of patients will benefit from additional inhaled 
corticosteroid therapy (GINA Report, 2012).  It has been proven that administration of 
regular low dose of inhaled corticosteroids significantly reduced asthma exacerbation in 
patients with mild persistent asthma compared to control (Suissa et al., 2000). 
Leukotriene antagonist could also be used as additional anti inflammatory agents in 
mild persistent asthma albeit they appear to be less effective than inhaled 
corticosteroids (Bleecker et al., 2000). 
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 Moderate persistent asthmatics are those who are using inhaled short acting 
ß2 agonist on a daily basis and whose symptoms occur daily with nocturnal symptoms 
more than once a week. They have more than 30% variability of their PEF values. 
Whereas severe persistent asthmatics refer to patients who have symptoms 
continuously therefore limiting their physical activity. They have high variability (more 
than 30%) of their PEF (GINA Report, 2012). 
Although moderate and severe persistent asthmatics seem to benefit from increase of 
their current corticosteroid dose, studies on this matter remain controversial. Some 
studies showed no significant clinical benefit with higher dose of inhaled corticosteroid 
(Adams and Jones, 2006) and some studies demonstrated improvement in lung 
functions and reduction of symptoms optima (O'Byrne et al., 2001). Based on modest 
benefit in increasing the dose of inhaled corticosteroid which might largely outweighed 
by the greater risk of side effects, this approach is not a first choice in managing 
moderate persistent asthma.  
The first choice for moderate and severe persistent asthmatic patients is long acting 
ß2 –agonist add-on therapy. Many studies demonstrated those patients may benefit 
from additional long acting ß2 –agonists (e.g. salmeterol and formoterol) on top of 
regular inhaled corticosteroids. The FACET and OPTIMA randomised controlled trial 
study results showed that the addition of formoterol to inhaled budesonide improved 
lung function, reduced symptoms and reduced acute exacerbation optima (Tattersfield 
et al., 1999; O'Byrne et al., 2001). Long acting ß2 -agonists do not have significant anti-
inflammatory properties, therefore they are recommended to be given only alongside 
regular inhaled corticosteroids (BTS/SIGN Asthma Guidelines, 2012; GINA Report, 
2012).  
Other therapeutic choices to be coupled up with  
regular inhaled corticosteroids to manage persistent asthma are leukotriene receptor 
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antagonists and theophylline. Leukotriene modifiers may reduce the dose of inhaled 
corticosteroid in this group of patients (Löfdahl et al., 1999). However, some studies 
showed that this group of medicines are inferior to long acting ß2-agonists as additional 
therapy (Ringdal et al., 2003; Deykin et al., 2007). The last choice of add-on therapy for 
moderate and persistent asthma is theophylline. It is reserved as the last choice due to 
adverse side effects. Theophylline is a bronchodilator and has modest anti-
inflammation activity in the lower dose (Barnes and Adcock, 2003). 
 
Figure 1.6. Asthma treatment ladder with stepwise approach as recommended by Global 
Strategy for Asthma Management and Prevention-GINA (2012).  
 
There are some patients whose severe asthma persists and is difficult to control albeit 
being given the highest dose of corticosteroids and coupled with the listed add-on 
therapeutics. This group of patients might benefit from the regular (once daily) oral 
corticosteroid, prednisolone, to control the symptoms and prevent exacerbation (GINA 
Report, 2012). 
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IV.2.  TREATMENT OPTIONS FOR VIRUS-INDUCED EXACERBATIONS 
OF ASTHMA 
 Viral induced exacerbation of asthma has not been yet treated effectively. The range 
of treatment options including antiviral therapy, interferons therapy, and corticosteroid 
therapy, have been studied and applied with mixed results. According to clinical 
guidelines, current treatment for virus-induced exacerbations of asthma is still limited to 
high-dose corticosteroids combined with bronchodilators for symptomatic treatment. 
Although antiviral therapy exists for influenza; it is not available for the most common 
respiratory viruses (Message and Johnston, 2001). 
The use of corticosteroids in virus-induced exacerbations of asthma remains 
controversial. There is growing evidence showing that the use of corticosteroids alone 
is only partially protective against virus-induced exacerbations of asthma (Farr et al., 
1990; Grunberg et al., 2001). There are studies on the use of prednisone or intranasal 
beclomethasone given for 3–5 days before antigen challenge as a prophylactic 
treatment in a model of experimental RV infection.  The corticosteroids treatments were 
effective in reducing nasal obstruction, nasal kinin and mucus concentration but had 
non-significant effects on other symptoms (Gustafson et al., 1996). However ,there is 
evidence that giving systemic corticosteroid in early onset of respiratory viral infection 
in asthmatics prevented the symptoms from progressing to severe acute exacerbation 
of asthma which require hospitalisation (Storr et al., 1987). 
In viral induced asthma exacerbations, corticosteroids may be given in combination 
with other reliever agents, mostly long-acting β2 agonists (LABA).  Several studies have 
demonstrated  that the combination of  corticosteroids and LABA has advantages in 
terms of alleviating inflammation, controlling smooth muscle remodelling and improving 
lung function compared to the use of corticosteroids alone, in severe or 
persistent asthma  (Greening et al., 1994; Matsunaga et al., 2013). 
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The use of corticosteroids in respiratory viral infection alone is also still in debate. 
There are some findings which showed treatment of corticosteroids in acute respiratory 
distress syndrome (ARDS) induced by H1N1 infection was associated with significant 
increase in morbidity and mortality (Estenssoro et al., 2010). Even though those 
findings were not concluded from randomized clinical trial, the reasons of not using 
corticosteroids in this setting are understandable. Corticosteroids are 
immunosuppressant which might interfere with the effectivity of eradication of the 
invading viruses by the host immune system. There is also a chance that the virus 
might take hold effectively in the immunosuppressive host. 
For those who support the use of corticosteroids in viral infection, however, there is 
strong biological rationale underlining the decisions. In acute respiratory distress 
syndrome due to H1N1 infection, acute lung injury was more a consequence of 
uncontrolled lung and systemic inflammation rather than uncontrolled viral infection 
(Mauad et al., 2010). There is a storm of pro-inflammatory cytokines, reactive nitrogen 
species, and reactive oxygen species released in the lung of the patient with ARDS 
(Vlahos et al., 2011). Therefore, the use of corticosteroids in ARDS is justified. 
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V. CORTICOSTEROIDS 
Corticosteroids are highly effective in the control of many inflammatory and immune 
diseases, including asthma.  Inhaled corticosteroids are by far the most effective anti-
inflammatory treatment for asthma and have now become the first-line therapy in all 
patients with persistent asthma (WHO/NHLBI Workshop Report, 1995).  
Corticosteroids have been proven to have many benefits in any asthmatic patients 
needing to use β2-adrenoreceptor agonist inhaler more than once a day. The benefits 
include decreased mortality (Barnes et al., 1998), reducing exacerbations and 
improving health status (Barnes, 2006). The majority of the benefits from inhaled 
corticosteroids are achieved in adults at relatively low doses (equivalent to 100 μg of 
fluticasone a day). In addition, increasing the dose might only give a little additional 
benefits in asthma control and increases the risk of side-effects (Kankaanranta et al., 
2004).  
The benefit of using corticosteroids must be weighed against their side effects. 
Corticosteroid therapy exerts various side effects including osteoporosis, fluid retention, 
hypertension, cataract formation, fat deposition, cushing syndrome, and myopathy. 
Giving corticosteroids to children also put them in the risk of growth and sexual 
maturation retardation.  Unlike oral corticosteroid, inhaled steroid therapy has been 
shown to decrease the risk of side effects. However, some molecules of inhaled 
corticosteroids deposited in the lung or swallowed into gastrointestinal tract are still 
able to undergo systemic absorption. Therefore, increasing the dose of inhaled 
corticosteroids to more than 5mg of cortisol per day may still increase the risk of 
osteoporosis (Ledford et al., 1998).  
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V.1. EFFECT CORTICOSTEROID ON CELL FUNCTIONS 
Corticosteroids are a group of chemicals which include endogenous cortisol produced 
by the adrenal cortex of the vertebrae. Corticosteroids are potent anti-inflammatory 
agents consisting of a 21-carbon that have inhibitory actions on several inflammatory 
cells implicated in asthma. Corticosteroids are also very effective in blocking the 
release of proinflammatory cytokines, which play an important role in the recruitment 
and survival of several inflammatory cells involved in asthmatic inflammation 
(Schleimer, 1990). 
 
Figure 1.7. Basic chemical structure of corticosteroid (Torres and Canto, 2010). 
 
Corticosteroids exert their biological effects via interaction with glucocorticoid receptors 
(GR), which are predominantly localized in the cytoplasm of target cells, and only on 
binding of the corticosteroids does it move into the nuclear compartment (McMaster 
and Ray, 2007). Different responses of cells and tissues to corticosteroids and its effect 
on different signaling pathways may be the results of interaction between the 
glucocorticoid receptor (GR) with different tissue specific co-activators or co-repressors 
(Yudt and Cidlowski, 2002). 
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V.2. GLUCOCORTICOID RECEPTOR 
The glucocorticoid receptor is a member of the hormone receptor super family of 
proteins which is part of the basic transcription apparatus to initiate transcription 
(transcription factor) (Robinson-Rechavi et al., 2001). GR is encoded from a single 
gene but several isoforms have been identified as splice variants (Adenuga and 
Rahman, 2007).  The most common one encodes GRα. A C-terminal variation results 
in GRβ. GRβ does not bind the glucocorticoid ligand and has a dominant negative 
action on GRα. Therefore GRβ is thought to affect corticosteroid responses in some 
groups of inflammatory diseases (Chikanza, 2002). GRα (subsequently will be 
mentioned as GR) is a single polypeptide chain consisting of 777 amino acids 
(Adenuga and Rahman, 2007) localized in the cytoplasm of almost all cell types  (Rhen 
and Cidlowski, 2005).  Corticosteroid function is depend on its binding to GRα  (Yudt 
and Cidlowski, 2002). 
Corticosteroids exert their action by diffusing trough the plasma membrane by a 
passive process where they bind to the intracellular GRα which is inactive and bound to 
Hsp90 (heat shock proteins 90) and immunophilins. Ligand binding causes dissociation 
of Hsp90 thereby exposing the nuclear localization signal (NLS), which allows active 
GRα -ligand complex to translocate to the nucleus. In the nucleus, GRα-ligand complex 
could either stimulate transcriptional responses (transactivation) or inhibit 
transcriptional responses (transrepression) of inflammatory genes by protein-protein 
interactions or binding directly to the DNA (Ito et al., 2006).  
V.3. MECHANISM OF GLUCOCORTICOID RECEPTOR INTERACTIONS 
Gene expression is controlled by how chromatin is packed in the nucleus. Chromatin 
consists of nucleosomes which contain DNA wound into a core of octomer of histone 
proteins (2 H2A, 2 H2B, 2 H3, 2 H4). The process of switching on and switching off the 
genes is associated with alteration of the chromatin structure. In the resting cells, the 
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gene expression is switched off, chromatin is condensed tightly into the histone core 
thus non accessible to the transcription factors. The gene is switched on when the 
chromatin structure is unwound allowing access of the transcriptional apparatus 
(Adenuga and Rahman, 2007) to start the transcription process of the DNA sequence 
of the gene into a molecule of mRNA which is subsequently translated into protein (i.e. 
enzymes, receptors, cytokines) 
The winding and unwinding structures of the chromatin depend on acetylation status of 
the histone complexes. Histone dissociates when acetylated, the DNA is then uncoiled 
and the sequence is exposed to the transcription factor leading to initiation of 
transcription. Histone acetylation is regulated by a group of histone- acetyltransferases 
(HATs). Some nuclear receptor co-activators such as cyclic AMP response element 
binding (CREB)-binding protein (CBP)/adenoviral protein E1A (p300) protein, steroid 
receptor co-activator 1 (SRC-1),  activator transcription factor- 2 (ATF-2) and 
CBP/p300 associated factor (P/CAF) have intrinsic HAT activity (Rahman et al., 2004). 
ATF-2 and CBP/p300 are important for the co-activation of important transcription 
factors for inflammation such as Nuclear factor κB (NF-κB) and activator protein 1 (AP-
1) (Rahman et al., 2004). Transcription is initiated when the co-activator/s-transcription 
factor complex interacts with RNA Pol II. Histone acetylation is reversed by histone 
deacetylases (HDACs) which deacetylate the histones and make them rewind back to 
the DNA thus blocking the gene expression (Smoak and Cidlowski, 2004). 
V.3.1. TRANSCRIPTIONAL ACTIVATION OF GR DEPENDENT GENES 
In the nucleus, upon nuclear translocation, two corticosteroid-GRα complexes bind 
together to form a homodimer where it associates to DNA at specific sequences in the 
promoter region of corticosteroid-responsive genes known as glucocorticoid response 
elements (GREs) and switches on gene transcription (Ito et al., 2006).  The association 
of ligand-GRα complex to the GRE causes its conformational change which promotes 
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the recruitments of coactivators such as CBP/p300, P/CAF and SRC-1 to the GRα-
GRE site. The mentioned coactivators have intrinsic HAT (histone acetylase) activity 
which seems to be important in remodeling chromatin and unwinding the DNA which 
subsequently allows transcription of anti-inflammatory proteins (Smoak and Cidlowski, 
2004). This mechanism of actions however, has only been proven at high 
concentration of corticosteroids (Ito and Adcock, 2000). 
Corticosteroids are also known  for their action to switch on the genes responsible for 
the synthesis of several anti inflammatory proteins, including annexin-1, serum 
leukoprotease inhibitor (SLI), IL-1 receptor antagonist, IL-10, neural endopeptidase, 
and mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) (Barnes, 2006). 
Corticosteroids also induce the production of IκBα which is an inhibitor of NF-κB and 
thus decreases the cellular inflammatory response which is known to be primarily 
through the NF-κB pathway (Adenuga and Rahman, 2007).  
V.3.2.  TRANSCRIPTIONAL REPRESSION OF GENE EXPRESSION BY 
CORTICOSTEROIDS 
The primary anti-inflammatory mechanism of corticosteroids is via repression of 
proinflammatory genes which encode the production of proinflammatory cytokines, 
chemokines, and adhesion molecules. It was originally believed that GRα switches off 
the proinflammatory genes by direct binding to a negative GRE (nGRE). However,  
most genes that are repressed in the presence of corticosteroids are not known to 
possess nGREs in their promoter regions (Barnes and Adcock, 2003).  
On the other hand, abundance of evidence shows that the repression of 
proinflammatory genes seems to be the result of direct protein-protein interaction 
between GRα and other transcription factors, mainly NF-κB and AP-1. The antagonism 
interaction results in repression of the synthesis of several cytokines such as TNF-α, 
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GM-CSF, IL-1β, IL-2, IL-3, IL-6, IL-8, and IL-11 and chemokines including eotaxin, MIP, 
and RANTES, iNOS, COX-2, ICAM-1 and VCAM-1 (Smoak and Cidlowski, 2004). 
1. TRANSREPRESSION BY INTERACTION WITH TRANSCRIPTION 
FACTORS 
Nuclear factor κB (NF-κB) is an abundant cytosol to nucleus translocating transcription 
factor which has an established important role in inflammatory signalling process. NF-
κB is a homo or heterodimer formed by an assembly of subunits. The most common 
assembly is the p65/p50 heterodimer. When inactive, NF-κB forms a complex with 
inhibitor IκB to maintain its position in the cytoplasm. IκB prevents NF-κB’s nuclear 
translocation and subsequent DNA binding activity by masking its nuclear localization 
signals. NF-κB is activated by some inducers including proinflammatory cytokines (IL-1 
and TNFα), lipopolysaccharides from microbes, and viral infections (dsRNA) (Barnes 
and Karin, 1997). These inducers transmit signal to the IκB kinase (IKK) then 
phosphorylates the complex which leads to post-translational modification and 
proteasome-dependent degradation of IκB which then set the NF-κB free. The released 
NF-κB then translocates to the nucleus to activate transcription of wide arrays of 
inflammatory genes including cytokines and some inflammatory mediators (Almawi and 
Melemedjian, 2002) . GRα is able to generate direct physical interaction with NF-κB 
subunit p65 (RelA) which results in reciprocal inhibition (Barnes and Karin, 1997). The 
protein-protein interaction and antagonism between GRα and NF-κB has been thought 
to repress the expression of many proinflammatory genes.  
AP-1 is also an abundant transcription factor in the cytoplasm which is responsible for 
the expression of many proinflammatory genes and tissue destructive enzymes such 
as collagenase (Johnson and Lapadat, 2002). AP-1 is formed by dimerisation of a Jun 
family member (c-Jun, v-Jun, Jun-B, or Jun-D) with another jun proteins or with a Fos 
protein (c-Fos, Fos-B, Fra-1, or Fra-2). GRα repress AP-1 via similar mechanisms on 
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which GRα represses NF-κB, such as direct protein–protein interactions between the c-
Jun subunit and GRα which results in a mutual antagonism of transcription  (Schule et 
al., 1990). AP-1 is also able to interact with GRα by the same mechanism that it 
interacts with NF-κB  which results in mutual inhibition of activity via the interaction of 
heterodimeric complexes of AP-1 and GR (Tuckermann et al., 1999).  
2. TRANSREPRESSION BY GR RECRUITMENT OF HDAC 
GRα may repress pro-inflammatory gene activation via histone modifications on 
chromatin remodeling. Activated GRα may bind to CBP to inhibit its HAT activity which 
leads to silencing the gene (Adcock and Caramori, 2001). Other reported mechanism 
on which GRα switched off proinflammatory genes is by GRα binding to the 
transcriptional complex which followed by recruitment of co-repressors (HDACs) 
leading to repressing pro-inflammatory genes. HDACs, especially HDAC2 have been 
shown to be crucial in corticosteroid mediated anti-inflammatory activity particularly at 
low concentration which relevant to asthma therapy (Ito et al., 2005). 
V.3.3. OTHER MECHANISMS 
These particular corticosteroid effects are thought not to be mediated by chromatin 
remodeling but by reducing stability of mRNA which in turn reduce the production of 
protein synthesis. In the inflammatory gene that codes GM-CSF, corticosteroids are 
suggested to inhibit the proteins that stabilize mRNA so they are more prone to break 
down and switching off the inflammatory protein expression (Bergmann et al., 2000). 
V.3.4. NON-GENOMIC EFFECTS 
Research has shown that corticosteroids can also have a relative rapid response which 
can occur within minutes. This effect does not seem to go through genomic 
mechanisms which requires hours to occur (Stellato C., 2004). Inhaled corticosteroids 
have shown to cause vasonconstriction and reduce blood flow by inhibiting 
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extraneuronal monoamine transporter uptake of norepinephrine in smooth muscle cells 
(Horvath and Wanner, 2006). In vitro, corticosteroids interact with their receptors in the 
cytosol and block the production of arachidonic acid production (Croxtall et al., 2000), 
although this effect was failed to be shown in vivo (Bisgaard, 2001). 
 
 
Figure 1.8. The mechanism of action of corticosteroids. After entering cells, glucocorticoids 
(GC) bind with glucocorticoid receptors (GR) in the cytoplasma forming GC/GR complex which 
then dimmerise. The complex or the dimmers might exert the anti-inflammatory effects via 
multiple mechanism (1). Transrepression of pro-inflammatory gene expression by blocking and 
binding into transcription factors such as NF-κB and AP-1; (2). Transrepression by binding into 
CPB which inhibits the HAT’s activity; (3). Transrepression by binding to negative GRE of pro-
inflammatory genes; (4). Transactivation of anti-inflammatory genes; (5). Reduce the stability of 
pro-inflammatory mRNAs (Fan and Morand, 2012). 
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VI. MODELLING ASTHMA IN MICE 
The best approach to investigate pathophysiology underlying asthma disorder, and to 
identify crucial pathways and potential novel targets for drug therapy, is to perform 
studies in human asthmatics. However, the required human studies are not acceptable 
because of ethical reasons. Experimental animal models provide an alternative for 
investigating disease mechanisms and progression as well as developing new 
therapies. Asthma is a complex disease with many factors involved, so, there is no 
single animal model of asthma which reflects all of the pathophysiological features of 
human asthma. However, experimental animal model can be used to simulate specific 
features of the disease, and disease processes in asthma and in particular their 
responses to treatment. Laboratory animals such as guinea pigs, rats and mice have 
been used as a model to understand the pathobiology of asthma (Wegmann, 2008).  
Mouse is the most widely used species. Many studies have used murine models of 
asthma for at least three reasons. First, transgenic animals are available. In addition, 
dense genetic and physical maps of the murine genome have already been 
constructed. Second is the wide range of specific reagents available for the need to 
investigate the cellular and mediator response. Third, mouse is a non endangered 
species and also relatively cheap (Wegmann, 2008). 
As for other animal species, murine models also have limitations. Mice are not human 
and do not spontaneously develop asthma. So, to study and evaluate the fundamental 
processes in asthma, an asthmatic-like reaction has to be induced. A murine acute 
allergic reaction mimicking the reaction of acute human asthma triggered by inhaled 
allergens has been widely used to investigate the immunopathological mechanism 
underlying asthma (Nials and Uddin, 2008). 
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Mostly, the murine models of asthma are performed by systemic sensitization to one of 
a number of allergens, which is then followed by a second exposure of the allergen via 
inhalation or intranasal (Epstein, 2004). Such models are also capable of portraying the 
immunological mechanisms of acute allergic inflammation with the involvement of Th2 
cytokines such as interleukin 4 (IL-4), IL-5 and IL-13 which play fundamental roles in 
the immunopathology of asthma (Wegmann, 2008). In this thesis, allergy in mice is 
generated by ovalbumin (OVA) adsorbed to the adjuvant aluminium hydroxide to skew 
the immune-response into a T-helper-2 (Th2) type responses with significant 
production of OVA-specific IgE. Inhalation or intranasal application of OVA in these 
sensitized animals will result in airway hyperresponsiveness and the migration of 
eosinophils into the airways. Airway hyperresponsiveness to a bronchoconstricting 
agent (methacholine) is measured post challenge.  
Acute viral respiratory infections trigger wheezing and exacerbations of asthma in 
children and adults. Viral respiratory tract infections are also responsible for around 
80% of wheezing episodes in school children (Johnston, 1995). Several animal models 
have been used to investigate the immunological mechanisms involved in the 
respiratory tract infections with respiratory viruses, allergic airway sensitization, and the 
development of obstructive airway disease and asthma. In these models, a range of 
respiratory viruses have been utilised, human parainfluenza virus (HPIV) 3 and 
influenza. These viruses are all proven to have potential in elucidating the mechanisms 
of interplay between respiratory tract viral infections and underlying allergic airways 
inflammation (Schwarze and Gelfand, 2002). 
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The anti-inflammatory properties of corticosteroids might be expected to inhibit the 
virus-induced airway dysfunction due to the influx of inflammatory mediators and cells 
in the airways. However, the studies on the efficacy of corticosteroids in virus-induced 
exacerbations of asthma showed controversial results. Contributing to the controversy 
are the variables of dose, duration, and timing of corticosteroid therapy, as well as the 
uncertainties of which exacerbations are caused by viral illness, even in the presence 
of viral-like symptoms (Message and Johnston, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I  
 
37 
 
VII. THESIS HYPOTHESIS AND AIMS 
VII.1. HYPOTHESIS 
Acute respiratory viral infection in ovalbumin-induced allergic airway inflammation will 
alter corticosteroid effectiveness to alleviate the allergic inflammation features in the 
murine model. 
VII.2. AIMS 
1. Develop a murine model of allergic airway inflammation exacerbation using 
respiratory virus infection which displays a worsening of airway inflammation and 
respiratory functions.  
OBJECTIVES: 
- Characterisation of respiratory virus infections on their 
susceptible/permissive cells and evaluation of possible antiviral effects of 
corticosteroids, compared to reference antiviral drugs 
- Characterisation of infection of some infective agent candidates in vivo 
- Reproduce a murine model of ovalbumin-induced allergic inflammation  
- Generation of exacerbation in the murine model of allergic airway 
inflammation which shows a worsening airway inflammation and respiratory 
functions. 
2. Determine the role of corticosteroids in the exacerbations or worsening of allergic 
airway inflammation associated with viral respiratory infection. 
OBJECTIVE: 
- Establish the sensitivity of the ovalbumin airway allergic inflammation 
model to corticosteroids in the absence and presence of respiratory viral 
infection. 
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I. IN VITRO METHODS 
I.1. HUMAN PARAINFLUENZA VIRUS TYPE-3 (HPIV3) 
I.1.1. BSC-1 CELL CULTURE 
BSC-1 cells, epithelial cells of African green monkey kidney origin were purchased 
from ECACC Salisbury UK at passage 57. BSC-1 cells were grown in Dulbecco’s 
modified essential medium (DMEM) supplemented with 1% 2mM L-glutamine, 1% non 
essential amino acids, and 10% foetal bovine serum (FBS) at 37°C in a humidified 
incubator with 5% CO2. The cell line was passaged when the cells achieved confluency 
using trypsin ethylene di-amine tetra acetate (EDTA) to detach the cells. Once cells 
had detached, the trypsin was neutralized with media. Harvested cells in the medium 
were then passaged into several dilutions in the new flask as required. Cell lines were 
fed with the medium 2-3 times a week. Splitting of the cells can be started either from 
the frozen cells or the new passaged cell line when it reached 100% confluence.  
I.1.2. PREPARATION OF HPIV3 SUSPENSION (VIRUS STOCK) 
The HPIV3 strain MK9 stock was purchased from the National Collection of Pathogenic 
Viruses (NCPV). To make batches of the HPIV3 stock, confluent BSC-1 monolayer 
was used. The medium was removed from the cells in a 75 cm2 flask and virus solution 
was added to the cell monolayer to give ~ 2.8 x 107 viral particles per flask. After 5 
minutes adsorption period at 37°C in a humidified incubator with 5% CO2, 10 ml BSC-1 
medium as virus growth medium was added to the flask. The infected cells were then 
incubated at 37°C as above for 2-3 days before harvesting. As a control or sham, a 
flask containing BSC-1 cells without viral infection was also treated similar to that 
containing HPIV3 infected cells. 
At the end of the incubation period, after a clear cytopathic effect (CPE) characterised 
by a formation of syncytia, the cells were scraped from the bottom of the flask into the 
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media. The scraped cells were centrifuged at 1000 G for 5 minutes at 20°C to pellet the 
cells. Virus containing media (supernatant) or sham/control media was aliquoted and 
stored at -80°C until required.  
I.1.3. QUANTIFICATION OF HPIV3 VIRAL TITRE 
A wide range of techniques can be used to identify virus isolates. The number of 
infectious or non-infectious viral particles can be quantified by PCR, by determining the 
highest dilution of virus stock to produce cytopathic effects in 50% of cells (TCID50), or 
by enumerating the number of plaques which originated from a single viral particle. 
These viral quantification methods are also essential in testing antiviral activities. 
Compounds which have antiviral activity will reduce the ability of virus to infect or 
replicate thus should also reduce the titre of the virus (Cann, 1999).  
Several standard virus quantification techniques (RT-PCR, TCID50, and plaque assay 
using crystal violet as well as immunocytochemistry) were conducted and compared in 
this thesis to determine which was the most appropriate for subsequent experiments. 
I.1.3.1. QUANTIFICATION OF HPIV3 RNA BY LIGHT CYCLER PCR 
PCR (Polymerase Chain Reaction) has become a new standard in virology. In this 
method, each of a pair of oligonucleotides called primers hybridises one of a double 
stranded DNA (dsDNA) target. The primers along with DNA polymerase enable 
selective and repeated amplifications of the target gene region. The primer used in the 
experiments was purchased from Primerdesign, but the primer sequence is not 
available due to commercial reasons. PCR usually uses heat stable DNA polymerase 
derived from thermophilic bacterium Thermus aquaticus and called Taq. The DNA 
template is amplified exponentially as the PCR progresses. There are 3 important 
steps in PCR; dsDNA separation at >90°C, primer annealing at lower temperature 50–
75°C, and optimal extension at 72–78°C. A thermal cycle program control the cycle, the 
rate of temperature change, and how long the incubation is needed at each 
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temperature (Holland et al., 1991). The LightCycler is a new technology which was 
designed to combine the features of rapid PCR and real-time detection of an 
amplification product by FRET (fluorescent resonance energy transfer) analysis (Uhl et 
al., 2003). Rapid thermocycling as the feature of the LightCycler instrument has made 
rapid PCR possible (Uhl et al., 2003). In "real-time PCR", the detection of the 
amplification product occurs after each PCR cycle.  
I.1.3.2. NUCLEIC ACID EXTRACTION 
RNA was extracted from HPIV3 stock solution using the High Pure Nucleic Acid Kit, 
according to the manufacturer instructions. Two hundred µL working solution 
containing poly (A) and binding buffer as well as 50 µL of 2 mg Proteinase K carrier 
RNA solution was added to 200 µL HPIV3 stock solution. The mixture was incubated 
for 10 minutes at 72°C to extract the nucleic acid content. After being washed with 
washing buffer and filtered with high filter tube with the aid of centrifuge at 8,000 G 
several times, the extracted viral RNA was then eluted with 50 µL elution buffer in 
nuclease free sterile distilled water. The extracted RNA was immediately stored at –
80°C until use.  
I.1.3.3. REVERSE-TRANSCRIPTASE PCR 
RT-PCR was performed according to the manufacturer instructions by mixing 8 µl viral 
RNA, 1 µl of 10 mM deoxynucleoside triphosphates (dNTPs), 1 µl primer (0.5 µg/ µl 
oligo (dT)12-18, and DEPC-treated water to make a final volume of 10 µl in a sterile 0.5 
ml tube). The mixture was incubated at 65°C for 5 minutes in a cycle, and then was 
placed on ice for 1 minute. A reaction mix consisting of 2 µl of 10x reverse transcription 
(RT)-PCR buffer, 4 µl 25 mM MgCl2 , 2 µl 0.1 M DTT, and 1 µl RNaseOUT (40U/µl) was 
then added to the tube before incubation at 25°C for 2 minutes. After the second 
incubation, 1 µl (50 units) of Superscript II was added to the tube,  followed by 
incubation at 25°C for 10 minutes, 42°C for 50 minutes, 70°C for 15 minutes, and the 
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program was terminated at 5°C. The sample was used immediately for the Lightcycler 
reaction 
A Lightcycler TaqMan Master Kit was used as the basis for the reaction mixture in the 
LC-PCR assay; a 20-µl volume was used in each reaction capillary. Briefly, 5 µl of DNA 
template from the RT reaction was added to a capillary previously loaded with a 15 µl 
mixture of 4 µl mixture of master mix-ready to use hot start PCR reaction mix which 
contains LightCycler FastStart Taq DNA polymerase, reaction buffer, MgCl2 stock 
solution, and deoxynucleoside triphosphates (dNTPs) mix; 1 µl of PIV-3 primer or β-
actin (ACTB) primer; and sterile PCR-grade water to make the mixture up to 15 µl. 
Along with the sample, six positive controls to generate a standard curve and no-target 
controls consisting of 15 µl of reaction mixture and 5 µl of PCR-grade water were also 
included. Reaction capillaries were capped, centrifuged at 13,000 g, and then placed 
into a carousel of the LightCycler instrument. The LC-PCR protocol included the 
following parameters: an initial 10 min of pre-incubation at 95°C for FastStart Taq DNA 
polymerase activation followed by 50 cycles of amplification at 95°C for 10 seconds, 
annealing at 60°C for 60 seconds, and extension for cooling at 40°C for 30 seconds. 
The data were obtained during the annealing period with the channel set to detect 
emission from fluorescein which labels the RNA.  
I.1.4. QUANTIFICATION OF OF HPIV3 TITRE BY TCID50 
TCID50 is units of virus required to infect 50% of cells. BSC-1 cells were seeded onto 96 
well plates at a density of 2.3 x 103 cells/ml and then incubated at 37 °C in a humidified 
atmosphere containing 5% CO2 until reaching at least 95% confluency. The cell 
monolayer was then infected with 50 μl/well of serial dilution starting from 1 in 10 
dilution of the virus stock in the maintenance medium. After 2 hours of inoculation, 100 
μl/well BSC-1 maintenance media was added to each well. After 3 days of incubation at 
37 °C in a 5% CO2, the cell monolayer was washed with PBS three times and then 
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fixed with 2% formaldehyde in 0.1 M phosphate buffered saline (PBS) for 15 minutes at 
room temperature. The formaldehyde solution was then removed and subsequently, 
cells were washed three times for 5 minutes with 0.1 M PBS. After fixing and washing, 
0.1% crystal violet in 10% ethanol was added for 15 minutes. The dye was then 
removed and stained plates were washed with tap water until no colour identified in the 
washing water, and dried overnight. The viral titres were determined with plaque 
forming unit/ml or TCID50 by using Reed and Muench method (Reed and Muench, 
1938) (fig 2.1). 
 
Dilution of 
Virus  
#infected/#total  %wells infected 
10
-1
 8/8 100 
10
-2
 8/8 100 
10
-3
 8/8 100 
10
-4
 8/8 100 
10
-5
 6/8 75 
10
-6
 2/8 25 
10
-7
 0/8 0 
10
-8
 0/8 0 
10
-9
 0/8 0 
10
-10
 0/8 0 
 
Figure 2.1. Illustration on how to calculate quantitative viral biological activity (viral titre) which 
expressed in units of virus required to infect 50% of cells (TCID50)/ml based on Reed and 
Muench method (1938). 
Log PD = 75-50 x (Log10) 
    75-25 Log  
PD =  0.5 
Log Dilution above 50 %  =  10
-5
        
Infection  10
-5.5 
TCID50/50 μl
  
Or  6.32 x 10
6
 TCID50/ml
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I.1.5. QUANTIFICATIONOF HPIV3 TITER BY PLAQUE ASSAY 
I.1.5.1. AVICEL OVERLAY CONCENTRATION OPTIMISATION 
Some viruses can be easily quantified using plaque assays in standard culture 
medium, because these viruses undergo direct cell to cell spread which formed 
localized plaques. However, HPIV3 does not seem to form a clear plaque (fig.2.2). 
In viral quantification using plaque assays, the infected cell monolayer is usually 
covered with a nutrient medium that causes the formation of a gel type substance 
before incubation to restrict the original infected cells releasing viral progeny to the 
neighbouring cells hence produce localised observable plaques (Matrosovich et al., 
2006).  Matrosovich  et al (2006) have developed an alternative overlay method which 
overcomes some of the difficulties of conventional overlay methods such as agar, 
which is a quite a challenge to be used in 96-well plates.  The method utilises Avicel™ 
(microcrystalline water insoluble cellulose). The avicel overlay also produces larger and 
more obvious plaques compared to the conventional overlays.   
A stock suspension of Avicel™ (which kindly given by FMC Biopolymer, USA) was 
prepared (Matrosovich et al (2006) and a 2.4% Avicel™ suspension in distilled water 
was then stirred for 1 hour. The suspension was then sterilized by autoclaving and 
stored at room temperature. To vary the concentration of Avicel™ in the overlays, the 
original 2.4% stock was diluted in BSC-1 media. Concentrated (2.4%) Avicel™ stocks 
did not separate during storage. However, 2.4% avicel stock was always mixed before 
each use to make sure that the suspension was homogenous before being used as an 
overlay. In the first experiment, the recommended 1.2% Avicel™ solution was used as 
an overlay. However, no plaques were identified even from the highest concentration of 
virus stock. Therefore, experiments with lower concentrations of Avicel™ overlay were 
tested to determine the optimum concentration of Avicel™ overlay to produce visible 
plaques.  
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Two overlay concentrations of Avicel (0.3% and 0.6%) were tested for their suitability. 
BSC-1 cells were seeded in 96 well-plates at the density of 2.3 x 103 cells/ml. The cell 
monolayer was then infected with 50 μl/well of serial dilution of HIPV3 in the 
maintenance medium starting from 105 TCID50. After 2 hours of inoculation, 100 μl/well 
overlay of Avicel™ RC/CL in BSC-1 maintenance media was added to each well. The 
infected cell monolayers were incubated for 3 days. The overlay medium was then 
removed and the cell monolayer was fixed and stained as described previously. The 
dyed 96 well plates were scanned and the plaques produced by HPIV3 were counted. 
As shown in Figure 2.2, plaques were visible with 0.6% and 1.2% concentrations of 
Avicel™ overlays tested, but plaques were clearer with 0.6% Avicel concentration. 
Therefore, for subsequent experiments, in order to make the plaque visible, HPIV3 
infection on BSC-1 cells was incubated for 3 days with 0.6% Avicel™ overlay. 
 
Figure 2.2. HIPV3 infection on BSC-1 cells using different concentration of Avicel overlays. 
After 2 hours of virus adsorption, different overlays were added: A. 0.3%, B. 0.6%, C. 1.2%. 
After 3 days cells were fixed with 2% formaldehyde and stained with 0.1% crystal violet solution.   
I.1.5.2. QUANTITATIVE DETECTION OF HPIV3 BY PLAQUE ASSAY 
Plaque assay of viral infection in cell culture monolayers is the most common and 
simple method for quantification of infectious viruses and potential antiviral agents (Zhu 
et al., 2009). The replication of each viral particle produces a circular zone of infected 
and destructed cells known as plaque. The plaques will eventually become large 
enough to be visible to the naked eye. The plaque can be observed either as an area 
of destroyed cells identified by cellular stains  such as crystal violet or as an area of 
infected cells identified by immuno-staining (Cann, 1999). 
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I.1.5.2.1. CRYSTAL VIOLET PLAQUE ASSAY 
BSC-1 cells were seeded onto well plates and then incubated at 37 °C in a humidified 
atmosphere containing 5% CO2 until reaching at least 95% confluency. The cell 
monolayer was then infected with serial dilution of the virus in the maintenance 
medium. After 3 days of incubation (or clear cytopathic effects were visible), the cell 
monolayer was washed with PBS three times and then fixed with 2% formaldehyde in 
0.1 M Phosphate Buffered Saline (PBS) for 15 minutes at room temperature. The 
formaldehyde solution was then removed and subsequently, cells were washed three 
times for 5 minutes with 0.1 M PBS ready to be observed with visualisation methods. 
The example of how to calculate plaque forming unit (PFU) is displayed on figure 2.3. 
 
Figure 2.3. Illustration on how to calculate quantitative viral biological activity (viral titre) which 
expressed in a pfu (plaque forming unit) per ml  
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I.1.5.2.2. IMMUNOCYTOCHEMISTRY PLAQUE ASSAY 
The confirmative presence of HIPV3 infection can be detected using antibodies against 
the viral antigen in infected cells. The method is known as immunohistochemical 
(IHC)/immunocytochemistry (ICC) staining.  Monoclonal antibodies (MAbs) have been 
produced to all four major serotypes of HPIV and are commercially available. Usually 
these MAbs are very specific, although minor cross-reactivity has been reported 
(Henrickson et al., 1994). The experiment was performed to determine the HPIV3 
antigens using ICC staining of formalin-fixed HPIV3 infected BSC-1 cell lines. 
On a well plate, the completed incubation of HPIV3 infected cells were dried and 
washed as above and stored in PBS at 4°C until use. ICC staining was performed with 
the avidin–biotin–peroxidase complex (ABC) procedure (Haines et al., 1992), using 
commercially available immunoperoxidase kits. For immunocytochemistry, infected cell 
lines were incubated for 30 minutes with 20% methanol/1.5% H2O2 to inhibit 
endogenous peroxidase activity, and then the cells were washed three times for 5 
minutes in 0.1 M PBS. Cells were blocked from aldehyde active sites, for 30 minutes 
with 3% horse serum, 1% bovine serum albumin (BSA). Triton-X-100 (0.1 % in 0.1 M 
PBS) was also added to the well to permeabilise the cells. Subsequently, cells were the 
incubated with primary antibody (the monoclonal mouse HPIV3 antibody) diluted to 
1 : 500 in blocking solution at 4°C overnight in a sealed plate. On the next day, after 
three washes in PBS, the cells were incubated for 2 hours with a biotinylated anti-
mouse secondary antibody 1:500 in blocking solution. After washing 3 times with PBS, 
cells were incubated with avidin–biotin–peroxidase complex (ABC) for 45 minutes at 
room temperature.  The ABC mix has to be prepared by mixing the reagent with 0.1% 
Triton-X-100 in 5 ml of PBS, 30 minutes before its use. Once finished, cells were 
washed 3 times with PBS, and then incubated with Vector VIP substrate kit for 
peroxidase for 15 minutes. Stained plates were washed with tap water to stop the 
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reaction. As a negative control, non-infected cells were processed in an identical 
manner to the HPIV3-infected cells. For a negative antibody control, replicate wells of 
the HPIV3 infected cells were processed by substituting the mouse anti-HPIV3 
antibodies with the blocking solution. The ICC staining was also performed with anti β-
actin antibodies (ACTB) as a control (1:1000). 
 
Figure 2.4. Immunocytochemistry (ICC) staining 3 days post HPIV3 infection using avidin–
biotin–peroxidase complex (ABC) procedure. A. HPIV3 antigen was raised with monoclonal 
mouse HIPV3 antibody (1:500) and ACTB, crystal violet was also performed to confirm the 
infection B. The same procedures of ICC performed on non-infected cells 
In ICC staining experiments, the presence of HPIV3 viral antigens was detected in cells 
infected with virus. The ICC techniques for the detection of HPIV3 in cell monolayer 
can be more sensitive and reliable (Haines et al., 1992). However in this experiment, 
the staining did not show the localised and defined plaques which easy to be counted 
(fig 2.4). Therefore, for the subsequent experiments, crystal violet was used as a 
staining solution as it offers several advantages over ICC method, including; sharply 
defined plaques observed, the possibility for counting the plaques accurately and 
easily; the dry plate can be preserved after being fixed and stained, and thus can be 
counted at a convenient time. If needed, representative plates can be retained as 
permanent records of plaque size and morphology for comparison with those of later 
experiments. In addition, this procedure has been shown to give a good results on 
monkey kidney cell lines (Holland and McLaren, 1959).  
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I.1.6. VIRAL GROWTH ASSAY 
This study was performed to observe the kinetics of HPIV3 growth on the BSC-1 cell 
line. Both plaque assay and RT-qPCR were used to quantify the viral titers to allow 
comparison between the 2 methods of quantification. Therefore the experiments were 
performed in parallel in 2 different plates.  Medium was removed from confluent 
monolayers of BSC-1 cells on 24 well plates then 200 µl of HPIV3 was added at a 
concentration of 105 TCID50 units/ml. After 2 hours incubation at 37°C, 200 µl of 0.6% 
Avicel™ overlay was added on each well. To determine the time course of viral growth 
and release of virions into the medium with the RT-PCR method, the culture 
supernatants were collected at either 1, 2, 3, and 7 days after HIPV3 infection. At the 
specified day, the bottom of the well plate was scrapped and the whole volume of 
medium was then taken for measurement of viral content.  The same experiment was 
carried out in a well plate containing only media with no virus. The medium collected on 
each of the specified days was centrifuged at 300 g for 5 minutes. The supernatants 
were stored at 80°C for the determination of viral content, by RT-PCR or quantitative 
cell culture (plaque assay). The other plate which similarly treated (replicate plate) were 
washed with PBS, 3 times, fixed with formaldehyde and stained with 0.1% crystal violet 
as mentioned above. 
Viral infection and replication were confirmed by RT-qPCR and plaque assay showed 
that viral titers of lysates from infected cells increased with time, viral content 
progressively increased between 1 and 7 days after infection (fig.2.5). There was a 
high correlation of viral load (r2 = 0.944; n = 15, P < 0.0001) measured by quantitative 
RT-qPCR and viral titer by plaque assay (fig 2.6.). 
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Figure 2.5. Viral titers in supernatants of BSC-1 cells obtained at different times after exposure 
to 10
5
 units of virus required to infect 50% of cells (TCID50)/ml of HIPV3. Results are 
means ± SEM from 3 samples. 
 
Figure 2.6. Correlation of RT-PCR versus plaque assay (r
2
 = 0.944; n = 15, P < 0.0001). All 
quantifications were performed in triplicate. Dotted lines represent the 95% confidence limits for 
the slopes.  
The new molecular assays like PCR are rapidly replacing the time-consuming plaque 
assay method in clinical virology. When compared to the specific limitations of 
quantification by culture, RT-PCR offers several theoretical advantages, including: a 
lower threshold of detection, the potential stability of the assay after specimen freezing 
and thawing, and a less subjective assay readout. .  However, PCR is often unable to 
discriminate between infectious (‘alive’) and inactivated (‘dead’) virus. In this study, RT-
PCR was used along with tissue culture methods to determine the viral titre. Both 
methods showed a good reproducibility between experiments and showed a very 
significant correlation. 
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I.2. INFLUENZA A (H1N1/PR8) VIRUS 
I.2.1. MADIN-DARBY CANINE KIDNEY (MDCK) CELLS  
Influenza A virus can be grown in primary or continuous epithelial cells. Epithelial cells, 
such as MDCK, MEK, Vero, MRC-5, and LLC-MK2 cells have been reported to support 
the growth of influenza A virus. However, among these influenza A 
susceptible/permissive cell lines, the highest titres of the virus is isolated from MDCK 
cells (Schepetiuk and Kok, 1993). Consequently, MDCK epithelial cells are the most 
widely used cells in influenza A and B studies (Schepetiuk and Kok, 1993; Reina et al., 
1997) and therefore being used in the experiments. 
MDCK is a kidney epithelial cells of cocker spaniel which were kindly given by Dr. 
Awen Gallimore and Dr. Sarah Lauder (Cardiff institute of infection and immunity). 
MDCK cells were cultured in Iscove's Modified Dulbecco's Media (IMDM) 
supplemented with 0.5% heat inactivated fetal bovine serum (FBS), 10% peptone 
primatone, penicillin and streptomycin, insulin-transferrin-selenium and β-mercapto-
ethanol. The cells were incubated in a humidified atmosphere containing 5% CO2 at 
37°C. The cell line was passaged when confluent. Trypsin-EDTA was use to detach the 
cells. When cells were detached from the flask, IMDM containing 10% FBS was used 
to neutralise trypsin-EDTA. The detached cells in the media were then centrifuged at 
1000 G for 5 minutes at 20°C to pellet the cells. Cell pellet was re-suspended in MDCK 
culture media in the new flask as required. 
I.2.2. INFLUENZA A (H1N1/PR8) VIRUS PROPAGATION  
The original influenza virus strain A Influenza A virus (A/Puerto Rico/8/1934(H1N1)) 
stock was kindly given by Dr. Awen Gallimore and Dr. Sarah Lauder (Cardiff institute of 
infection and immunity). For propagation, 10-days old embryonated chicken eggs 
(Dekalb white from Henry and Stewart Co.) were inoculated with 100 μl of virus solution 
(virus stock 1:1000 in PBS) or PBS, applied to the allantoic cavity of the egg and the 
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punctured hole was then sealed with molten wax (fig 2.7). The influenza A and PBS 
inoculated eggs were then kept at 37°C for three days in an egg incubator. After 3 
days, egg embryos were killed by storing egg in 5°C for 90 minutes. Chorioallantoic 
fluid was collected and centrifuged (2000 rpm, 10 min) to remove cell debris. Virus 
stocks were aliquoted and stored at -80°C until needed to use. 
 
Figure 2.7. Embryonated chicken egg was inoculated with influenza A H1N1/PR8. Virus stock 
was injected into the allantoic fluid 
 
I.2.3. THE PRODUCTION OF ANTI-INFLUENZA A H1N1/PR8 MONOCLONAL 
ANTIBODY 
The hybridoma cell line producing anti-influenza A (H1N1/PR8) antibody was kindly 
given by Dr. Awen Gallimore and Dr. Sarah Lauder (Cardiff institute of infection and 
immunity). The production of antibody was carried out using Iscove's Modified 
Dulbecco's Media (IMDM) supplemented with 10% heat inactivated fetal bovine serum, 
1% penicillin and streptomycin, 10 ppm of IL-6, 0.1% of β -mercapto-ethanol, and 10% 
of cloning supplement. 
Cells were brought up from frozen by adding 20 ml of hybridoma growing media (37°C) 
into thawed hybridoma cells. The cell suspension was then centrifuged at 15000 rpm 
for 5 minutes. The cell pellet was suspended in 2.5 ml of media and then transferred 
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into 25 ml culture flask which was then incubated in a humidified atmosphere 
containing 5% CO2 at 37°C until they reached confluence (a week) and were ready to 
be harvested. 
I.2.4. ANTI-INFLUENZA A (H1N1/PR8) MONOCLONAL ANTIBODY 
PURIFICATION 
Once confluent, the media were collected and spun at 1000 rpm for 5 minutes at room 
temperature. The supernatant was then filtered by transferring into Ultracel® 100K tube 
which filters protein less than 100 KDa and concentrates the antibody. The tube was 
then subsequently centrifuged at 3000 G for 30 minutes at 10°C.  
The concentrated monoclonal antibody was then purified using MAb Trap Kit™ as per 
manufacturer instruction. MAb Trap Kit™ employs a chromatography principle to purify 
monoclonal antibody.  The MAb Trap Kit™ column was stored in 20% ethanol so this 
needs to be washed out with water before being used to elute the monoclonal antibody. 
The column was then equilibrated with 3 ml of binding buffer (0.2 M sodium phosphate 
pH 7). The monoclonal antibody was then loaded into the column to bind into the 
protein G which is highly crossed-linked with agarose beads. The column was 
subsequently washed with binding buffer to remove contaminant proteins. The bound 
monoclonal antibody (IgG) was then eluted with 3ml elution buffer (1.0 M glycine-HCl 
pH 2.7). The concentration of pure IgG produced was detected with Nanovue 
spectrophotometer™.   
I.2.5. QUANTIFICATION OF INFLUENZA A (H1N1/PR8) VIRUS TITRE BY 
PLAQUE ASSAY 
Trypsinised MDCK cells were plated on 24 well-plate at a density of 10 x 105/ml (200l 
of cells/well) then incubated at 37°C in 5% CO2 atmosphere for 24 hours. The next day, 
the media was replaced by 200l of a serial dilution of virus influenza A (H1N1/PR8) in 
the MDCK growing media (starting from 1:250 dilution and then diluted 1:3 afterward).  
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The plate was then incubated at 37°C in 5% CO2 for 5 hours to allow the virus to infect 
MDCK cells. After incubation, 300 l of 1.2% avicel overlay solution (from a mixture of 
2.4% avicel stock and MDCK growing media 1:1) was added to the well. The plate was 
then incubated at 37°C in 5% CO2 for further 48 hours. 
After 48 hours, the media was removed and cells were washed three times with 600 l 
of PBS. Cells were then fixed with 400 µl of 4% formaldehyde/well for 45 minutes and 
washed with PBS. The cells were permeabilised by adding 250µl/well solution 
containing 0.5% TritonX-100 in PBS for 30 minutes. The residual aldehyde groups 
were subsequently blocked with 400 µl/well of 10% FCs in PBS for 90 minutes. After 
being washed with PBS three times, cells were incubated with 200 µl/well of primary 
antibody (1:500) for 90 minutes, washed with PBS 5 times then followed by 90 minutes 
incubation with 200 µl/well of antimouse IgG-HRP antibody (1:1000). Finally, a 300 
µl/well developing solution of aminoethylcarbazole (AEC) (0.4 mg/ml) in 0.05 M sodium 
acetate buffer, pH 5.5, containing 0.03% H2O2 was added to the well and incubated in 
the dark for 60 minutes then washed with tap water 3 times. The infected cells will 
develop pink-reddish colour (fig. 2.8) which can be scanned and analysed. 
 
 
 
 
Figure 2.8. Infection with Influenza A (H1N1/PR8) in MDCK cells. Cultures were immunostained 
with aminoethylcarbazole (AEC) 
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II. IN VIVO METHODS 
II.1. ANIMAL 
Male BALB/c mice weighing 20-25 g were obtained from Harlan UK Ltd.  All animals 
were housed at the laboratory animal facilities of Cardiff University. Cages which were 
equipped with a sawdust base, cardboard tubes, and a removable grid roof were 
placed in an air-conditioned room at 24°C in a 12-hours light–dark cycle at 
approximately 50% humidity. Food and water were available ad libitum. All animals 
were acclimated for a period of at least 7 days upon arrival before any experimental 
work began. The mice were also exposed to the system that measures their airway 
functions adapt them to a new environment and to make the animal familiar with the 
equipment when readings were taken. The studies were conformed to the U.K. Animals 
(scientific procedures) Act 1986, under valid Home Office project and personal 
licenses.  
II.1.1. INDUCTION OF ALLERGIC INFLAMMATION OF THE AIRWAYS  
II.1.1.1. SENSITISATION 
Mice were sensitized on days 0 and 5 by 0.25 ml intra peritoneal (i.p.) injection of 
ovalbumin (OVA, 50μg/mouse) and Al (OH)3 (aluminium hydroxide) (10%, 50 
mg/mouse) suspension in saline solution which had been mixed for at least 2 hours to 
ensure ovalbumin being absorbed properly on the particle of aluminium hydroxide. 
Al(OH)3 is needed as an adjuvant to boost the immune response and promote the 
production of Th2 cytokines (Kumar et al., 2008).  
II.1.1.2. NONINVASIVE MEASUREMENT OF AIRWAY RESPONSIVENESS  
Unrestrained whole body plethysmography is commonly used to evaluate bronchial 
responsiveness in mice because it is easy to use and non-interventional. As no 
restraint is involved, stress is reduced and normal breathing patterns occur. Despite 
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this, in this experiment, mice still need to be habituated by introduces them to the 
chamber at least a week before any experiments began. 
 In unrestrained plethysmography, mice are placed inside a closed chamber, where 
they are free to move within. Pressure changes which are caused by respiration are 
measured within the chamber. Changes in the mouse's breathing pattern can be 
predicted and measured during bronchoconstriction and the changes in breathing 
pattern are correlated with the change in airway physiology. Therefore the calculation 
of enhanced pause (Penh) can be made. Changes in Penh have been commonly used 
as a measure of airway responsiveness to monitor the respiratory dynamics of 
unrestrained mice in a quantitative manner before and after bronchococonstrictor 
(methacholine) challenge. Penh is increased when airway obstruction is observed 
(Lundblad et al., 2002). Figure 2.9 shows the plethysmography system used in the 
experiments. 
On day 11 and 18, body weight of each mouse was recorded and mice were allowed to 
acclimate to the chamber before recordings were made. Then, respiratory activity was 
recorded for 5 min, to establish baseline value for Penh. Mice were subsequently 
exposed to increasing concentration of aerosolized methacholine 
(acetyl‐β‐methylcholine chloride) dissolved in saline. The procedures were performed 
with preselected flow rate; length of intermittent methacholine exposures, and length of 
dryer time according to buxco equipment guideline.  Plethysmographic data are 
recorded for another 5 minutes after aerosol administration. The Penh values 
measured during each 5 minutes sequence were averaged and were expressed for 
each methacholine concentration.  
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Figure 2.9.  A schematic of the equipment for the measurement of respiratory function 
expressed as enhanced pause (Penh) in unrestrained, conscious mice (Buxco®). The 5 main 
parts of the equipment are indicated: A. Airflow regulator, which maintains a constant flow of 
clean air inside the plethysmographic chambers; B. Whole body plethysmograph with mouse 
plexiglas chambers, where it is free to move. A port at the top of the chamber is connected to a 
nebulizer to allow administration of aerosolized chemicals i.e. methacholine chloride. Each 
chamber has a coupled transducer that transforms the respiratory signal into an electrical signal 
and sends it to the amplifier; C. Amplifier, which receives the signals from the transducer in 
each chamber, amplifies and translates them into data which can visualized and analysed on 
the computer (D) using FinePointe software; E. Nebulizer, which delivers methacholine chloride 
as an aerosol into each chamber at a preselected, constant flow rate. 
 
II.1.1.3. OVALBUMIN CHALLENGE 
On day 17, to trigger the effector of asthma, mice were challenged by inhalation of a 
0.5% (w/v) OVA aerosol in 0.9% sodium chloride solution (saline) for 1 hour, twice on 
the same day, 4 hours apart. The exposure was carried out in a perspex chamber (38 
cm length; 20 cm width; 20 cm height) with a DeVilbiss nebuliser attached. Values of 
Penh following allergen challenge were recorded for 3 minutes at 0, 20, 40, 60, 90 and 
120 minutes, then hourly until 10 hours followed by a final reading at 19 hours (or 24 
hours after the first ovalbumin challenge). The Penh values which were measured 
during each 3 minutes sequence were averaged and were expressed for each time 
point as the percentage of baseline Penh values. 
Aerosol inlet 
  0.000  1.000  2.000  3.000  4.000  5.000  6.000  7.000seconds
-135.000
-130.000
-125.000
-120.000
-115.000
-110.000
m
l 
a
ir
/s
e
c
F
lo
w
-13.6000
-13.5000
-13.4000
-13.3000
-13.2000
-13.1000
m
l 
a
ir
B
o
x
 V
o
lu
m
e
E 
CHAPTER II  
 
58 
 
 
Figure 2.10. Diagram of murine model of ovalbumin induced allergic airway inflammation  
 
II.1.2. ASSESSMENT OF PULMONARY INFLAMMATION 
II.1.2.1. CELLULAR INFILTRATION 
After the second methacholine chloride provocation, mice were sacrificed. Terminal 
anaesthesia was induced with pentobarbitone sodium (Euthatal 400 mg/kg) overdose 
(intraperitoneally). An incision of the skin above the thymus was performed; the tissue 
was retracted until the trachea was visible. An incision was made in the trachea and a 
cannula was inserted and held in place. One ml of PBS solution was introduced via the 
trachea, 3 minutes later, bronchoalveolar lavage (BAL) fluid was withdrawn from the 
lungs of the mice. This process was repeated three times. The fluid withdrawn was 
stored on ice. Two measurements of cellular influx i.e. total cell count (per ml of lavage 
fluid) and differential cell count were performed on BAL fluid (BALF).   
II.1.2.1.1. Total Cells Counts 
Total cells were manually counted using a Neubauer hemocytometer under a light 
microscope at 40 x magnification. The tip of pipette contained BAL fluid (100 μl) was 
held at an angle of approximately 45
o
 (higher or lower to control flow rate) at the 
leading edge of the coverslip on the haemocytometer. Capillary action allows the fluid 
to flow quickly and distributed evenly into the chamber. The cells were allowed to set 
for 1 min. The haemocytometer has two grids of 25 squares which can be observed 
under the microscope. The number cells in 5 of the squares was always counted in the 
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same manners starting from the top left, top right, middle, bottom left and then bottom 
right. The total number of cells obtained was multiplied by 5 to give an estimated 
amount of cells in 25 squares. The process was repeated for another grid on the 
haemocytometer and then the results were averaged. As each of the squares measure 
0.04 mm2 and 25 were counted, a figure of number of cells per 1 mm2 was established. 
However, the depth of the chamber was 0.1 mm, therefore giving a number of cells per 
0.1 mm3. As the number of cells per 1 ml (1 cm3) was required, the cell count figure 
was multiplied by 104.    
II.1.2.1.2. Differential Cells Counts 
The differential cell count was performed to determine the different number of 
leucocyte types. Smears of BAL fluid cells on microscope slides were prepared for 
differential cell count by cytocentrifugation of 100 µl samples at 1000 rpm for 7 min 
using a Cytospin at room temperature. After they had been air dried for approximately 
1 hour, all slides were differentially stained with 0.15% Leishman's stain (eosin-
polychrome methylene blue) in 100% methanol, pH 6.4-6.6 for 7 minutes. The stained 
slides were then air dried overnight. A minimum of 200 cells were counted and 
differentiated under a light microscope at 100 × magnification. Standard 
haemocytological procedures were used to identify four different types of leucocytes in 
the BAL fluid samples: lymphocytes, macrophages, eosinophils and neutrophils. 
Results are expressed as a percentage of the total number of cells counted. The 
remaining BAL fluid was centrifuged at 3800 rpm for 6 minutes; the supernatant was 
then aliquoted and stored at -800 C.  
II.1.2.2. LUNG OEDEMA/PROTEIN EXTRAVASATION 
The albumin concentration in BAL fluid has been used as a marker of the pulmonary 
tissue permeability (Minne et al., 2008). Increase in tissue permeability leads to the 
movement of protein-rich fluid into the tissue space. Inflammatory leukocytes 
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accumulation also contributes to the permeability oedema by releasing their mediators 
which increase the microvessel permeability and attract more leukocytes into the site of 
inflammation (Scallan et al., 2010). 
Total protein content in the BAL fluid was determined using bicinchoninic acid (BCA) 
method. Briefly, 10 µl of BALF samples were added to the 96 well-plate. In the same 
plate, PBS was also added as a negative control (blank) and serial dilution of albumin 
with a range of 0.025-2 mg/ml was used to determine a standard curve. Samples were 
mixed with 200 µl working reagent (a mixture of 50 part of reagent A and 1 part of 
reagent B) and then incubated at 37°C for 30 minutes. After 10 minutes period to cool 
the plate, it was read at 540 nm on a plate reader. The absorbance of the samples 
were plotted against the albumin standard curve to determine the BALF protein 
concentrations. 
II.1.2.3. LUNG HYSTOLOGY 
Once BALF withdrawal was completed, the ribcage was opened then the trachea and 
lung were removed from the animal. The right lobes of the lung were excised and 
frozen at -800 C for viral titre quantification or cytokines measurement if required. The 
large left lobe of the lung was immersed in phosphate buffered formaldehyde for 
histological analysis. 
II.1.2.3.1. Fixation and Tissue Processing 
To be able to be viewed and analysed under microscope, lung tissue must be prepared 
as a very thin translucent section before they were stained. This process involves fixing 
the tissue in 4% buffered formaldehyde to preserve it and then embed the tissue in a 
paraffin block to harden and support it in the slicing process. 
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The fixed tissues were placed in histology cassettes then processed by dehydrating the 
tissues with ethanol, clearing ethanol with chloroform and infiltrating/embedding them 
with paraffin/wax as follows: 
- 50% ethanol for 1 hour 
- 70% ethanol for 1 hour 
- 90% ethanol for 1 hour 
- 100% ethanol for 1 hour 30 minutes 
- 100% ethanol for 1 hour 30 minutes 
- 100% ethanol for 1 hour 30 minutes 
- 50% ethanol:50% chloroform overnight 
- Chloroform for 1 hour 30 minutes 
- Chloroform for 1 hour 30 minutes 
- Paraffin wax for 2 hours 
- Paraffin wax for 2 hours 
- Paraffin wax for 2 hours 
At the end of the procedure, the tissues were removed from cassettes then placed with 
the desired orientation on a stainless steel base mould. The mould allowed the wax to 
be decanted into the cassettes during the embedding and secure the tissue in the wax 
when the moulds were cooled on a cooling plate at -300C. The tissue now secured and 
set in the paraffin wax was ready to be sliced with microtome as a thin section (5 µm). 
The sliced thin section was placed on a microscope slide by floating the section out on 
a water bath (300C) and then picked it up with the slide. The slide sections were then 
dried at room temperature overnight ready to be stained on the next day. 
II.1.2.3.2. Tissue staining 
The first procedure in the tissue staining is de-waxing by using Histoclear to remove 
the wax from the slides and rehydrated it with a series of graded ethanol for 5 minutes 
before being stained. At the end of staining, the reverse process, dehydration, is 
CHAPTER II  
 
62 
 
applied to the tissue, and completed with the use of Histoclear to rinse ethanol out of 
tissue. 
II.2.1.3.2. Haematoxylin and Eosin (H and E)  
H and E staining is a routine staining procedure because it shows very detailed view of 
the morphology tissue by clearly stain cell structure including differentiation between 
the nucleus and cytoplasma. The step by step procedures of H & E staining described 
as follow: 
- Histoclear for 5 minutes 
- Histoclear for 5 minutes 
- 100% ethanol for 5 minutes 
- 100% ethanol for 5 minutes 
- 90% ethanol for 5 minutes  
- 70% ethanol for 5 minutes 
- Distilled water for 5 minutes 
- Mayer’s Haematoxylin for 3 minutes 
- Running tap water for 5 minutes 
- Rinse in distilled water 
- Scott’s tap water for 5 seconds 
- Running tap water for 5 minutes 
- Rinse in distilled water 
- Eosin Y for 1 minute 30 seconds 
- Running tap water for 5 minutes 
- Rinse in distilled water 
- 70% ethanol for 5 minutes 
- 90% ethanol for 5 minutes  
- 100% ethanol for 5 minutes 
- 100% ethanol for 5 minutes 
- Histoclear for 5 minutes 
- Histoclear for 5 minutes 
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II.1.2.3.3. Histopathology 
When staining was completed, the slide was mounted with Histomount and covered 
with a coverslip to make the tissue permanent on slide. Analysis of the dried prepared 
tissue was performed under a Leica DMRAZ microscope equipped with Leica DC500 
camera and Leica QWin software to capture the picture. 
II.2.1.3.3. Haematoxylin & Eosin for general morphology 
The H & E staining is mainly aimed to assess histological change in the lung 
particularly peribronchial inflammation and inflammatory cells infiltration. The sections 
were graded subjectively by blinded investigators using semiquantitative scoring 
method on three (upper, middle, and lower parts) 100 times fields of lung section 
images. The parameter used in scoring system was peribronchial inflammation (0-3), 
perivascular inflammation (0-3), epithelial desquamation (0-3), and the evidence of 
haemorrhage (0-3) to give a score ranging from 0 – 12 (Table 2.1) (Longhi et al., 2007; 
Nandedkar et al., 2008). 
 
Figure 2.11. Photomicrograph showing lung histology of OVA sensitised and challenged mice. 
Tissue was stained with H & E, 100X magnifications. 
 
 
CHAPTER II  
 
64 
 
Table 2.1.Lung histology scoring system  
Feature Scored Score Descriptions 
Peribronchial inflammation 0 = None 0 - 3 layers of inflammatory cells 
1 = Mild 3 -6 layers of inflammatory cells 
2 = Moderate 6 - 10 layers of inflammatory cells 
3 = Severe More than 10 layers of inflammatory cells 
Perivascular inflammation 0 = None 0 - 3 layers of inflammatory cells 
1 = Mild 3 -6 layers of inflammatory cells 
2 = Moderate 6 - 10 layers of inflammatory cells 
3 = Severe More than 10 layers of inflammatory cells 
Epithelial desquamation 0 = None Normal intact airway epithelial lining  
1 = Mild 
Elongation and distortion of the cuboidal/columnar 
epithelial cells lining the airways  
2 = Moderate 
Elongation associated with in folding of the epithelium 
and narrowing of the airway lumen  
3 = Severe 
Epithelial cells shedding or loss of epithelial cells with 
cell debris inside the bronchial lumen 
Haemorrhage 0 = None No haemorrhage  
1 = Mild Vascular or alveolar haemorrhage  
2 = Moderate Vascular and alveolar haemorrhage  
3 = Severe 
Severe vascular and alveolar haemorrhage, affecting 
more than 50% of the captured area  
 
III. STATISTICAL ANALYSIS 
Statistical analysis was performed using the software package PRISM, version 5.0. 
ANOVA (One way analysis of variance) followed by Bonferroni’s post hoc test were 
used to compare 2 or more groups. Student’s t-test was used to compare the 
difference between groups. P values <0.05 were considered significant and were 
denoted with an asterisk. 
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CHAPTER III 
EFFECTS OF CORTICOSTEROIDS ON RESPIRATORY 
VIRAL INFECTION IN VITRO 
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I. INTRODUCTION 
Viruses are an infectious agents of small size and simple composition that can multiply 
only in living cells of animals, plants, or bacteria (Wagner, 2013). According to its 
definition, viruses which are composed of either DNA or RNA, are basically parasites 
because outside the host cell, these organisms do not have any metabolic activity 
hence are totally dependent on the host cells for life (Harper, 1998).  
Respiratory viral infections are responsible for most cases of medical consultation with 
the consequence of morbidity, hospitalization and mortality, throughout the world (Abed 
and Boivin, 2006). Respiratory viral Infections also cause significant socio-economic 
loss mostly because of lost of productivity or absenteeism. Respiratory viral infections 
affect any age group. The more severe clinical complications particularly affect 
immunocompromised patients, children and the elderly (Message and Johnston, 2001).  
Respiratory viruses are mostly airborne and tend to have a higher level of circulation 
during winter in subtropical countries. In the UK, the most common viruses to cause 
seasonal outbreaks are Respiratory Syncytial Virus (RSV), influenza and 
parainfluenza, rhinovirus, adenovirus, coronaviruses, coxsackievirus and human 
metapneumovirus (Tregoning and Schwarze, 2010). This chapter will focus on the 
infection of 2 of the most common respiratory viruses i.e human parainfluenza virus 
type 3 (HPIV3) and influenza virus 
I.1. PARAINFLUENZA VIRUSES  
Human parainfluenza viruses belong to the Paramyxoviridae family which also include 
mumps, measles, and RSV. They account for a major cause of respiratory disease 
particularly in neonates and infants. The parainfluenza viruses are divided into four 
different serotypes: HPIV-1, 2, 3 and 4. HPIV-1 and HPIV3 are responsible for roughly 
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15% cases of colds, croups, bronchitis and pneumonia in children which usually last for 
7-10 days (Denny and Clyde, 1986).  
I.1.1. STRUCTURAL ORGANISATION  
HPIV3 which is described as a pleomorphic enveloped virus, is a single-stranded, 
nonsegmented, negative strand RNA virus. Its 15,462 base genomic RNA of negative 
polarity encodes six common structural proteins critical for viral replications i.e. 3'-N-P-
C-M-F-HN-L-5' (Bose et al., 2001). The N, P, and L HPIV proteins are the RNA 
polymerase proteins and nucleocapsid protein, whereas HN (hemagglutinin-
neuraminidase) and F (Fusion) proteins are two surface glycoproteins and M protein is 
the matrix protein which is responsible for viral assembly and budding (Henrickson, 
2003). 
 
Figure 3.1. Structure of human parainfluenza virus type 3 (Moscona, 2005) 
 
I.1.2.  VIRAL REPLICATION  
HPIV3 infection is started by viral binding into the target cells. The HN glycoprotein of 
the HPIV3 interacts and attaches to the sialic acid-containing cell surface receptor. 
Subsequently, the viral envelope fuses with the plasma membrane of the cells via viral 
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fusion protein F and then uncoats the genome RNAs. Transcription in the cell 
cytoplasma is aided by virus-specific RNA-dependent RNA polymerase (L protein) 
(Henrickson, 2003; Moscona, 2005). The viral mRNAs produced are then translated 
into viral proteins by the host’s ribosomes which directs the replication of the virus 
genome into a positive-sense RNA strand and then into the negative strand. The single 
negative strands of RNA which is then encapsidated with NP may be used in further 
transcription and replication or exported as a new virion (Holtzman et al., 2002).  
 
Figure 3.2. Schematic representation of the life cycle of parainfluenza virus (Moscona, 2005). 
I.1.3. PATHOGENESIS  
Airways epithelium seems to be major site of virus binding and infection. The HPIV 
replications result in the influx of inflammatory cells into the airways and this seems to 
be more responsible for the manifestation of clinical symptoms than the cytotoxicity of 
viral infection.  Epithelial damage as a result of the secondary inflammation leads to 
necrosis of cells, increasing mucus secretion, as well as airway obstruction 
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accompanied by wheezing and coughing known as bronchiolitis, cold, croups, and 
pneumonia (Moscona, 2005, Henrickson, 2003).  
I.1.4. PREVENTION AND CONTROL  
Several compounds including neuraminidase inhibitors (zanamivir), protein
 
synthesis 
inhibitors (puromycin), and nucleic acid synthesis inhibitors (acyclovir) have been found 
to have antiviral activity against paramyxoviruses
 
in vitro (Henrickson, 2003). However, 
none of those drugs have been applied clinically. Ribavirin has been proven to have in 
vitro and in vivo antiviral activity
 
against HPIV (Browne, 1981). However, it also has 
been reported that established
 
HPIV3 pneumonias responded poorly to ribavirin (Nichols 
et al., 2001). So, currently no antiviral drugs have been proven to have clinical efficacy 
against HPIV3 infections. There is also no licensed HPIV vaccine available at the 
moment in the market. Although there is a study which shows that the live attenuated 
HPIV3 vaccine can induce good humoral immune responses in seronegative children 
(Belshe and Hissom, 1982). Several studies, some of which are meta-analysis, have 
shown the effectiveness and efficacy of oral or systemic
 
steroids in improving 
symptoms of croup as early
 
as 6 h after treatment (Somani and Evans, 2001). 
Therefore the administration of a corticosteroid, particularly dexamethasone, is 
recommended to be considered even in mild croup (Zoorob et al., 2011).  
I.2.  INFLUENZA VIRUS  
Influenza virus infection is causing a massive global burden of 1 billion cases per year, 
with an estimated 300,000-500,000 number of mortalities worldwide (Girard et al., 
2008; Girard et al., 2010). Influenza virus is highly contagious, spreading via droplets of 
aerosols from infected people and causing acute respiratory diseases.  Epidemics and 
sporadic pandemics because of the virus are regarded to be a major cause of morbidity 
and mortality worldwide (Cox and Subbarao, 1999). Influenza-related pneumonia has 
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been established as a leading cause of infectious disease-related deaths especially in 
the elderly.  The common clinical symptoms of influenza infection are fever and chills, 
accompanied by dry cough, headache, fatigue, myalgias, and general discomfort (Cox 
and Subbarao, 1999; Hilleman, 2002).  
Influenza viruses i.e. Influenza A, B and C viruses make up 3 of the 5 genera of the 
Orthomyxoviridae family. Influenza A is clinically the most important to humans, as it 
has the ability to undergo antigenic drift and shift to survive in the human population. 
As a consequence of this antigenic shift and drift, influenza A viruses are categorised 
into several subtypes, based on the type of their hemagglutinin (HA) and 
neuraminidase (NA) proteins. Seventeen different types of hemagglutinin (H1-H17) 
antigen and 10 different type of neuraminidase antigens (N1-N10) have been identified 
so far (Das et al., 2010).  H1N1 is a subtype of Influenza A which has been declared by 
the World Health Organization as a pandemic in June 2009. This virus is also endemic 
in pigs and birds (WHO, 2009). Influenza A H1N1/PR8 is a historic strain which caused 
a local outbreak of infection in Puerto Rico in 1934 (Hannoun, 2013). 
I.2.1. STRUCTURAL ORGANISATION  
Influenza A, is an enveloped virus with a genome made of a negative single-stranded 
segmented RNA. The segmented genome, contains 8 segments which encode for 11 
viral genes i.e. HA (hemagglutinin), NA (neuraminidase), M1 (matrix 1), M2 (matrix 2), 
NP (nucleoprotein), NSP1 (non-structural protein 1), NS2 or NEP (non-structural 
protein 2), PA (polymerase acidic protein), PB1 (polymerase basic protein 1), PB2 
(polymerase basic protein 2) and PB1-F2 (polymerase basic protein 1 – F2) (Zhang et 
al., 2000). 
Most of influenza virus virions are roughly spherical in shape. Three viral 
transmembrane proteins: HA, NA, and M2 make up the lipid bilayer viral envelope 
(Deng et al., 2006). The most abundant (80%) envelope protein is HA, while NA protein 
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makes up around 17 percent and M2 protein is only making up a small proportion of 
envelope protein in about 16 to 20 molecules per virion. Covered by the viral lipid 
membrane envelope is the core of the virus, the viral ribonucleoproteins (vRNPs), 
which are held by a matrix made up from M1 protein. The vRNPs which are viral 
negative stranded RNAs, are coiled up around NP and a bit of NEP. The three 
polymerase (3P) proteins (PB1, PB2 and PA) which function as the viral RNA 
polymerase complex are positioned at one end of the vRNP (Zhang et al., 2000). 
I.2.2. VIRAL REPLICATION  
The surface of the viral envelope is spiked with membrane glycoproteins, hemagluttinin 
(HA) and neuraminidase (NA) and a small number of M2 (figure 3.3). The HA binds to 
the host cell sialic acid receptors and initiates receptor mediated endocytosis.  The 
virus is entering the cell via the endocytic vesicle formed. The endosomal vesicle has a 
low pH which enables the fusion of the viral and endosomal membrane as well as 
opening up the M2 ion channel. The opening of the M2 ion channel leads to the release 
the vRNPs from M1 to enter the host cell’s cytoplasm (Watanabe et al., 2003). NP, PA, 
PB1, and PB2 which make up vRNP have nuclear localization signals (NLSs) 
properties which aid the entry of the vRNP into the nucleus to start transcription and 
replication.  The viral genome then enters the nucleus to begin transcription by 
performing a ‘cap–snatching’ mechanism. The viral polymerase complex (PB1, PB2 
and PA) binds to the 5’ cap of the host mRNA and cleaves the 10-13 nucleotides. So, 
the capped host mRNA fragments can be used as primers for each of 8 viral mRNA 
gene segment transcriptions.  After being transported into the cell cytoplasm, viral 
mRNAs subsequently perform a translation process.  Each of the 6 newly transcribed 
mRNAs encodes 1 viral protein, while each of 2 other RNA transcripts are spliced to 
encode 2 proteins. The viral membrane glycoproteins (HA, NA, and M2) are processed 
in the endoplasmic reticulum and glycosylated in the golgi apparatus.  The viral 
polymerase complex also primes the old negative sense viral mRNA, through the 
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production of cRNA (copy RNA) which then translated into the new negative sense viral 
mRNA. The assembly of the newly formed virions are performed at the host cell 
membrane where the virus budded out and then released by the help of NA protein to 
cleave the sialic acid receptor binding to make them free to invade other host cells das 
(Samji, 2009; Das et al., 2010). 
 
Figure 3.3. Structure and schematic illustration of the life cycle of influenza virus (Das et al., 
2010).  
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I.2.3. PATHOGENESIS  
Epithelial cells of the airways are the primary site of influenza virus replication.  The 
infection causes destruction and desquamation of the epithelium in the trachea and 
bronchi. Oedema and congestion are also often observed. Pathological changes due to 
the infection occur throughout the respiratory tract, particularly in the lower respiratory 
tract. The destructed epithelial cells trigger the influx of inflammatory cells into the 
airways which contributes to the clinical characteristics of the infection, such as fever, 
myalgia and dry cough. Depending on the host’s immune system, influenza infection 
could recover within a few days but could also develop into primary pneumonitis 
especially in immunocompromised individuals. The influenza infection might also lead 
to secondary bacterial infections which could develop into a fatal form of pneumonia 
(Wright and Webster, 2001; Hilleman, 2002).   
I.2.4. PREVENTION AND CONTROL  
Currently, vaccines are by far the most effective means of preventing influenza virus 
infection, either for prevention, or minimising the severity of the disease caused by the 
influenza virus. However, it is still hard to predict whether vaccine alone would be able 
to prevent an influenza pandemic break (Nistal-Villan and Garcia-Sastre, 2009).  
At the moment, there are four antiviral drugs for approved treatment of influenza virus 
infections including; M2 ion channel inhibitors (amantadines and rimantadines), which 
inhibit viral replication of influenza by interfering with the M2 protein and neuraminidase 
inhibitors (oseltamir and zanamivir). Neuraminidase inhibitors prevent virus release 
from the host cell by competing with sialic acid to bind with NA consequently the viral 
cleaving process from the host cells is blocked and the virus would be inhibited to infect 
the neighbouring cells (Abed and Boivin, 2006). However, albeit being proven to be 
effective, some studies found that many influenza strains have developed resistance 
toward M2 inhibitor and there is also increasing evidence of viral resistance towards 
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oseltamivir (Carr et al., 2002; van der Vries et al., 2010). Although there is an 
interesting fact that most oseltamivir resistant strain are still sensitive to zanamivir (Hurt 
et al., 2006). The reason could be because of the different chemical structure between 
those two. Zanamivir contains a guanidine group, hydrophilic chain and can only be 
administered via inhalation hence has limited use, while oseltamivir structure contains 
an amino group, hydrophobic chain, and has a high oral bioavailability hence has been 
used extensively (Collins et al., 2008).  
I.3. THE AIRWAY EPITHELIUM AND RESPIRATORY VIRAL 
INFECTION 
The airway is protected physically and functionally from the external environment by 
epithelial cells. The cells also play an important role in initiating and regulating innate 
and adaptive immune responses in the airways. Most if not all respiratory tract viruses 
enter and replicate within airway epithelial cells.  During the infection, the epithelium 
can be injured, which causes of loss of integrity and protection of both ciliated and non-
ciliated respiratory epithelial cells, and leads to necrosis of the airway epithelium, 
ciliostasis, loss of cilia, and impairment of mucociliary clearance (van der Schans, 
2007; Thornton et al., 2008). However, it is likely that the clinical manifestations might 
be secondary to the release of pro-inflammatory mediators by damaged bronchial 
epithelial cells rather than a direct cytotoxic effect of the virus (Jackson and Johnston, 
2010). 
Several cell lines support the growth of HPIV3. The most common are LLC-MK2, Vero, 
CV-I, primary cynomologus and rhesus monkey kidney, Wish, HMV-II, HEp-2, MDCK, 
BHK, HeLa, primary human embryo, KB, Am, HEB' L929, HEF and BSC-1 (Genest and 
Daniel, 1966; Frank et al., 1973; Belshe and Hissom, 1982; Moscona and Galinski, 
1990). HPIV3 can also replicate in organ cultures from mouse, guinea pig, ferret, and 
human fetal respiratory epithelium (Bando et al., 1991).  All HPIV demonstrate greater 
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cytopathic effects on adaption to a particular cell line, with HPIV3 being the most 
aggressive (Henrickson, 2003).  
Apart from the growth in allantoic sac of embryonated egg, influenza A virus can also 
be grown on primary or continuous epithelial cells. Madin-Darby canine kidney (MDCK) 
epithelial cells are the most widely used cells in influenza A and B studies (Schepetiuk 
and Kok, 1993; Reina et al., 1997). Other epithelial cells, such as MEK, Vero, MRC-5, 
and LLC-MK2 cells also have been reported to support the growth of influenza A virus, 
although the titres of the virus isolated from these cell lines were significantly less than 
MDCK (Schepetiuk and Kok, 1993). 
In terms of in vitro viral studies, cell lines are said to be permissive when they support 
the replication and multiplication of the virus. Viral infection in permissive cells usually 
results in cells death, so the infection is known as cytocidal or cytolitic infection. The 
characteristic of cytocydal infection is morphologic changes of the infected cells defined 
as cytopathic effects (CPE) which can be visualised in stained cells or in unstained 
cells under light microscope (Albrecht et al., 1996).  
Depending on the type of infection, there are various kinds of CPE such as formation of 
syncytia which is multinucleated cells formed because of fusion of nuclei, detachment 
of cells from monolayer and rounding of cells (Albrecht et. al., 1996). In monolayers, 
most new isolates of the HPIV3 virus produce cytopathic changes including focal cell 
necrosis and formation of multinucleate syncytia (Craighead and Brennan, 1968). 
Cytopathic effects produced by human influenza are quite complex. The effects 
predominantly occur at the columnar epithelial cells in the airways which then result in 
acute respiratory disease. The influenza viral replication leads to epithelial cell damage 
because of host cell protein synthesis downregulation and apoptosis or programmed 
cell death (Kamps et al., 2006). The apoptosis in the influenza infection is 
characterized by some morphological changes, such as condensation of cytoplasm 
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and chromatin, cytoskeleton disruption, DNA fragmentation, loss of mitochondrial 
function, which all lead to the formation of apoptotic bodies which are a small 
membrane bound particles ready to be cleared by phagocytic cells (Kamps et al., 
2006). 
I.4. TESTING ANTIVIRAL DRUGS IN VITRO 
Compounds which have potential antiviral properties usually exert their effect by 
interfering with viral attachment, inhibiting viral stages of replication, or inhibiting the 
viral/virion release from host’s cells.  One of the principles of testing whether 
compounds have antiviral properties includes the consideration of the type of cell line 
chosen. The main purpose of testing antiviral compounds in vitro is not to simulate 
human infection but to maximize the opportunity to discover potential lead compounds 
for their antiviral activities. The infectivity of respiratory viruses can vary on different 
type of cells. Cells are ideal to be chosen in antiviral assay if they have the ability to 
support viral entry and produce viable virions or the infectivity of the virus. However, it 
is not only the type of cells that affect the infectivity of the virus, the procedures 
performed to infect the cells, such as how long the virus is left in contact with the cells 
and how many virus should be put on cells (the titer) are also important to be 
considered. In term of the tested compounds, the success of the antiviral test is also 
determined by the length of time the drug is allowed to penetrate into cells and reach 
equilibrium. A positive control known to have antiviral properties should be carefully 
selected for comparison for antiviral activity (Cann, 1999). 
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Figure 3.4. Corticosteroids tested in the study 
 
II. AIMS 
The aim of this study was to investigate the potential antiviral properties of 
corticosteroids and compare the effects of corticosteroids on viral replication to the 
reference antiviral agents effective for the HPIV3 infection (i.e. ribavirin) and influenza 
A infection (i.e. zanamivir). Corticosteroids: budesonide, dexamethasone, fluticasone 
propionate, and prednisolone  (Fig 3.4) are among the most effective anti-inflammatory 
agents which are commercially available, clinically important in asthma therapy, and 
becoming part of treatment in respiratory viral infections.  
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III. METHODS 
III.1. ASSAY FOR CELL VIABILITY  
III.1.1. MTS ASSAY FOR BSC-1 CELL VIABILITY  
Monolayers of BSC-1 cells were grown on 96-well plates with the density of 2.3 x 103 
cells/well. When cells reach at least 95% confluency, 50 μl of media or 0.5% DMSO in 
media, or corticosteroids (budesonide, dexamethasone, fluticasone propionate, and 
prednisolone) in (10-8-10-2mM; 10-8-10-1mM; 10-8-10-2mM; 10-8-10-1mM respectively) 
were added per well. The cells were then incubated for 24 hours at 37 °C in 
atmosphere of 5% CO2. The MTS assay for cell viability on positive control ribavirin 
was also carried out, 50 µl of ribavirin (1.6x10-4- 3.3x10-1mM) was added on the 
confluence cells. The cells were incubated with the vehicle or ribavirin for 1 hour at 
37 °C.  After incubation, 150 μl/well of media was added to each well. All plates were 
then further incubated at 37 °C in 5% CO2 for 3 days, after which 40 µl of the 
tetrazolium-based dye 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium inner salt (MTS) was added to each well to determine cell 
viability and quantify compound toxicity. MTS is metabolized to a soluble formazan 
product by mitochondrial enzymes of metabolically active cells, thereby allowing the 
rapid quantitative analysis of cell viability and compound cytotoxicity. The plate was 
incubated in the dark for 2 hours at 37°C. After incubation, the foil wrapped plate was 
placed on a plate rocker for 5 minutes to mix the soluble formazan product. The 
quantity of formazan product was measured at 490 nm in a plate reader  and was 
directly proportional to the number of living cells in culture. The drug concentration was 
plotted against the optical density of each sample. Corticosteroids and ribavirin MTS 
assay were carried out in 4 replicates each concentration per plate in 3 different cell 
passages. 
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III.1.2. CRYSTAL VIOLET ASSAY FOR MDCK CELL VIABILITY  
Crystal violet is a dye that binds electrostatically to nuclear proteins and stains DNA. 
Lower amounts of crystal violet bound to the cells suggested a decrease in cell 
number. MDCK cells were plated on 24-well plate at a density of 10 x 105/ml (175 µl of 
cells/well). The corticosteroids (budesonide, dexamethasone, fluticasone propionate, 
and prednisolone) in (10-8-10-1mM; 10-8-10-1mM; 10-8-10-1mM; 10-8-10-1mM respectively) 
was then added (175µl/well) to the cells. The plates were incubated for 24 hours at 
37°C in 5% CO2 atmosphere. The next day, the media was replaced by a mixture of 
fresh media (200 µl /well) and a fresh serial dilution of the corticosteroid (175 µl /well). 
The crystal violet assay for cell viability on positive control zanamivir (10-7-10-1mM) was 
also carried out, 175 µl of zanamivir was added to the cells seeded on the previous 
day. The plates were then incubated at 37°C in 5% CO2 for 5 hours. After incubation, 
300 μl of 1.2% avicel solution (from a mixture of 2.4% avicel stock and MDCK growing 
media 1:1) was added to the well. The plate was then incubated at 37°C in 5% CO2 for 
further 48 hours. 
After 48 hours, the media was removed and cells were washed three times with 600 μl 
of PBS. Cells were then fixed with 400 µl of 4% formaldehyde/well for 45 minutes and 
washed 3 times with PBS. The cells were then stained with 0.1% of crystal violet in 2% 
ethanol for 30 minutes. Cells were then rinsed extensively with water until no diluted 
dye was identified and dried in room temperature overnight. Cell-associated dye was 
then eluted with 10% acetic acid (1 ml/well) on a rocker for 15 minutes. Extracted dye 
was then diluted 1:7 with distilled water and transferred into 96-well microtiter plates, 
and the absorbance was measured at 560 nm using microplate reader. 
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III.2.  PLAQUE REDUCTION ASSAY FOR ANTIVIRAL ACTIVITY 
III.2.1. HUMAN PARAINFLUENZA VIRUS TYPE 3 (HPIV3) 
The plaque reduction assay was performed according to the standard method 
described by Cann (Cann, 1999). BSC-1 cells were grown on 96-well plates to reach at 
least 95% confluency (day 3 after seeding). Fifty microlitres per well of the 
corticosteroid (budesonide, dexamethasone, fluticasone propionate, and prednisolone) 
in (10-8-10-4mM; 10-8-10-1mM; 108-10-2mM; 10-8-10-1mM respectively) was added. The 
cells were incubated with the vehicle (BSC-1 media for dexamethasone; DMSO for 
fluticasone propionate, budesonide, and prednisolone) or drug for 24 hours at 37 °C in 
5% CO2. Positive control ribavirin (1.6x10
-4- 3.3x10-1mM), was also tested on confluent 
cells. Fifty microlitres per well of ribavirin was added to each well. The cells were 
incubated with the vehicle or ribavirin for 1 hour at 37 °C in 5% CO2. After the 
incubations, plates were then infected with 50 μl/well of virus in the maintenance 
medium at 105 TCID50. The virus was allowed to adsorb for 2 hours at 37 °C in 5% 
CO2, after which, a 100 μl/well overlay of 0.6% Avicel RC/CL (FMC BioPolymer) 
supplemented with maintenance medium was added. After further incubation for 3 days 
at 37 °C in 5% CO2, the Avicel overlay was removed by pipetting and cells were fixed 
and stained with crystal violet.  
III.2.2. INFLUENZA A (H1N1/PR8) 
MDCK cells were plated on 24-well plates at a density of 10 x 105/ml (175 μl /well). The 
tested corticosteroids: budesonide, dexamethasone, fluticasone propionate, and 
prednisolone in (10-8-10-2mM; 10-8-10-1mM; 10-8-10-1mM; 10-8-10-1mM respectively) 
were then added (175 μl /well) to the cells. The plates were incubated for 24 hours at 
37°C in 5% CO2 atmosphere. The next day, the media was replaced by a mixture of 
fresh media (175 μl /well) and the fresh serial dilution of corticosteroids (175 μl /well). 
Fifty μl /well influenza A (H1N1/PR8) (1.25 x 104 pfu/ml) in the MDCK growing media 
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was then added to each well. Positive control zanamivir (10-8-10-1mM), was also tested 
on confluent cells (175 μl /well).The plates were then incubated at 37°C in 5% CO2 for 
5 hours to allow the virus to infect MDCK cells. After incubation, 300 μl of 1.2% avicel 
solution (from a mixture of 2.4% avicel stock and MDCK growing media 1:1) was added 
to the well. The plate was then incubated at 37°C in 5% CO2 for further 48 hours. 
After 48 hours, the media was removed and cells were washed three times with 600 μl 
of PBS. Cells were then fixed with 400 µl of 4% formaldehyde/well for 45 minutes and 
washed with PBS. To visualise the plaques immunocytochemistry method with 
aminoethylcarbazole (AEC) was performed. The cells were permeabilised by adding 
250µl/well solution containing 0.5% TritonX-100 in PBS for 30 minutes. The residual 
aldehyde groups were subsequently blocked with 400 µl/well of 10% foetal calf serum 
(FCS) in PBS for 90 minutes. After being washed with PBS three times, cells were 
incubated with 200 µl/well of primary antibody (1:500) for 90 minutes, washed with PBS 
5 times then followed by 90 minutes incubation with 200 µl/well of antimouse IgG-HRP 
antibody (1:1000). Finally, a 300 µl/well developing solution of aminoethylcarbazole 
(AEC) (0.4 mg/ml) in 0.05 M sodium acetate buffer, pH 5.5, containing 0.03% H2O2 was 
added to the well and incubated in the dark for 60 minutes then washed with tap water 
3 times. The infected cells will develop pink-reddish colour which can be scanned and 
analysed. 
III.2.3. PLAQUE REDUCTION ASSAY 
The concentrations of drug sufficient to reduce plaque number by 50% (IC50 values) 
were calculated by standard methods (Cann, 1999). The percentage of plaque 
formation was calculated as follows: [(mean number of plaques in test)/(mean number 
of plaques in control)] × 100 
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III.3.  ICAM-1 ASSAY 
BSC-1 cells were seeded onto 24 well plates and then incubated at 37 °C in a 
humidified atmosphere containing 5% CO2 until reaching at least 95% confluency. The 
cell monolayer was then incubated with 294 μl/well of the highest non toxic 
concentration of corticosteroid or vehicle overnight. The next day 294 µl of HPIV3 at a 
concentration of 105 TCID50 units/ml was added to the wells. Avicel overlay was added 
after 2 hours incubation to let virus infect the cells. After 3 days of incubation, the 
media was removed and the cells were washed 3 times with PBS before undergo cells 
lysis. 
III.3.1. CELL LYSIS 
Infected BSC-1 cells was lysed with cell lysis buffer (20mM Tris-HCl pH 8, 1% Triton X-
100, 10% glycerol, 2mM EDTA, 137 mM NaCl) supplemented with 1mM NaVO4, 1mM 
PMSF, 1μg/ml aprotinin, 10μg/ml leupeptin. Plate on ice was put on rocker for 20 
minutes. Cells were then scraped with the tip of a pipette, transferred to eppendorf 
tubes, and finally centrifuged at 15,000 x g for 5 minutes at 4°C. Supernatant was 
transferred into an ice-cold 1 ml plastic tube for subsequent protein concentration 
analysis by BCA assay using bovine serum albumin (BSA) as a standard. 
III.3.2. PROTEIN ASSAY  
Protein concentration from cell lysate was determined using BCA protein Assay. The 
BCA protein assay is an assay based on formulation of bicinchonic acid. Serial 
dilutions of bovine serum albumin (BSA) (2.0, 1.0, 0.5, 0.25, 0.125, 0.0625, 0.01325, 
0.0078 mg/ml) were used as standards. Five μl of standard solutions were applied in 
duplicates to 96-well plates. The BSC-1 cells extracts were added into the 96-well 
plates. The working solution contained a mixture of 50 parts of BCA reagent A and 1 
part of BCA reagent B was made fresh and then added (200 μl) to each well, and 
subsequently mixed thoroughly on a plate shaker for 30 seconds. The plate then was 
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incubated for 30 minutes at 37ºC and subsequently left at room temperature for 5 
minutes to cool down. The plate was then read at 562 nm wavelength using a plate 
reader. Using the optical densities of the standards, a graph of optical density against 
concentration was plotted and extrapolated to calculate the concentrations of the 
unknown values of the BSC-1 cells extract. 
III.3.3. PROTEIN SAMPLES 
The remaining protein lysate was then vortexed with one third volume of 3x Laemmli 
buffer (0.25 M Tris-HCl pH 6.8, 20% (v/v) glycerol, 2% (v/v) SDS, 0.2% (w/v) bromo-
phenol-blue, made up to 20 ml with deionised water, plus 4% mercaptoethanol) and 
frozen at -20°C until assayed. 
III.3.4. WESTERN BLOT 
Protein samples were electrophoretically size–fractionated using sodium 
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). A mixture of 5.27ml 
H2O; 3.33ml Acrylamide; 1.25ml Tris.HCl; 100µl SDS; 50 µl APS; and 5 µl TEMED 
were made and transferred into a cassette (2x3.1ml).  Once set, stacking gel (5.77ml 
H2O; 1.67 ml Acrylamide ; 2.5ml Tris/SDS; 50 µl APS; 8 µl TEMED)  was added with 
the insertion of  a 12 wells comb. Gel in the cassettes then was put  into the tank filled 
with SDS running buffer (Tris-base 30.3 g, glycine 144 g, 20% SDS 50 ml made up to 1 
L deionised water). Samples were boiled at 95ºC for 5 min then loaded in each well 
with volume equals to 10 μg protein. The gel was run at 40-50V until samples have 
stacked and then run the main gel at 100-130V until the dye front reaches the slot.   
III.3.5. PROTEIN TRANSFER 
Once the gel has run, the cassette was removed from the tank and opened using a gel 
knife. The comb like section and bottom of the gel was trimmed off and the gel was 
placed in transfer buffer (Tris-base 30.3 g, glycine 144 g, up to 1 L deionised water). 
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The semi dry blotting system was used. The bottom (an anode) of the system was pre-
wet before setting up a sandwich consisting of of pre-wet filter paper (20 layers), 
nitrocellulose membrane, gel, and more filter papers (20 layers). A glass rod was rolled 
on the sandwich stack before running to remove trapped air bubbles. The blotting 
system was then run at 39 Amp for a duration of 60 minutes.  
III.3.6.  ICAM-1 DETECTION 
Once transfer was complete, the transferred nitrocellulose membrane was blocked with 
TBST containing 5% dried skim milk (5% Blotto) for 1 hour under room temperature 
with shaking. After blocking, ICAM-1 monoclonal antibody was added into the 
membrane and then incubated overnight at 4°C. 
The next day, membrane was briefly rinsed in 1 x TBST, then 2 x 5 minutes, and 1 x 15 
minutes. After washing completed, the membrane was then incubated with anti rabbit 
HRP-conjugated secondary antibody in 5% Blotto on the roller for 60 min at room 
temperature.  In order to remove excess secondary antibody, the membrane was then 
washed again briefly in 1 x TBST, then 2 x 5 minutes, and 1 x 15 minutes. Then it was 
developed by ECL development reagent after washing, and exposed to hyperfilm in a 
darkroom. 
After treating with stripping buffer, the membrane was reprobed with GAPDH primary 
antibody to confirm equal protein loading. Primary antibody stripping was performed by 
incubating membranes with stripping buffer at room temperature for 15 minutes with 
shaking. After washing with TBST, 2 x 5 minutes, then 1 x 15 minutes, nitrocellulose 
membrane was incubated again with blocking solution before new protein detection 
The film scanned and then analysed with densitometry using ImageJ software. The 
area obtained from the blot was then normalised with the corresponding area of 
GAPDH as a housekeeping protein. 
CHAPTER III  
 
85 
 
IV. RESULTS 
IV.1.  CELL VIABILITY ASSAY 
The main purpose of assaying for cell viability under treatment with corticosteroids and 
antiviral agents was to ensure that the compound concentrations would not affect the 
host cell viability. Only the compound concentration which does not have any 
significant different viability to untreated cells will be used for subsequent antiviral 
assays. Cell Viability assay was also carried out to ensure that the antiviral effects 
observed are not due to the tested compounds’ cytotoxicities.  
 
Figure 3.5. In vitro cell viability assay of ribavirin and corticosteroids determined by MTS assay. 
The effect of DMSO 0.5% as budesonide, fluticasone, and prednisolone vehicle on cell viability 
was also determined, to eliminate the possible cytotoxic effect of the solvent. Each point 
represents average value ± SEM of 3 independent experiments. 
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Figure 3.6. In vitro cell viability assay of zanamivir and corticosteroids determined by crystal 
violet assay. The effect of DMSO 0.5% as budesonide, fluticasone, and prednisolone vehicle on 
cell viability was also determined, to eliminate the possible cytotoxic effect of the solvent. Each 
point represents average value ± SEM of 3 independent experiments.   
 
IV.2. ANTIVIRAL EFFECT OF CORTICOSTEROIDS 
The inhibitory effect of corticosteroids on HPIV3 and influenza A infections were 
investigated by plaque reduction assays. Dexamethasone significantly decreased 
HPIV3 and Influenza A (H1N1/PR8) titre compared to other steroids (Fig 3.8 and Fig 
3.10).  
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                                     A                    B                   C 
Figure 3.7. Example of plaque reduction assay for HPIV3 on BSC-1 cell lines. After 2 hours of 
virus adsorption, Avicel™ overlay were added. After 3 days cells were fixed with 2% 
formaldehyde and stained with 0.1% crystal violet solution. A: cells were incubated with 0.1 
mM of Dexamethasone  B: cells were incubated with 0.01 mM of Dexamethasone C: Control 
wells where cells were incubated with media. 
 
Figure 3.8.  Concentration-response curve of corticosteroids and the positive control ribavirin of 
HPIV3 infection on BSC-1 cells. Each point represents average value ± SEM of 3 independent 
experiments.  
Dexamethasone was the only corticosteroid which reached 50% inhibition of viral 
replication. The IC50 of dexamethasone was 0.5±0.3.10
-1mM compared to     
0.7±0.2.10-1mM for ribavirin. Budesonide and fluticasone propionate had a negligible 
antiviral effects but their activity did not reach 50% inhibition in plaque formation over 
the tested range of concentrations. Prednisolone did not show any inhibition of HPIV3 
replication. 
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                 A                 B          C                 D                E                  F 
Figure 3.9. Example of plaque reduction assay for influenza A (H1N1/PR8) on MDCK cell lines. 
After 5 hours of virus adsorption, Avicel™ overlay were added. After 48 hours of further 
incubation, cells were fixed with 2% formaldehyde and immunostained with 
aminoethylcarbazole (AEC). A: Control well where cells were incubated with media; B: cells 
were incubated with 0.1 mM of Dexamethasone;  C: cells were incubated with 0.01 mM of 
Dexamethasone C: cells were incubated with 0.001 mM of Dexamethasone; D: cells were 
incubated with 0.0001 mM of Dexamethasone; E: cells were incubated with 0.00001 mM of 
Dexamethasone. 
 
Figure 3.10.  Concentration-response curve of corticosteroids and the positive control 
zanamivir of influenza A (H1N1/PR8) infection on MDCK cells. Each point represents average 
value ± SEM of 3 independent experiments.  
As expected, zanamivir inhibited influenza A replication with an IC50 value of 
1.5±1.2.10-5mM. Dexamethasone also demonstrated a significant inhibitory effect on 
influenza A replication with an IC50 value of 0.3±0.01.10
-1mM. In contrast, budesonide 
and prednisolone showed negligible antiviral properties against influenza A (H1N1) 
infection. Fluticasone propionate, budesonide and prednisolone antiviral activities did 
not reach 50% inhibition over the tested range of concentrations.  
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IV.3. EFFECT OF CORTICOSTEROIDS ON ICAM-1 EXPRESSION 
HPIV3 infection on BSC-1 cells increased the level of ICAM-1 expression although this 
may not statistically significant. Treatment with dexamethasone, fluticasone propionate 
or prednisolone reduced the expression of ICAM-1 but again the reduction was not 
statistically significant (fig 3.11). 
 
Figure 3.11.  A. A western blot analysis for intercellular adhesion molecule (ICAM)-1 level in 
BSC-1 cells infected with HPIV3 and incubated with corticosteroids (BUD=Budesonide; 
DEX=Dexamethasone; FP=Fluticasone Propionate; PRED=Prednisolone). GAPDH was used as 
housekeeping protein. B. The density ratio of ICAM-1 expression normalised to GAPDH. 
Results are expressed as mean±S.E.M. Data were analysed using one-way ANOVA, followed 
by post hoc Bonferroni’s test (P < 0.05; n=3). 
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V. DISCUSSION 
Respiratory viral infection places an exceptional challenge to the host immune system 
for not only to rapidly eliminate the culprit but also control the excessive inflammation to 
prevent acute respiratory failure and support tissue repair to restore the normal 
respiratory function. Corticosteroids are anti-inflammatory agents whose activities are 
to suppress potentially damaging excessive proinflammatory immune responses, but at 
the same time might also suppress the necessary immune responses to eliminate the 
virus (Webster et al., 2002).  
Corticosteroids (dexamethasone) are recommended for treatment of croup which is 
usually due to HPIV3 infection. Corticosteroid treatment in croup patient has shown to 
reduce relapse and improve symptoms (Bjornson et al., 2004). The role of 
corticosteroid in influenza infection however is still controversial, although, some 
guidelines recommend the use of a corticosteroid in the case of influenza infection in 
patient with asthma (World Health Organisation, 2010).  
Currently, little has known about the contribution of corticosteroid treatments to HPIV3 
and influenza A replications. Therefore, in order to study the effect of corticosteroids on 
viral replication and to further evaluate if there is any potential antiviral effect of 
corticosteroids, viral inhibition assays using plaques reduction assays were carried out 
in this study. 
Epithelial cells may be one of the most important targets for corticosteroid. Some 
previous studies have been carried out to evaluate the role of corticosteroid in viral 
infections. There is some evidence which shows the possible antiviral effects of 
corticosteroids. Dexamethasone and hydrocortisone have shown to inhibit the infection 
and reduce the viral titers of RV14 (Rhinovirus 14) (Suzuki et al., 2000). 
Dexamethasone has also been shown to posses antiviral activity by reducing the 
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release of avian sarcoma virus progeny in vitro (Wainberg et al., 1982). However, some 
studies while showing alteration of proinflammatory cytokines by corticosteroid 
intervention did not show any reduction in viral release and replication (Noah et al., 
1998). In the current studies, dexamethasone was shown to have antiviral properties 
against HPIV3 infection on BSC-1 cells. Fluticasone propionate and budesonide were 
also shown to inhibit HPIV3 replication although both drugs failed to reach 50% plaque 
reduction. There was no inhibition of HPIV3 replication by prednisolone. 
Respiratory viruses enter into and replicate within epithelial cells lining the airways. 
Entry is dependent on interaction of specific virus with specific receptors, for example 
some group of rhinoviruses exploit intercellular adhesion molecule (ICAM)-1 to aid the 
virus entrance to the host cell (Hofer et al., 1994). Influenza viruses bind sialic acid 
residues on the surface of the host cell via hemmaglutinin to enter the host cell. 
Previous study suggested that the mechanism by which dexamethasone inhibits RV14 
infection in human tracheal epithelial cells is most likely via reducing the expression of 
ICAM-1 (Suzuki et. al., 2000). This study was supported by the finding which 
demonstrated that corticosteroids e.g. hydrocortisone, dexamethasone and 
mometasone furoate also inhibits RV16-induced increases in ICAM-1 surface 
expression albeit showing no alteration of virus infectivity or replication (Papi et al., 
2000).  
Gao  et al. (2000) showed that HPIV3 infection upregulates ICAM-1 expression on 
airway epithelial cells, an effect that has been thought would facilitate viral cell 
attachment and entry (Gao et al., 2000). In this present study, while some 
corticosteroids investigated were shown to reduce ICAM-1 production , the antiviral 
effect of corticosteroids did not have any correlation with ICAM-1 expression on BSC-1 
cells. Therefore, the inhibition of HPIV3 replication by dexamethasone might not only 
be mediated by inhibition of ICAM-1. 
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In the current study, dexamethasone significantly reduced the replication of influenza A 
(H1N1/PR8) on MDCK cells, while other corticosteroids tested i.e. budesonide, 
fluticasone propionate, and prednisolone, were shown to have negligible antiviral 
activity against influenza A infection. 
One of corticosteroid mechanism of actions is to suppress proinflammatory 
mechanism, via interaction with transcription factors, including nuclear factor (NF)-κB 
which is known to regulate the expression of many inflammatory genes and play an 
important role in the inflammatory processes (Barnes and Adcock, 2003). The NF-κB 
signaling pathway plays a significant role in generating immune response and 
mediating inflammation especially in the case of infection (Bonizzi and Karin, 2004). 
When inactive, NF-kB is complexed with an inhibitory protein subunit (IkBα). NF-kB is 
activated by signal either originating from the cytoplasm (i.e TNF-α and IL-1β) or 
nucleus due to DNA damage. The signals trigger the degradation of IkBα and then 
release the NF-kB to activate transcription factor of responsive genes including those 
which encode pro-inflammatory cytokines (Adenuga and Rahman, 2007). Many of the 
anti inflammatory actions of corticosteroids are suggested to be mediated by inhibition 
of transcription factor NF-kB which leads to transcriptional repression of many pro-
inflammatory mediators (Barnes and Adcock, 2003).   
Some groups of viruses have the ability to exploit the NF-kB pathway for their own 
benefits i.e. facilitate replication and escape from immune system surveillance. Dengue 
and Sindbis virus activate NF-kB to induce apoptosis of host cells which lead to viral 
spread.  NF-kB is also suggested to be involved in retrovirus, herpes simplex virus, 
adenovirus, and CMV genes expression (Hiscott et al., 2006; Kumar et al., 2008).   
Influenza virus life cycle also relies on the NF-kB signalling pathway. Host cells with 
low NF-kB activity are resistant to influenza infection (Flory et al., 2000). Therefore, 
activation of NF-kB is a prerequisite for effective influenza infection. The activation of 
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NF-kB pathway has been suggested to be caused by over expression of influenza viral 
proteins such as HA, NP and M1 (Flory et al., 2000). The NF-kB activation is essential 
to increase the synthesis of vRNA of influenza virus during replication to enhance virus 
production. Influenza virus also induces apoptosis of the host cells via NF-kB-
dependent induction of pro-apoptotic factors tumor necrosis factor-related apoptosis-
inducing ligand to enhance viral spreading and propagation (Wurzer et al., 2004). 
The NF-kB signalling pathway activation seems to be a trade off in influenza infection.  
In one hand, NF-kB activation enhances viral propagation and spreading, but on the 
other hand, NF-kB activation means activating host immune response against the 
infection.  To counter innate immune response activated by NF-kB during viral 
infection, influenza virus evolves to encode NS1 protein which is also an antagonist to 
interferon cellular responses by which the influenza virus is able to counteract the 
antiviral response from the NF-kB pathway and at the same time exploit the same 
pathway to enhance viral replication (Garcı et al., 1998). If the antiviral action of 
dexamethasone is mediated via NF-kB transrepression, in this study dexamethasone 
seems to have the ability to combat the influenza A (H1N1/PR8) virus counteraction in 
favour of reducing viral replication. 
HPIV1 or Sendai virus and HPIV3 are also known to increase NF-kB activation during 
the start of infection although little has known as why there is a prominent NF-kB 
activation (Algarte et al., 1999). It is possible that NF-kB activation could be exploited 
by the viruses for their own benefits i.e. facilitate replication or it could be an aggressive 
immune response to eradicate the viruses. So there is an open possibility which 
requires further study that the inhibition of NF-kB activation by dexamethasone might 
also be proposed as one of dexamethasone antiviral mechanisms against HPIV3 
infection on BSC-1 cells. 
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The data from the studies comparing the specific agonistic properties of synthetic 
corticosteroid are still quite elusive to define as they are generated from diverse in vivo 
and in vitro studies under various conditions with different parameter measured. In 
addition, corticosteroids are covering a very large group of compounds. Therefore, the 
studies on corticosteroids are usually only carried out only on some of the member of 
the group which are relevant to the study.  For that reasons, it is quite a challenge to 
compare the activity of corticosteroid tested in this study on their transactivation and 
transrepression activities to further evaluate as why  one corticosteroid i.e. 
dexamethasone has antiviral properties while others (i.e budesonide, fluticasone 
propionate, and prednisolone) do not. 
Hofmann et al. (1998) evaluated a series of corticosteroids including dexamethasone 
and prednisolone. The study revealed that hydrocortisone and predisolone have a 
lower reduction on NF-kB activation on L929 cells compared to the rest of the 
corticosteroid group tested including dexamethasone (Hofmann et al., 1998). Albeit 
carried out in a different cell line which could have cell-specific NF-kB activity. This 
study therefore underlines the fact that antiviral activity of dexamethasone could be 
mediated by several mechanisms, not only by reducing ICAM-1 expression but also by 
NF-kB transrepression. 
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VI. CONCLUSION 
Dexamethasone has antiviral activity against HPIV3 and influenza A (H1N1/PR8). 
While other corticosteroids tested (i.e. budesonide, fluticasone propionate and 
prednisolone) do not have or have negligible antiviral activities. The antiviral activity 
against HPIV3 is not only mediated by inhibition of ICAM-1 expression. 
Dexamethasone, a potent anti inflammatory drug, reduces the excessive pro 
inflammatory mediators via transrepression of NF-kB activation. Both Influenza A and 
HPIV3 has been known to increase NF-kB activity during infection, therefore, 
suppression of NF-kB activation by dexamethasone could be proposed as one of 
mechanism by which it reduce viral replication. 
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IN VIVO SCREENING OF MURINE RESPIRATORY 
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I. INTRODUCTION 
The respiratory tract has a vast surface area with a direct contact with the environment. 
The lung is always in direct and continuous exposure to air from the surrounding 
environment. However, most respiratory pathogens are recognized quickly by the 
immune surveillance which then defends the airway and eradicates the pathogens by 
combined functions of the innate and adaptive immune responses (Vareille et al., 
2011). 
Respiratory viruses, such as respiratory syncytial virus (RSV), rhinovirus, influenza virus, 
parainfluenza virus, and adenovirus cause acute localized respiratory tract infections.  
During primary respiratory viral infection, both adequate innate and adaptive immunity 
are needed to eradicate the viruses. The study of these immune responses has 
demonstrated that the dysfunction of any single immune mechanism results in 
devastating consequence for the host. During secondary infection, the adaptive 
immune mechanism developed from the first infective agent encounter, facilitates faster 
response to eradicate the virus (Vareille et al., 2011).  
I.1. VIRUS DETECTION BY THE HOST 
The mucosal surface and airway epithelial cells are the main portal for a wide range of 
respiratory pathogens including respiratory viruses. Epithelial cells, macrophages and 
dendritic cells carry out a continuous surveillance to detect the pathogen or virus 
invasion. The early detection of the viruses by the immune system is a critical step in 
controlling the invasion as well as their replication and initiating the immune response 
to facilitate their clearance. The host has a set of receptors which recognise the basic 
viral component initiating the immune response. The basic component of the viruses is 
defined as PAMPs (pathogen-associated molecular patterns). The PRRs-(pattern-
recognition receptors) bearing cell such as epithelial cells, alveolar macrophages and 
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dendritic cells recognise the PAMPs triggering a cascade of signals to produce 
cytokines and chemokines, which orchestrate the immune response to establish 
antiviral activity in the airways. Chemokines attract circulating leukocytes to the site of 
infection.  The cytokines and PRRs also trigger the development of adaptive immune 
response by initiating the maturation and migration of dendritic cells (Kohlmeier and 
Woodland, 2009). 
Among the most studied PRRs are those of the TLR (Toll-like receptor) family. 
Currently there are 10 TLRs (TLR1 to TLR10) identified to be expressed in human 
respiratory tracts. Invading viruses can be detected by TLR either on the cell surface or 
in cytoplasmic endosome. In term of respiratory viral infections, TLR3, TLR7, TLR8, 
and TLR9, which found in endosomes recognise viral nucleic acids i.e. dsRNA (double-
stranded RNA), ssRNA (single-stranded RNA), and CpG DNA, respectively. TLR4 
which is expressed on the surface of cells also has been shown to recognise the RSV’s 
F (Fusion) protein.  The interactions of TLRs and PAMP’s then induce the expression 
of type I IFNs (interferons)  (Kawai and Akira, 2006) (fig 4.1).  
Viral RNA is also detected by several RNA helicases which reside in the cytosol such 
as retinoic acid-inducible gene I (RIG-I), and melanoma differentiation-associated gene 
5 (MDA-5). The viral RNA recognition by RNA helicases also induces transcription 
factor IRF-3 (Interferon Regulatory Factor -3) which leads to the synthesis of Type I 
and III interferons.   In addition, NOD-like receptors (NLRs) particularly NLRP3 have 
also been shown to have the ability to recognise and initiate an immune response to 
respiratory viruses (fig. 4.1) (Tregoning and Schwarze, 2010). 
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Figure 4.1. Respiratory viruses are detected by host innate immune system, in extracellular 
compartment by TLR2, TLR4, and TLR6, in endosome by TLR3, TLR7, and TLR 9, and in 
cytoplasm by RIG-1, MDA-5, and NLRP3. IV: influenza virus, PIV: parainfluenza virus, RSV: 
respiratory syncytial virus, HMPV: human metapneumovirus, RV:rhinovirus (Tregoning and 
Schwarze, 2010). 
 
I.2. VIRUS-INDUCED INNATE IMMUNE RESPONSE 
The detection and recognition of basic viral components via PRRs initiates a cascade 
of immune responses which aim to defend against the viral infection by releasing 
cytokines and chemokines which then recruit inflammatory cell including neutrophils, 
eosinophils, NK cells, and macrophages to the site of infection (Vareille et al., 2011). 
Dendritic cells (DC) which circulate in  2 forms i.e. cDCs (conventional DCs) and pDCs 
(plasmacytoid DCs) have an important role in triggering adaptive immunity as well as 
producing type I IFNs respectively after their PRRs interact with PAMPs. After antigen 
internalisation, cDCs undergo maturation and migration to lymph nodes where they 
mature into antigen presenting cells (APCs) bearing major histocompatibility complex 
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(MHC) class I and II molecules which then interact and stimulate CD8+ and CD4+ cells 
respectively (Wu and Dakic, 2004). 
Prompted by type I IFNs, DCs, macrophages, and epithelial cells initiate a cascade of 
chemokines and cytokines storm to recruit inflammatory cells such as neutrophils, NK 
cells, monocytes and T-cells. Neutrophils are recruited to the site of infection as a 
response to the production of IL-8, CXCL1 and CXCL5. Neutrophils protect the host 
from respiratory virus by releasing antiviral proteins i.e. lactoferrin and defensin. There 
is a thought that neutrophils only play a minor role in viral infection as inhibition of 
neutrophils has no significant effect on influenza clearance (Vareille et al., 2011).  
Eosinophils are recruited and activated by GM-CSF (granulocyte-macrophage colony-
stimulating factor), eotaxin-1/CCL11, eotaxin-2/CCL24, and RANTES/CCL5. Once 
activated, eosinophils secrete ECP (eosinophil cationic protein) and eosinophil-derived 
neurotoxin which have antiviral activities (Gleich, 2000). 
NK-cells play a significant role in eradicating invading virus as these cells are the 
producers of IFN-γ which has strong antiviral properties as well as has essential role in 
activating antigen presenting cells. NK-cells are recruited and activated by IFN-α, IFN-
β, and MIP-1α/CCL3 (Biron et al., 1999). 
Macrophages or monocytes release IL-12 and IL-10 which are important in NK cell 
activation, Th1 responses regulation, and B-cell survival and proliferation and antibody 
production. Macrophages are recruited and activated by IL-1β, MIP-1α/CCL3, MCP-1 
(monocyte chemo attractant protein 1)/CCL2, and TNF-α (tumour necrosis factor 
alpha).  The cells phagocytes, processes, and present viral antigen therefore have a 
significant role in priming adaptive immunity (Vareille et al., 2011). 
T-cell and B-cell lymphocytes are the hallmarks of adaptive immune response to virus 
infection. The Th1-cells are trafficked to the site of infection through the production of 
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RANTES/CCL5 and IP-10/CXCL10 whereas the Th2 cells via production of IL-1β. The 
antiviral substances IFN-γ, IL-2, IL-12, and TNF-α are produced by Th1 cells hence 
Th1 cells play a key role in immune responses against viral infection. Th2 cells to a 
lesser extent also contribute in the humoral immunity against the invading viruses by 
the production of IL-4, IL-5, and IL-13 (Ramshaw et al., 1997). 
I.3. VIRUS INFECTIONS AND AIRWAY RESPONSIVENESS 
Respiratory viral infections increase airway responsiveness even in non asthmatic 
persons. In the airway, the neural control of the smooth muscle is primarily provided by 
the vagus nerve. The bronchoconstriction due to parasympathetic nerve activity is 
initiated by the release of acetylcholine (ACh) from the nerve endings which then binds 
to and stimulates the M3 subtype excitory muscarinic receptors. This action leads to 
smooth muscle contraction. ACh also feeds back to M2 subtype muscarinic receptors 
on the nerve ending to decrease further Ach release (fig 4.2). Therefore the M2 
receptors inhibit or limit vagally induced bronchoconstriction  (Jacoby and Fryer, 1999). 
Viral respiratory infection induces airway hyperresponsiveness in human via the vagus 
nerve. The dysfunction of the M2 receptor has been thought to mediate the increase of 
airway responsiveness in viral infection. Guinea pigs infected with HPIV3 which were 
experiencing airway hyperresponsiveness to inhaled histamine were identified to have 
M2 dysfunctions  (Jacoby and Fryer, 1991). The M2 dysfunction and airway 
hyperresponsiveness was also observed in virus infected rat  (Sorkness et al., 1994). 
Loss of negative feedback leads to increased parasympathetic activity.  
The M2 receptor is highly glycocylated. The M2 glycocylation particularly sialation plays 
an important role in the interaction of the receptor with acetylcholine. Influenza and 
parainfluenza virus exert neuraminidase enzyme which interact with sialic acid residue 
from glycol protein on the cell membrane to facilitate entrance of the virus into targeted 
cells. The viral neuraminidase is thought to play a role in causing an M2 receptor 
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dysfunction by cleaving the sialic acid residues on the receptor (Gies and Landry, 
1988; Fryer et al., 1990).  
Viral infection and exposure of IFNγ to the parasymphatetic neurons in culture have 
also been shown to cause the M2 receptors dysfunction as well as causing 10 folds 
reduction in the M2 receptor gene expression. Therefore, the virus itself and the 
inflammatory response to the virus contribute to the lost of functions and gene 
expression which lead to potentiate the airway responsiveness (Jacoby and Nadel, 
1989). 
 
 
Figure 4.2. Airway smooth muscle contraction and bronchoconstriction as a ersult of 
acetylcholine binding to M3 receptors. Acetylcholine also binds to M2 receptor on the nerve 
ending to give negative feedback to reduce the further release of acetylcholine (Jacoby and 
Fryer, 1999). 
 
 
 
 
 
 
 
 
 
CHAPTER IV  
 
103 
 
I.4. SMALL ANIMAL MODEL TO STUDY RESPIRATORY VIRUSES 
The type of respiratory viruses which infect humans is extensive. In infancy and 
children parainfluenza virus type 3 (HPIV3) is thought to be an important cause of 
bronchiolitis and croup which are seen in endemic and epidemic patterns. The 
influenza viruses have a greater role in older children and adults (Clyde, 1980).  
Animal models of viral respiratory infection have given better understanding of the 
pathophysiology of respiratory viral infection as well as the mechanism of virus-host 
interaction. In vivo models also give a better simulation on how viral respiratory 
infection involves in and affects other respiratory diseases such as asthma, COPD, and 
cystic fibrosis. The use of small animal models in respiratory viral infection can also 
provided an insight into the dynamic of host immune response, which has central role 
for the successful resolution of infection. Rodents, especially mice, rats, and guinea 
pigs, are the most commonly used as an animal model for respiratory infection 
because they usually have lower purchase costs, wide availability, and have a relative 
extensive availability of reagents and antibodies to study immunological pathways 
essential for the infection (Mohtasham et al., 2004).  
Murine models of respiratory infection have been developed for many viruses. The 
model has provided an important contribution to the understanding of viral life cycle in 
the airway as well as the role of inflammatory cells and cytokines/chemokines. The 
mouse models of influenza and parainfluenza are probably the best characterised 
small animal model at the moment. Those models usually have robust inflammatory 
responses particularly T-cells and B-cells response similar to human infection. 
Although findings from such studies cannot be extrapolated directly to the human 
situation, they can provide indicators to whether the model employed is pointing in the 
right direction in the simulation of disease states or health outcomes sought (Kohlmeier 
and Woodland, 2009). 
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Some careful considerations have to be taken into account before developing animal 
model of respiratory viral infection as there is significant variation on how different 
species responds to the given infecting virus. A wide variety of host defence 
mechanisms toward pathogens have been identified so the most appropriate study 
parameters should be chosen with the consideration for both the virus and the host. 
Some of the factors that have to be concerned including the typical host immune 
response, the amount of virus infected, the pattern of viral replication, and the time 
course of infection. The animal models have also represented human infection in the 
similarity of clinical symptoms, histopathological changes, viral replication and also viral 
transmission (Mohtasham et al., 2004). 
I.4.1. PARAINFLUENZA TYPE 3 VIRUS INFECTIONS MODELS 
HIPV3 is a major cause of lower respiratory syndrome in young children, infant, elderly, 
and immunocompromised patients. The clinical syndromes of HPIV3 infection in 
humans include acute laryngotracheobronchitis (croup) with symptoms such as fever, 
cough, and laryngeal obstruction; bronchiolitis, tracheal bronchitis, and pneumonia with 
symptoms such as fever, wheezing, and rales; and to a lesser account neurologic 
disease such as multiple sclerosis, Guillain-Barré syndrome, and adults with 
demyelinization syndromes (Henrickson, 2003).  
HPIV3 infect the host (human and animals) both naturally and under experimental 
conditions. The natural host of this virus includes man, guinea pigs and monkeys 
(Henrickson, 2003). Guinea pig is a natural host of HPIV3. In our laboratory, HPIV3 
infection of guinea pig has proven to be successful. The infected animal showed 
increase in airway inflammation, airway oedema, and airway hyperresponsiveness to 
histamine provocation (Toward et al., 2005; Ford et al., 2013) . The HPIV3 model 
developed in our laboratory could be a good basis to elucidate the mechanism of viral 
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induced asthma exacerbation in mice and their response to asthma treatment i.e. 
corticosteroids.  It will initially be determined if HPIV3 will infect mice. 
I.4.2. INFLUENZA INFECTION MODELS 
In humans, influenza virus primarily infects the respiratory tract causing fever, chills, 
headache, myalgia, lethargy and anorexia. Respiratory symptoms include dry cough, 
pharyngeal pain and nasal congestion. Acute onset of symptoms occurs within one or 2 
days after infection (Cate, 1987).  
Several animal species have been exploited as a host in influenza studies, each with 
their own merits. Ferret, guinea pigs, hamster, cotton rats, and non human primates 
are natural host of influenza viruses without the need of viral adaptation with human 
influenza strain. However, mice are apparently resistant to human influenza infection 
therefore the virus would need prior adaptation in order to make the murine model to 
be more useful. Virus adaptation to the aimed host is usually done by passaging the 
virus in the lung of the aimed species until it shows expected viral growth kinetics and 
signs of disease. Some animals like ferrets and macaques have shown symptoms of 
influenza infection resembling those of humans such as fever, nasal discharge, 
lethargy, myalgia, anorexia, and sneezing. The infection of influenza in mice and cotton 
rats although less symptomatic  than the other mentioned models, still show 
hypothermia and weight loss (Bouvier and Lowen, 2010).  
I.4.3. POLY (I:C) MODELS 
TLR3 activation by the virus is thought to be an important step in inducing a cascade of 
immune responses by releasing of cytokines and chemokines. DsRNA is the ligand for 
TLR3. There are 8 families of dsRNA viruses identified including rotaviruses. Poly (I:C) 
[Polyinosinic:polycytidylic acid] is a a synthetic double-stranded RNA (dsRNA) 
analogue. As a dsRNA analog of dsRNA virus, poly (I:C) is able to interact with toll-like 
receptor 3 (TLR3) in the membrane of dendritic cells, macrophages, and B-cells 
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mimicking certain effects which occur in the context of dsRNA virus infections 
(Alexopoulou et al., 2001). 
Poly (I:C) is an immunostimulant which induces the production of  interferon (IFN) . In 
vivo, Intraperitoneal injection of Poly (I:C) in mice caused IFN-α/β production and NK 
cells activation (Djeu et al., 1979). In vitro, in lung epithelial cells, stimulation with poly 
(I:C) was able to induce the expression of C-jun-amino-terminal kinase (JNK) and 
nuclear factor kappa B (NF-kB) signaling pathways which are important in the 
inflammatory response. Therefore understanding the effect of TLR3 activation by poly 
(I:C) might give a better insight to the mechanism underlying a virus infection (Takeda 
and Akira, 2004).  Poly (I:C) could also be a useful substitute for viral infection in 
animals model as it avoids the risk of infecting the experimenter.  
 
II. AIMS 
The aim of this study was to develop an animal model of viral infection in the airways of 
mice which expresses moderate inflammatory features of viral infection such as influx 
of inflammatory cells into the airways and airway hyperresponsiveness towards 
methacholine provocation. The model has to be able to provide a good basis for further 
investigation of roles of the respiratory virus in asthma exacerbation. Three approaches 
will be used: HPIV3, Poly (I:C), and influenza A (H1N1/PR8).  
The objective of this study was to determine a dose of the infective agents which 
produced a significant increase in airway cellular inflammation and airway 
hyperresponsiveness but which did not affect survival of the animals. 
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III. METHODS 
III.1. DEVELOPMENT OF MICE MODEL OF HPIV3 INFECTION 
III.1.1. INFECTION OF MICE 
Male BALB/c mice 20-25 grams (n=6) were infected on day 1 and day 2. On the day of 
infection, a vial of HPIV3 virus was thawed and retained on ice. Mice were intranasally 
infected with 50 µL of virus stock (2.12x109 HPIV3 particles per ml). Each mouse was 
inoculated with 12.5 µL of virus stock in one nostril and then 12.5 µL was given to 
another nostril twice to give 50 µL of virus stock in total. After nasal inoculation, the 
mice were held in upright position for 2 minutes to facilitate the delivery of the virus to 
the airways. The procedure was repeated twice giving the animal 50 µL of virus stock 
in total. The second viral inoculation was also carried out in similar procedures as the 
first inoculation. The 50 µL volume was decided to be given for intranasal applications 
in mice based on a previous  study which suggested that giving 50 µL was able to 
achieve relative distribution of more than 50% instilled substance in the lungs 
compared to 5 µL which seems to be undistributed.  The same study also revealed that 
instillation of substance in anaesthetised mice result in 6 folds more distribution in the 
airways compared to intranasal application in conscious mice with the same volume 
(Southam et al., 2002). 
Therefore, as the intranasal infection of HPIV3 in conscious mice did not result in the 
expected response, and in order to assess the effect of anaesthesia on the HPIV3 
infection, an intranasal inoculation of HPIV3 in anaesthetised mice (n=6) was also 
carried out. Mice were lightly anesthetized by isoflurane (Oxygen 40%: isoflurane 
60%). While anesthetized, the mice were intranasally infected with 50 µL of virus stock. 
The second viral inoculation was carried out in conscious unanaesthetised animals.  
Control mice (n=6) were also anesthetized and subjected to intranasal administration of 
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conditioned media (sham). Inoculation of HPIV3 and sham were performed in a class II 
safety cabinet 
Following infection, HPIV3 infected mice were returned to their cages, and then housed 
in a mice isolator for a further 4 days. On 4 days post second infection, mice were 
sacrificed. The time of sacrificing was selected based on the HPIV3 infection in the 
guinea pigs in our laboratory (Toward et al., 2005; Ford et al., 2013). 
III.1.2. AIRWAY RESPONSIVENESS AND LAVAGE 
Airway hyperresponsiveness provoked by increasing dose of methacholine was 
measured on day 0 and day 6 using unrestrained whole body plethysmography 
(Buxco) as described in CHAPTER 2.  Baseline airway functions and body weight were 
also monitored every day until the procedures were completed. 
Mice were euthanized by intraperitoneal injection with pentobarbitone sodium overdose 
on day 6. The tracheas were exposed surgically, tracheal cannula was inserted, and 
the lung was lavaged in situ with 1 ml of sterile PBS as described in CHAPTER 2. The 
left upper lobe of the lung tissues from each mouse was bisected after being lavaged 
and then the lung quickly frozen at −80°C until assayed. Frozen lung was used for 
detection of virus by reverse -transcription polymerase chain reaction (RT-qPCR and 
plaque assay. HPIV3 infection protocol is shown in figure 4.3. 
 
Figure 4.3. Experimental protocol of HPIV3 infection in BALB/c mice 
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III.1.3. DETERMINATION OF VIRAL TITRES  
III.1.3.1. QUANTITATIVE DETECTION OF HPIV3 RNA BY LIGHT CYCLER RT-
QPCR 
Unless stated otherwise, the detailed procedure is detailed in CHAPTER 2 
III.1.3.1.1. Nucleic Acid Extraction 
The 100 mg thawed lung was transferred into a homogenization tube containing 1 ml 
sterile phosphate buffered saline. The lungs were homogenized two times at 224 G for 
twenty seconds with 5 seconds pause between the intervals with a tissue homogenizer. 
The homogenate was then centrifuged at 170 G for 6 minutes. Lung supernatant was 
then aliquoted and frozen at −80°C until assayed. On the day of assay, RNA was 
extracted from 200 μL lung supernatant and the subjected to RT-qPCR with lightcycler 
as described in CHAPTER 2. 
III.1.3.1.2. Determination of HPIV3 titre on by Plaque Assay 
The BSC-1 media in this experiment was supplemented with 1% penicillin 
streptomycin, to prevent any contamination from BALF. BSC-1 cells were seeded onto 
96 well plates and then incubated at 37 °C in a humidified atmosphere containing 5% 
CO2 until reaching at least 95% confluency. The cell monolayer was then infected with 
50 μl/well of fresh BALF of each animal, and then 100 μl/well of Avicel monolayer was 
added. HPIV3 virus stock was used as control. After 3 days of incubation, the cell 
monolayer was fixed with formaldehyde and stained with crystal violet as detailed in 
CHAPTER 2. 
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III.2. DEVELOPMENT OF MICE MODEL OF POLY (I:C) INOCULATION 
III.2.1. INSTILLATION OF MICE 
Mice were lightly anesthetized as previously described with isoflurane. Under 
anaesthesia, mice were administered 30 µg poly (I:C) or 100 µg poly (I:C)  in 50 µL 
PBS, via the nares. Each mouse was given 12.5 µL of poly (I:C) stock in one nostril 
and then 12. 5 µL was given to the other nostril twice to give 50 µL poly (I:C) stock in 
total. After intranasal administration, the mice were held in upright position for 2 
minutes to facilitate the delivery of the poly (I:C) to the airways. The procedure was 
repeated. Mice received three administrations of poly (I:C) with a 24 hour rest period 
between each administration (day 1; day 2; and day 3).  In the control group, mice were 
instilled with PBS.  After administration, mice were allowed to recover and returned to 
their cage. Baseline respiratory function reading was taken everyday. Poly (I:C) 
administration protocol is shown on the following diagram (fig. 4.4). 
 
Figure 4.4. Experimental protocol of poly (I:C) instillation in BALB/c mice 
 
III.3. AIRWAY RESPONSIVENESS AND LAVAGE 
Airway hyperresponsiveness to methacholine was measured on day 0 and day 4 using 
unrestrained whole body plethysmograph obtained from Buxco as described in 
CHAPTER 2.  
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III.4. DEVELOPMENT OF MICE MODEL OF INFLUENZA A (H1N1/PR8) 
INFECTION 
Mouse-adapted influenza A H1N1/PR8 stock was grown in embryonated egg and kept 
at −80°C as described in CHAPTER 2. 
III.4.1. INFECTION OF MICE 
The animals were anaesthetized lightly with isoflurane. Influenza A (H1N1/PR8) 10 or 
25 pfu in 50 µl PBS per mouse was inoculated intranasally. Each mouse was given 
12.5 µL of virus stock in one nostril and then 12.5 µL was given to the other nostril 
twice to give 50 µL virus stock in total.  After nasal inoculation, mice were held in 
upright position for 2 minutes then were put back in the transfer cage in prone position 
to facilitate the virus to spread evenly to the right and the left lungs. Control mice were 
treated the same and subjected to intranasal administration of PBS. All procedures 
were conducted in class II biosafety hood/cabinet. Mice were then returned to the 
mouse isolator once the infection finished.  
III.4.2. AIRWAY RESPONSIVENESS AND LAVAGE 
 Airway responsiveness on methacholine provocation was measured on day 0 and on 
the specified sacrificed day using unrestrained whole body plethysmography described 
in CHAPTER 2.  On days 4, 7, and 10 after infection, 8 mice (4 mice infected with 10 
pfu and 4 mice infected with 25 pfu of virus) were sacrificed and bronchoalveolar 
lavage was performed. Control mice were sacrificed on day 10 after PBS instillation. 
Baseline respiratory functions and body weight were also monitored every day until the 
procedures was complete. Left lobe of the lung tissues from each mouse was used for 
histologic analysis and immersed in phosphate buffered formaldehyde solution. The 
remaining lungs were quickly frozen at −80°C for later detection of virus plaque forming 
assay. Influenza A infection protocol is shown in figure 4.5. 
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Figure 4.5. Experimental protocol of influenza virus infection in BALB/c mice 
 
III.4.3. INFLUENZA VIRUS TITRES  
Plaque forming assays were performed to measure virus loads in the lung of infected 
mice. The frozen lungs were thawed and, transferred into homogenisation tube 
containing 1 ml of MDCK medium without foetal calf serum.  Using a Precellys beaded 
tube, the lungs were homogenised in a tissue homogeniser 2 times at 224 G for 20 
seconds with 5 seconds pause between the spin and then clarified by centrifugation at 
224 G for 10 minutes at 4°C. The clear supernatants containing virus were diluted 
serially using MDCK media, 1:2000 then 1:3 for 6 times. The diluted viruses were 
infected to a confluent MDCK monolayer, incubated for 5 hour at 37°C to facilitate 
infection, then were overlaid with 1.2% Avicel in MDCK media and incubated at 37°C 
for a further 48 hours. The monolayer cells were then immunostained with AEC as 
described in CHAPTER 2. 
III.4.4. LUNG HISTOLOGY  
Lung was stained with H and E and was analysed with histopathology scoring as 
described in CHAPTER 2. 
CHAPTER IV  
 
113 
 
IV. RESULTS 
IV.1. HPIV3 INFECTION IN MICE 
IV.1.1. BASELINE BODY WEIGHT AND RESPIRATORY FUNCTIONS 
In order to study HPIV3 respiratory infection, 6 BALB/C mice were intranasally 
inoculated with 2.12x109 HPIV3 particles per ml of HPIV3. The baseline respiratory 
functions and body weight were monitored until the day they were sacrificed (day 4 
post second infections). Significant change of body weight was absent in all HPIV3 or 
sham infected mice (fig. 4.6). At no time point did mice infected with HIPV3 or sham 
(media) exhibit clinical signs suggesting respiratory distress (fig. 4.7).   
 
Figure 4.6. Body weight changes of mice infected with HPIV3 or instilled with sham. Results are 
expressed as means ± SE of a percentage of the baseline values. 
 
Figure 4.7. Changes in the baseline airway function expressed as means ± SE of absolute 
Penh in mice infected with HPIV3 or instilled with sham. 
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IV.1.2. AIRWAY RESPONSIVENESS 
 
HPIV3 infection in either conscious or anaesthetised mice did not result in significant 
increase of airway responsiveness as shown in figure 4.8. 
 
Figure 4.8. Dose response curve of HPIV3 infection on conscious (B) and isoflurane 
anaethetised (C) mice. Mice were instilled intranasally with HPIV3 on day 1 and day 2 while 
they were anaesthetised or conscious. Sham instilled anaesthetised mice were used as control 
(A). Mice were challenged with increasing concentration of methacholine chloride (0.1 mg/ml; 
0.3 mg/ml; 1 mg/ml; 3 mg/ml; and 10 mg/ml). Baseline lung function and responses to 
increasing doses of methacholine was measured by whole body plethysmography. Results are 
expressed as mean ± SEM of absolute Penh. Data were analysed with unpaired two tailed t-test 
(* P< 0.05; n=6).   
 
IV.1.3. CELLULAR INFLAMMATORY RESPONSES TO HPIV3 INFECTION  
Inflammatory cells recruitment in the airway and cell recovery in bronchoalveolar 
lavage (BAL) was used to characterize the airway inflammatory response to HPIV3. 
Compared to sham instilled animals, there was no significant increase in either total 
cells influx or in individual inflammatory cells as shown by figure 4.9. 
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Figure  4.9.  The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar lavage fluid of sham or HPIV3 infected mice. Results are 
expressed as mean ± SEM. Data analysed for each differential cell type and total count using 
one-way ANOVA, followed by post hoc Bonferroni test to determine the difference in cell counts 
(*P < 0.05, n=6). 
 
IV.1.4. HPIV3 TITRES IN THE BALF AND LUNGS 
The animal was infected with 50 µl of 2.12x109 HPIV3 particles per ml. The titre of the 
virus in anaesthetised animals was determined by qRT-PCR compared to those of 
sham treated animals. However, there was no difference in the count of RNA particle in 
HPIV3 infected animal compared to those instilled with sham. The results are 
presented in table 4.1. 
In order to make sure that there is no live infectious virus in the BALF, the fresh BALF 
from HPIV3 infected animals were also infected on HPIV3 sensitive cells (BSC-1 cells). 
After 3 days incubation, there is no cytopathic effect (CPE) observed which shows no 
sign of infection in the cells. 
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Table 4.1. RNA was extracted from fresh BALF and lung from HPIV3 or sham infected animals. 
Virus titres were determined using qRT-PCR and are expressed as particles per ml, β-actin was 
used as a housekeeping gene. Statistical analysis (unpaired t test, two tailed) shows no 
significant difference in the titre of sham and HPIV3 infected animals. 
 
IV.2. POLY (I:C) INSTILLATION  
IV.2.1. BASELINE BODY WEIGHT AND RESPIRATORY FUNCTIONS 
Both concentrations of poly (I:C) (100µg/50µl and 30µg/50µl) on mice had no effects on 
either baseline airways function or body weight. Mice’s body weight and baseline 
respiratory functions which were monitored throughout the study did not show 
significant change (fig. 4.10 and fig 4.11 respectively).  
 
Group  Virus titre in particles mL
-1
 β-actin concentration mL
−1
 
HPIV3 infected BALF 29.4±6.3 26.6±12.0 
HPIV3 infected lungs 27.9±8.4  157.7±35.9 
Sham infected BALF 42.0±10.8 18.2±8.4
 
Sham infected lungs 30.4±5.4 117.0±23.0  
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Figure 4.10. Body weight changes of mice instilled with poly (I:C) or PBS. Results are 
expressed as means ± SE of a percentage of the baseline values. 
 
Figure 4.11. Changes in the baseline airway function expressed as means ± SE of absolute 
Penh in mice instilled with poly (I:C) or PBS. 
 
IV.2.2. AIRWAY RESPONSIVENESS 
 
Low concentration of poly (I:C) (30µg/50µl) did not result in significant increase of 
airway responsiveness. So, a higher dose (100µg/50µl) of poly (I:C) was delivered 
which revealed  airway hyperresponsiveness provoked by the highest dose of 
methacholine chloride (Fig 4.12). 
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Figure 4.12. - Mice were instilled with PBS (A), 30µg/50µl (B), or 100µg/50µl (C) of poly (I:C) 
intranasally every 24 h for three days (day 1-3). On day 0 and 24 h after the last poly(I:C) 
administration, mice were challenged with increasing concentration of methacholine chloride 
(0.1 mg/ml; 0.3 mg/ml; 1 mg/ml; 3 mg/ml; and 10 mg/ml). Baseline lung function and responses 
to increasing doses of methacholine was measured by whole body plethysmography. Results 
are expressed as mean ± SEM of absolute Penh. Data were analysed with unpaired two tailed t-
test (* P< 0.05; n=6).   
 
IV.2.3. CELLULAR INFLAMMATORY RESPONSES TO POLY (I:C) 
INSTILLATION 
  
 
Figure 4.13.  The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar lavage fluid of PBS or poly (I:C) instilled mice. Results are 
expressed as mean ± SEM. Data were analysed for each differential cell type and total count 
using one-way ANOVA, followed by post hoc Bonferroni test to determine the difference in cell 
counts. 
#
significantly different from all other groups (P < 0.05; n=6).  
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Intranasal administration of three once-daily doses of poly (I:C) resulted in 
inflammatory cell influx into the lung. There was a significant increase in total cells in 
the BALF samples at 100µg/50µl and also with 30µg/50µl of poly (I:C) compared to 
PBS instilled mice (Figure 4.13). There were significant increase in the numbers of 
macrophages, neutrophils, and lymphocytes; eosinophils were not detected in either 
PBS or poly (I:C) treated mice.  
 
IV.3. INFLUENZA A (H1N1/PR8) INFECTION 
The PR8 (H1N1) influenza A virus was initially isolated from human and subsequently 
adapted to mice.  
IV.3.1. BASELINE BODY WEIGHT AND RESPIRATORY FUNCTIONS 
BALB/c mice were infected with 10 pfu/50µl and 25 pfu/50µl of H1N1/PR8 virus via the 
intranasal route. Baseline lung functions and weight loss was recorded for the following 
10 days after infection. The weight loss kinetics was not significantly different between 
mice infected with 10 or 25 pfu of virus. There was a trend of weight loss starting from 
day 6 after infection which slowly recovered on day 10 after infection in mice infected 
with influenza A virus. Control mice instilled with PBS did not experience any weight 
lost on those time points (fig. 4.14). However, due to the small number of animal used 
in the experiment, the difference of the mice weight lost was not significantly different 
between H1N1/PR8 infected mice and PBS instilled mice at any time point. 
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Figure. 4.14. Body weight changes of mice infected with influenza A (H1N1/PR8). Results are 
expressed as mean ± SEM of a percentage of the baseline values. 
 
Baseline lung functions of infected mice, expressed in Penh, had similar kinetics to 
those of body weight. The baselines Penh were starting to escalate on day 6 after 
infection and then persistently increased and peaked on day 8 for mice infected with 10 
pfu of virus, while baselines Penh of the group of mice infected with H1N1/PR8 25 pfu 
peaked on day 7. Penh subsequently decreased and recovered on day 10. The peaked 
baselines Penh on virus infected group were significantly different compared to mock 
(PBS) instilled group of mice as depicted in figure 4.15. 
 
Figure 4.15. Changes in the baseline airway function expressed as means ± SE of absolute 
Penh in mice infected with influenza virus. Data were analysed with unpaired two tailed t-test 
(*P< 0.05).  
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IV.3.2. AIRWAY RESPONSIVENESS 
Airway responsiveness to inhaled methacholine increased following H1N1/PR8 
infection with 10 and 25 pfu in mice starting at day 4 after infection with an increase in 
the maximal response at a methacholine concentration of 10 mg/ml.  A significant 
increase in baseline lung functions (Penh) was detected on day 7 in the group of mice 
infected with 25 pfu of virus. The airway responsiveness was returning to control levels 
by day 10. Infected mice were more sensitive to methacholine compared to PBS 
instilled mice, requiring lower concentrations to elicit the same Penh (fig 4.16). 
 
 
Figure 4.16. -  Mice were infected with 10 pfu (B, C, and D) or 25 pfu (E, F, and G) of influenza 
A virus (H1N1/PR8) intranasally. On day 4 (B and E), 7 (C and F), and 10 (D and G) days after 
infection, mice were challenged with increasing concentration of methacholine chloride (0.1 
mg/ml; 0.3 mg/ml; 1 mg/ml; 3 mg/ml; and 10 mg/ml). Baseline lung function and responses to 
increasing doses of methacholine was measured by whole body plethysmography. Results are 
expressed as mean ± SEM of absolute Penh. Data were analysed with unpaired two tailed t-test 
(* P< 0.05; n=4 except for group of mice infected with 25 pfu of H1N1 for 7 days (F), n=3).   
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IV.3.3. CELLULAR INFLAMMATORY RESPONSES TO INFLUENZA A 
(H1N1/PR8) INFECTION  
The recruitment of inflammatory cells in the airways recovered in BAL fluid was also 
monitored on day 4, 7 and 10 after infection to characterise the inflammatory response. 
Inflammation was markedly increased. On day 4 after infection with influenza A virus, 
there was an increasing trend of total cell count compared to controls even though not 
statistically significant. The cell count was not significantly different from PBS instilled 
animals probably because the small number of animals used.  On day 7 and 10 after 
infection of influenza A virus, the number of cells significantly increased compared to 
PBS instilled animals (fig 4.17 and 4.18) 
 
Figure 4.17.  The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar lavage fluid of of mice infected with 10 pfu of influenza A virus.  
Results are expressed as mean ± SEM. Data were analysed for each differential cell type and 
total count using one-way ANOVA, followed by post hoc Bonferroni test to determine the 
difference in cell counts. *connected with corresponding bar is significantly different from each 
other (P<0.05; n=4).  
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Differential cell counts show a considerable influx of both macrophages and neutrophils 
on day 7 after virus infection. Neutrophil counts decreased gradually whereas 
lymphocyte counts progressively increased from day 4 until day 10 post infections. 
Eosinophils were not identified or were in very low counts. 
 
 
Figure 4.18.  The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar lavage fluid of of mice infected with 25 pfu of influenza A virus.  
Results are expressed as mean ± SEM. Data were analysed for each differential cell type and 
total count using one-way ANOVA, followed by post hoc Bonferroni test to determine the 
difference in cell counts. 
#
significantly different from all other groups; *connected with 
corresponding bar is significantly different from each other (P<0.05; n=4 except for group of 
mice infected with 25 pfu of H1N1 for 7 days, n=3).  
 
IV.3.4. INFLUENZA VIRUS TITRES IN THE LUNGS 
Influenza infection in the lungs was confirmed with plaque assay. Influenza virus was 
recovered and peaked on day 4 after infection but was below the level of detection on 
day 10 after infection. Even though there was a trend of decreased viral titres after day 
4 post infection, the viral titres on different time points were not significantly different 
(Fig 4.19). 
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Figure 4.19.  Viral titres of lungs of mice infected with influenza A 10 pfu and 25 pfu. The lungs were 
harvested on day 4, 7, and 10 after infection. Virus titres were determined by plaque assay on MDCK cells. 
Virus titres are expressed as mean ± SEM of pfu per sampled lungs. Data were analysed using 
one-way ANOVA, followed by post hoc Bonferroni’s test to determine the difference in viral titres 
(*P < 0.05, n=4 except for group of mice infected with 25 pfu of H1N1 for 7 days, n=3). 
 
IV.3.5. LUNG HISTOLOGY 
Histological analysis of influenza infected lungs showed evidence of bronchiolitis and 
perivascularitis (Fig 4.20). By day 7 post infection, infected lungs showed a severe 
cellular inflammation which characterised by a massive amount of cellular infiltrates in 
peribronchial and perivascular area.  Epithelial cell shedding, alveolar collapse, and 
pulmonary haemorrhage were also observed on day 7 after influenza virus infection 
(Fig 4.21).   There was no significant difference in the mean of pathology score of mice 
infected with 10 or 25 pfu of influenza A which killed at 4, 7, or 10 days after infection. 
Only the histopathologycal score from mice infected with 25 pfu of influenza virus 
(5.5±1.7) was significantly different from un-infected animals (1.2±0.3) (Fig 4.22). 
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Figure 4.20.  Histopathological changes of lungs of un-infected mice (A) or mice infected with 
10 pfu (B, D, and G) or 25 pfu (C, F, and H) influenza A virus. The lungs were harvested on day 
4 (B and C), 7 (D and F), and 10 (G and H) after infection. The lungs were stained with 
haematoxylin and eosin to display general morphology (100x magnification). Arrowhead () = 
pulmonary haemorrhage: * = debris of epithelium shedding: # = perivascular and peribronchial 
cellular inflammation. 
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Figure 4.21.  Histopathological features of lungs of mice infected with influenza A virus on 7 days after 
infection. Arrowheads show A. Epithelial cells shedding; B. Alveolar collapse; C. Pulmonary haemorrhage. 
The lungs were stained with haematoxylin and eosin to display general morphology (100x magnification).  
 
 
Figure 4.22.  The mean lung pathology scores of influenza A infected mice. Results are 
expressed as mean±S.E.M. Data were analysed using one-way ANOVA, followed by post hoc 
Bonferroni’s test to determine the mean pathology score (*P < 0.05). 
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IV.4. INFLUENZA A (H1N1/PR8) INFECTION: 5 DAYS 10 PFU 
This study was planned to be followed by a series of experiments in which introducing 
the respiratory infective agent was added to the murine model of ovalbumin-induced 
allergic airway inflammation in order to observe viral associated exacerbation. For that 
reason, moderate doses of virus were needed so that when allergen (ovalbumin) 
challenge was delivered, the animal would survive without severe pneumonia but still 
showed considerable inflammatory cell recruitment into the airways and airway 
hyperresponsiveness. 
Based on the above results, 4 days infection with 10 pfu of influenza A virus seems to 
be capable of fulfiling the desired effects on the allergen challenge day. However, the 
logistic of the experiment required that mice would need to be culled on the day after 
the allergen challenge day (day 5).  An experiment to ensure that on day 5 after 
infection with 10 pfu of influenza A, mice still have the desired inflammatory state was 
therefore conducted.  
On day 5 after inoculation with 10 pfu of influenza A, there was no increase in 
respiratory function baseline. There was a significant increase in airway 
responsiveness and inflammatory cell influx as depicted on figure 4.23 and figure 4.24. 
 
Figure 4.23. Mice were infected with 10 pfu of influenza A virus (H1N1/PR8) intranasally. On 
day 0 and 5 days after infection, mice were challenged with increasing concentration of 
methacholine chloride (0.1 mg/ml; 0.3 mg/ml; 1 mg/ml; 3 mg/ml; and 10 mg/ml). Baseline lung 
function and responses to increasing doses of methacholine was measured by whole body 
plethysmography. Results are expressed as mean ± SEM of absolute Penh. Data were 
analysed with unpaired two tailed t-test (* P< 0.05; n=6).   
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Figure 4.24 The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar lavage fluid of mice infected with 10 pfu of influenza A virus for 5 
days or PBS for 10 days.  Results are expressed as mean ± SEM. Data were analysed for each 
differential cell type and total count using one-way ANOVA, followed by post hoc Bonferroni test 
to determine the difference in cell counts (*P < 0.05; n=6). 
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V. DISCUSSION 
This study was conducted to understand better the pathogenesis of respiratory viral 
infection and associated host responses during acute infection. 
V.1. HPIV3 INFECTION IN MICE 
The design of the experiment by infecting the animals on day 1 and day 2 and then 
terminating on day 6 was based on successful in vivo experiments in our laboratory 
carried out by Toward et al. (2005) and Ford et al. (2013) who infected guinea pigs with 
the virus. In addition, in vitro work carried out previously (CHAPTER 2; Fig. 2.5) also 
showed that HPIV3 reached the highest titre on day 3-7 post infection.  
The present study demonstrates that HPIV3 in the titres previously used for guinea 
pigs, does not infect mice. Despite two sets of HPIV3 infection experiments performed 
with and without anaesthesia, there was no reduction of lung functions throughout the 
study. There was also no increase in airway responsiveness as well as in inflammatory 
cells influx in the airways of the infected animals compared to sham instilled animals.  
Viral titres, determined with RT-PCR, from the lungs and BAL fluids of HPIV3 infected 
animal were not significantly different compared to those of sham instilled mice. 
 The RT-PCR is a quick and very sensitive method to determine viral titre. However, 
RT-PCR is not able to differentiate between infectious and non-infectious viral particles. 
Therefore, a cell culture method was also conducted to test the infectivity of the 
recovered virus from HPIV3 infected mice. There is no sign of viral replication when the 
BALF of the infected mice was applied to sensitive cells (BSC-1 cells) whereas 
cytophathic effects were observed on cells incubated with virus stock. 
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This model was tried to be developed as it has been successfully conducted in guinea 
pigs and it also successfully induced exacerbation in OVA induced allergic airway 
inflammation in guinea pigs. However, the results of the current experiment show that 
there is no considerable benefit in continuing to develop the HPIV3 in mice model for 
subsequent studies. 
V.2. POLY (I:C) INSTILLATION IN MICE 
The failed HPIV3 experiment lead the search for an effective alternative respiratory 
infective agent and next to be used was poly (I:C), a synthetic dsRNA which also a 
TLR3 ligand. Activation of TLR3 by dsRNA resulted in impairments in lung function 
marked by AHR to methacholine and inflammation. The changes described are similar 
to those of mice infected with Respiratory Syncytial Virus (RSV) (Schwarze and 
Johnston, 2004; Schwarze and Schauer, 2004). 
In the current study, administration of a high dose (100µg/50µl) of poly (I:C), 
intranasally induced a significant  increase in  airway responsiveness towards 
increasing dose of methacholine challenge which was accompanied by an increase in 
airway inflammation. All leukocyte types were increased except eosinophils. This is not 
the first study showing that the administration of poly (I:C) in mice caused airway 
inflammation accompanied by airway hyperresponsiveness. Some studies have 
reported that acute or chronic poly (I:C) instillation induced airway 
hyperresponsiveness and cellular inflammation  (Stowell et al., 2009; Starkhammar et 
al., 2012). 
The TLR family has been found in the lung especially in smooth muscle cells and 
primary bronchial epithelial cells (Sha et al., 2004). TLR are also expressed by 
monocytes and neutrophils (Zarember and Godowski, 2002). The activation of TLR by 
dsRNA in vivo and in vitro results in a significant increase in the expression of pro-
inflammatory cytokines, chemokines, and growth factors (Ritter et al., 2005). The 
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increase in expression of the cytokines and chemokines leads to the infiltration of 
inflammatory cells into the respiratory airways and the lung. Both low dose 
(100µg/50µl) and high dose (100µg/50µl) of poly (I:C) were able to induce inflammatory 
cells influx into the airways. 
In summary this study has shown that administration of poly (I:C)  increases airways 
responsiveness and inflammatory cells influx similar to viral infection. Therefore, poly 
(I:C) is worth to be considering as  a potential agent to be exploited in subsequent 
studies as it may trigger an exacerbation if applied to allergic mice. In addition, poly 
(I:C) as a synthetic agent bears no risk of infection to the investigator.  
However, being a synthetic agent, poly (I:C) is not able to replicate as viruses. Poly 
(I:C) might  also only activate TLR 3  while viral infection activates a plethora of PRRs 
(pattern recognition receptors), therefore it might fail to completely simulate the 
pathogenesis induced by respiratory viral infection.  
V.3. INFLUENZA A (H1N1/PR8) INFECTION 
The consideration that poly (I:C) is a synthetic agent which may not represent the 
complete response expressed by respiratory viral infection led us to search for a 
respiratory infective agent and we selected influenza A (H1N1/PR/8) virus. Several 
studies have shown that the mouse is a useful model to study the virulence of influenza 
virus particularly the H1N1 influenza A virus (Kash et al., 2006; Inn et al., 2013; Shi et 
al., 2013). The models have been proven to be able to be utilised to study the 
infectivity, pathogenesis, as well as subsequent application such as in the evaluation of 
the role of viral infection in asthma.  
Infection of influenza H1N1/PR8 virus in mice in the present experiment increased the 
cellular inflammation. On day 4 after infection the total cell number recovered in BAL 
fluid was increased in both infective dose 10 and 25 pfu per mouse, even though not 
statistically significant. On day 7, the airway cellular inflammation was augmented 
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compared to that of day 4. The airway inflammation was marked with neutrophilia. The 
recruitment of neutrophils in the early course of influenza infection, has been shown in 
some animal models of influenza infection, including mouse, ferret, and macaque 
(Smith and Sweet, 1988; Baskin et al., 2007; Wareing et al., 2007). Related to the 
neutrophilia, the upregulation of several genes associated with neutrophil recruitment 
and activation are also observed in macaque model on day 4 after infection (Kobasa et 
al., 2004).  
The number of macrophages was also gradually increased from day 4 to day 7 after 
the H1N1/PR8 infection. Apart from neutrophils, the recruitment of macrophages is also 
regarded as an important response to acute virus infection (Papadopoulos et al., 2007). 
Macrophages have important roles to kill and perform phagocytosis to viruses/virions 
and virus infected cells (Hashimoto et al., 2007). Neutrophils and macrophages 
contribute to viral elimination in animal models of influenza infection cells (Hashimoto et 
al., 2007). 
Lymphocytes, particularly CD8+ T (cytotoxic T cells = CTL) and CD4+ T (T helper 1) 
cells are also essential in the process of resolution from influenza infection (Doherty et 
al., 1997). In the current study, the number of lymphocytes was progressively 
increased started from day 7. The number of lymphocytes on day 7 was 6 folds higher 
than the number of lymphocytes on day 4 in mice infected with 10 pfu of virus. The 
increase was 8 folds in mice infected with 25 pfu of virus. It needs 5-7 days after initial 
influenza infection for the T-lymphocytes to present in the lungs to eliminate the virus 
(White et al., 2008). In the current study, the highest level of lymphocytes number 
occurred on day 10 after infection when viral titre was unidentified in the lung 
homogenate. This is in agreement with Flynn et al. study which reported that the CTL 
number peaked at day 9-10 coincided with viral elimination (Flynn et al., 1998).  
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Infection of mice with 10 or 25 pfu of influenza virus per mouse also increased airway 
hyperresponsiveness. Some suggestions can be proposed to explain the enhancement 
of the airway responsiveness. The first suggestion is the defect of M2 receptors due to 
viral infection as previously discussed in the INTRODUCTION section in this chapter. 
The second hypothesis involves macrophages and neutrophils. In vitro, viral infected 
macrophages released reactive oxygen species and inflammatory mediators including 
prostaglandin E2, platelet activating factors, and thromboxane X2 (Folkerts et al., 
1998). Neutrophils have been reported to be activated by viral infection which then 
increases the release of superoxide enzymes (Folkerts et al., 1998).  Those processes 
were noted to contribute to the enhancement of airway hyperresponsiveness 
(Matsumoto et al., 1999). However, in the present study, on day 10 after infection the 
baselines respiratory function was returned to normal and airway hyperresponsiveness 
was also resolved even though cell influx in the airway was still markedly high. This 
suggests that the inflammatory cell influx in the airway in this influenza A infection was 
not the only key factor in determining the pulmonary function and airway 
responsiveness. A study of influenza A infection in cotton rat suggested that epithelial 
cell damage plays a more crucial role in inducing pulmonary function deterioration 
rather than inflammation  as the tachypnea of the cotton rats had resolved even though 
the evidence of pneumonitis, peribronchiolitis, alveolitis, and perivascularitis still 
persisted (Trias et al., 2009).  
As formerly mentioned, influenza virus is known to target epithelial cells lining the 
airways. Decreased baseline lung function or increased Penh and increase in airway 
responsiveness coincided with epithelial damage (Trias et al., 2009). Bozanich et al. 
(2008) reported that the increase of airway hyperresponsiveness in influenza A infected 
mice provoked by methacholine was associated with the increase of protein level in 
BAL fluid. They then proposed that the alteration of epithelial barrier permeability might 
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increase the exposure of metacholine to the nervous system which lead to the increase 
of airway hyperresponsiveness (Bozanich et al., 2008). 
Recent study identified IL-33 – IL-13 pathway to contribute to the development of 
airway hyperresponsiveness in influenza infection (Chang et al., 2011). This pathway is 
independent from the Th2 pathway which is responsible for the development of airway 
hyperresponsiveness in asthma. Influenza infection increases the level of IL-33 
expression in the lungs of mice (Le Goffic et al., 2011). IL-33 has been thought to play 
a role as a danger signal and being released when cells undergo apoptosis or necrosis 
(Zhao and Hu, 2010; Borish and Steinke, 2011). In the acute influenza infection, IL-33 
is released from both macrophages (Chang et al., 2011) and viral infected epithelial 
cells (Le Goffic et al., 2011). In the milieu of IL-33, natural helper (NH) cells, an innate 
lymphoid cells which bear ST2, the receptor for IL-33, secrete a high level of IL-13 
which contribute to the development of airway hyperresponsiveness (Chang et al., 
2011)  
The data from this current experiment suggests that there was a clear dose-dependent 
relationship of the dose of inoculum on the severity of influenza A (H1N1/PR8) infection 
in mice. The influenza A (H1N1/PR8) virus showed a significant replication in the 
respiratory tract of the infected mice. After an intranasal application, virus titres found in 
lung homogenates from 4 days infected mice were the highest. The titres were then 
gradually decreased and becoming undetected on day 10 after infection. The reduced 
viral replication after day 4 post infection might probably be because either most of the 
targeted epithelial cells have become shed and necrotic and therefore did not allow 
further increase in viral replication or because of the effectiveness of inflammatory cells 
along with their respective inflammatory mediators to eradicate the virus.  
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Histopathological analysis showed a gradual increase in lung inflammation form day 4 
and peaked on day 7 after infection. In a study of mice infected with LC50 of the same 
virus (influenza A H1N1/PR8), a marked lung cellular inflammation was started on day 
2 after infection (Fukushi et al., 2011). In the same study, histopathological features 
such as peribronchial and perivascular inflammation, epithelial cells shedding, alveolar 
collapse, and pulmonary haemorrhage were also observed as they were in the current 
study.  
The plan of subsequent studies to induce exacerbation in respiratory allergic mice   has 
made a moderate viral respiratory infection which not lethal to mice a necessity. To 
determine the dose of the influenza A (H1N1) virus and the length of infection required 
to cause moderate inflammation without apparent pneumonia, 2 doses of intranasal 
instillation i.e. 10 pfu and 25 pfu were inoculated and 3 time points were determined. 
Moderate infection was verified by observing the pattern of baseline lung functions, 
kinetics of weight loss, inflammatory cell influx, and airway hyperresponsiveness at 4, 
7, or 10 days after inoculation.  
Moderate infection with no increase in baseline respiratory function but marked airway 
hyperresponsiveness was obtained by infecting mice with 10 pfu of influenza A virus for 
4 days. Therefore the subsequent experiment by introducing this respiratory viral 
infection model into ovalbumin induced allergic mice will be conducted by infecting the 
mice with 10 pfu of influenza A virus, then challenged with ovalbumin on day 4 after 
infection. The subsequent experiment will require the mice to be sacrificed on day 5 
after infection. Therefore an additional experiment infecting mice with 10 pfu of virus for 
5 days was conducted, and the results which showed moderate inflammation ensuring 
the following experiments to be executed as planned. 
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VI. CONCLUSION 
HPIV3, Poly (I:C), and influenza A (H1N1/PR8) inoculation of mice has been screened 
and studied. HPIV3 infection in mice did not result in expected inflammatory responses 
such as an increase in airway responsiveness as well as influx of inflammatory cells 
into the airways. To the best of my knowledge, this is the first study reporting the 
infection of HPIV3 in mice. The lack of demonstrable HPIV3 infection explains why this 
has not been published elsewhere. 
Poly (I:C) was able to produce some inflammatory responses. A high concentration of 
poly (I:C) (100µg/50µl) increased airway responsiveness and inflammatory cell influx in 
the airway with neutrophilia as seen in respiratory viral infection. However, poly (I:C) is 
a synthetic dsRNA and is not a virus and therefore does not replicate and induce an 
immune response as complete as viral infection.  
Influenza A (H1N1/PR8) infection resulted in marked increase in airway 
responsiveness and inflammatory cell recruitment into the airway. This study extended 
previous published work (Julander et al., 2011) by investigating the infectious dose of 
the virus and the duration of the infection. The infection of mice with 10 pfu of influenza 
A (H1N1/PR8) for 4/5 days was able to produce a moderate infection with moderate 
inflammation yet marked airway hyperresponsiveness as required to be integrated with 
the murine model of ovalbumin induced allergic disease to cause an exacerbation. 
Therefore, influenza A (H1N1/PR8) was selected to be used in subsequent studies. 
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I.  INTRODUCTION 
Asthma is a complex syndrome which is characterised by many clinical phenotypes 
most commonly are chronic inflammation with reversible airway limitation accompanied 
by airway hyperresponsiveness.  Animal models of asthma have provided a significant 
contribution to better understand the pathophysiology of asthma particularly to study 
the pathogenetic pathway and to suggest therapeutic targets for intervention (treatment 
by drug). 
The mouse is the most widely used animal to model asthma as it offers numerous 
advantages compared to other animal models.  Strain BALB/c is the most used among 
mouse strains as genetically it has a well characterised immune response which bears 
a Th2 dominant immune mechanism in response to allergic stimulation. An ideal animal 
model has to have a close resemblance to human asthma. Most of the mouse models 
show some characteristics which make them suitable for evaluating the 
pathophysiology and immunology of allergic asthma. Several characteristic of the 
mouse model such as inflammatory cell infiltration, production of antigen specific IgE, 
elevation in Th2 type immune cytokines such as IL-4, IL-5, and IL-13 resemble the 
features of human asthma (Wills-Karp, 2000). Mouse also exhibits airway 
hyperresponsiveness and some murine models also demonstrate the early and late 
phase allergic reactions after encounter with specific allergen. Lung function monitoring 
is also possible with unrestrained conscious mice, hence it is easy to assess the 
alteration in an airway function which have cardinal features of asthma. Some mouse 
chronic models of asthma also show some evidence of airway remodelling with smooth 
muscle hyperplasia, collagen deposition, mucus hypersecretion, and membrane 
fibrosis (Kannan and Deshpande, 2003; Stevenson and Birrell, 2011).  
As in any other animal models, the mouse asthma model does not fully simulate 
human asthma. Therefore it needs a judicious approach to extrapolate the findings into 
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human. Asthma does not spontaneously develop in mice (Taube et al., 2004). It needs 
to be induced. The most widely used model is acute allergic response to inhaled 
allergen. There are also anatomical and physiological differences between mouse and 
human. Mouse is quadrupeds which may have influence on the lung response to 
airflow limitation as a result of different interaction between forces acting on the lung 
and the gravity (Bettinelli et al., 2002). Branching pattern of the airways of mouse and 
human is also different. Mouse has less branching airways than human which has  an 
impact in aerosol deposition (Wenzel and Holgate, 2006). Unlike human eosinophils, 
mouse eosinophils seem to be insensitive to many stimuli which degranulate human 
eosinophils (Gelfand, 2002). Inflammatory cells distribute in vascular and perivascular 
areas of mice which does not occur in human asthma (Wenzel and Holgate, 2006). 
Mouse acute models of asthma lack chronicity features such as development of airway 
remodelling which is seen in human asthma (Zosky and Sly, 2007) although chronic 
allergen challenge does lead to remodelling in mice (Evans, 2009). However, the 
presence of those differences does not mean that mouse models are not able to give a 
valuable insight to study human asthma, because every model has its own merits, its 
strength and weaknesses. 
The basic protocol of asthma induction in mice includes multiple sensitisations with 
allergen in conjunction with adjuvant which is followed by a repeated inhaled or 
intranasal exposure of allergen challenge. Allergens including OVA (ovalbumin), house 
dust mite (Lambert et al., 1998), cockroach antigens (Warner et al., 2004), Aspergillus 
fumigatus  (Kurup et al., 1997), and ragweed extracts  (Chapoval et al., 2002) are the 
most popular.  
At present, mice acute ovalbumin (OVA) models have been used in most studies. OVA, 
an antigen from chicken egg white is relative cheap and has a well established immune 
characterisation. Some may say that OVA lacks of clinical relevance because it is not 
the normal antigen which triggers asthma in humans. However, the OVA model offers 
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more detailed endpoints of the experiments as many choices of antibodies-specific to 
OVA are commercially available (Schröder and Maurer, 2007). Murine models of OVA-
induced allergic respiratory inflammation are also able to robustly reflect many of 
human asthma cardinal features such as IgE production elevation, Th2 immunity 
responses, airway inflammation with eosinophilia, airway hyperresponsiveness, EAR, 
LAR, increased mucus production and oedema (Nials and Uddin, 2008).  
Mice are usually sensitised with 1 – 8000 ug of OVA, commonly by multiple intra 
peritoneal injections. OVA is usually injected in combination with adjuvant. The most 
commonly used adjuvant is aluminium hydroxide which is added in the sensitisation to 
skew the immune development towards the Th2 phenotype. Adjuvant-free protocols 
are also possible to be performed even though it needs more antigen injections to 
achieve complete sensitisation. Animals are challenged with ovalbumin usually about 
2-4 weeks after completion of sensitisation. The challenge models are mostly short 
term (1-8 days).The endpoint assessments are usually performed 24 hours after 
challenge (Kumar et al., 2008). 
Currently, there is no standardised protocol of an OVA model of asthma. Most 
laboratories have their own protocol. Protocols vary according to the endpoints 
evaluated in the study. As a result, it is also difficult to directly compare results from 
different mouse OVA model. Our laboratory also has developed a mouse acute 
ovalbumin model that demonstrated some important features in asthma including 
elevation of IgE and OVA-specific ovalbumin IgG, eosinophilia, EAR, LAR, and airway 
hyperresponsiveness (Fernandez-Rodriguez et al., 2008). Therefore this model will be 
used in this and subsequent chapters. 
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II. AIMS  
This chapter’s aim was to study the effects of acute exposure of OVA in OVA 
sensitised mice. The endpoints investigated were lung function expressed as Penh, 
airway responsiveness to methacholine provocation, and influx of inflammatory cells 
into the airways. 
III. METHODS 
The details of the methods used are described in CHAPTER 2. 
III.1. ANIMAL 
Six Male BALB/c mice (20-25g) per group were used for all studies 
III.2. SENSITISATION 
Mice were sensitised on day 0 and 5 by intraperitoneal injections (0.25 ml) of the 
mixture of OVA (50 μg/mouse) and Al(OH)3 (50 mg/mouse) in saline (fig 5.1). 
III.3. OVALBUMIN CHALLENGES 
On day 17, mice were exposed to aerosolised OVA (0.5%) or saline (in a control group) 
inhalation challenges in a perspex box for 2 x 1 hour, with a 4 hour gap between 
exposures.  
 
Figure 5.1. Experimental protocol of ovalbumin sensitised ovalbumin induced allergic airway 
inflammation in mouse  
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III.4. EARLY PHASE AND LATE PHASE DETERMINATION 
Measurement of the lung function of unrestrained mice was recorded as Penh using a 
Buxco system. Values of Penh after allergen challenge were recorded at 0, 20, 40, 60, 
90 and 120 minutes, then hourly until 10 hours followed by a final reading at 19 hours 
after the second ovalbumin challenge.  
III.5. AIRWAY RESPONSIVENESS MEASUREMENTS 
Airway responsiveness in mice was measured after methacholine 
(acetyl‐β‐methylcholine chloride) provocation. Respiratory activity was recorded for 5 
min, to establish baseline value for  Penh. Mice were subsequently exposed to 
increasing doses of aerosolized methacholine dissolved in saline (1, 3, 10, 30, 100 
mg/ml). The procedures were started with preselected flow rate at 1.0 min; with 1.5 
minutes of intermittent methacholine exposures (at 25% duty: 1.5 second exposure 
followed by 4.5 seconds without exposures on a continuous cycle), and 2 min dryer 
time.  Plethysmographic data were recorded for another 5 minutes after aerosol 
administration. The Penh values measured during each 5 minutes sequence were 
averaged and are expressed for each methacholine concentration as absolute Penh 
values. Airway responsiveness measurements were performed on day 11 of 
experimental protocol and 19 hours after the final ovalbumin exposure. 
III.6. TOTAL AND DIFFERENTIAL CELL COUNTS 
After the final airway responsiveness measurements, the mice were administered a 
lethal dose of sodium pentobarbitone, the lungs were then removed and lavaged. 
Using the BAL fluid, recovered total and differential cell counts were then carried out 
using the methods described in CHAPTER 2. A naive, non-sensitised, group of mice 
was also included as a reference to establish the normal cell counts in a mouse.  
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IV. RESULTS 
IV.1. EARLY AND LATE-PHASE REACTIONS 
The bronchoconstriction in ovalbumin (OVA) and saline challenged mice were 
monitored every hour for 19 hours. OVA sensitised and challenged mice showed an 
early marked bronchoconstriction (Early asthmatic responses - EAR) (27.82±4.3%), 1.5 
hours after the second challenge. The brochoconstriction resolved on hour 4 and then 
peaked again between 6 and 12 hours (44.9±7.9%). This second brochoconstriction 
was a late phase reactions (LAR) which recovered to baseline after 19 hours. In 
contrast with ovalbumin challenged group, saline challenged group showed 
bronchorelaxation at most of the time points monitored. The detailed comparison of the 
mean time course changes in Penh between OVA challenged and saline challenged 
group was depicted on fig 5.2.  
 
Figure 5.2. – Mean time-course values of Penh in OVA sensitised mice that were challenged 
with saline or 0.5% OVA. Mean changes in Penh are expressed as mean±S.E.M. percentage 
change from baseline. Data were analysed with unpaired two tailed t-test (* P< 0.05; n=6).  
IV.2. AIRWAY RESPONSIVENESS TO METHACHOLINE 
Enhanced airway responsiveness is a well-established characteristic of asthma. Saline 
challenged mice showed no significant increase in responsiveness toward increased 
dose of methacholine inhalation, compared to the values before saline challenge (Pre-
Saline challenge). In contrast, there was a remarkable AHR increase in OVA 
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challenged mice from the airway responsiveness before OVA challenge (Pre-OVA 
challenge). Figure 5.3 depicts the response of saline and OVA challenged mice toward 
increasing dose of methacholine chloride.  
 
Figure 5.3. Mice were challenged with saline or 0.5% OVA on day 17. On day 11 and 24 h after 
the challenges (day 18), baseline lung function and AHR to increasing doses of methacholine 
were measured by whole body plethysmography . OVA challenge increased Penh levels from 
the Penh values before OVA exposures, while there is no significant increase of Penh on the 
saline challenged group. Results are expressed as mean ± SEM of absolute Penh. Data were 
analyzed with unpaired two tailed t-test (*P<0.05; n=6).  
IV.3. TOTAL AND DIFFERENTIAL CELL COUNTS 
OVA challenge led to a significant increase in total and differential cell counts 
compared to saline challenged group as shown on figure 5.4. The number of individual 
leukocytes number, particularly eosinophils, in OVA challenged group are significantly 
greater than in the saline challenged group. 
 
Figure 5.4. The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar fluid of naïve (non-sensitised), OVA and saline challenged mice. 
Results are expressed as mean±S.E.M. Data were analysed with one-way Analysis of Variance 
followed by a Bonferroni post-test.  
#
significantly different from all other groups (P<0.05; n=6).  
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V. DISCUSSION 
The model of acute asthmatic mice was performed based on the study carried out by 
Fernandez-Rodriguez et al., (2008).  Models of asthma should be able to consistently 
replicate most, if not all, of the key features of asthma. These are inflammatory cell 
migration into the airway with eosinophilia, airway hyperresponsiveness, early and late 
asthmatic responses, and airway remodelling. The acute mouse model developed by 
Fernandez-Rodriguez et al., (2008) demonstrated most of these features.  
An elevation of inflammatory cells influx was observed in these models which imitate a 
feature of human asthma. A significant increase in the percentage of eosinophils 
present in the BAL fluid of OVA challenged mice was also observed. Eosinophils influx 
has been thought to play an important role in determining the LAR. Eosinophil products 
which are released on degranulation also led to epithelial injury which may further 
contribute to the development of airway hyperresponsiveness (Barnes, 2008).  
Few mice models of asthma were able to show clear early and late asthmatic 
response. Both early and late asthmatic response will only expressed with multiple 
challenge, so in this study, OVA challenge was given twice, 4 hours apart. EAR peaked 
at 1-2 hours and LAR peaked 7-8 hours after the second OVA challenge.  
Airway hyperresponsiveness was assessed using the increased dose of a non-
selective muscarinic receptor agonist, methacholine. Many factors have been 
suggested to contribute to the development of airway hyperresponsiveness in asthma, 
one of them is the accumulation of inflammatory cells (Meurs et al., 2008) which might 
be the case in this present study.  
Eventhough acute models of asthma successfully replicate many cardinal features of 
asthma, there is a major drawback as the acute model with short term exposure to 
allergen would not exert the key features seen in chronic human asthma, such as 
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airway remodelling. The exhibition of the central features of asthma also tends to be 
temporary which usually resolve within a week of the allergen challenge (Mcmillan and 
Lloyd, 2004). However, many of these robust and consistent acute models of 
ovalbumin-induced allergic inflammation in mice have given a significant contribution to 
provide a better understanding in the patho-immunology of asthma and will continue to 
do so.  
VI. CONCLUSION 
The developed acute murine model of ovalbumin induced airway inflammation 
replicates most of central features in human asthma such as increase in inflammatory 
cell influx, eosinophilia, airway hyperresposiveness, early and late asthmatic 
responses. This model would be a good base for subsequent studies in modelling 
asthma exacerbation and investigating the effect of corticosteroid on the developed 
model. 
 
 
 
CHAPTER VI [Year] 
 
147 
 
 
CHAPTER VI 
INFLUENZA INFECTION IN A MURINE MODEL OF 
ALLERGIC AIRWAYS INFLAMMATION 
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I. INTRODUCTION 
Respiratory viral infection has a close association with asthma. There is an implication 
that childhood respiratory viral infection has been involved in the inception of asthma 
(Busse et al., 2010). A substantial body of evidence also suggests that viral infection 
triggers wheezing and exacerbation in both children and adults with asthma (Cypcar et 
al., 1992; Nicholson et al., 1997) . Viral infection was responsible for most of childhood 
asthma exacerbation accounting for up to 80-85% of all cases and roughly 44% of 
asthma exacerbations in adults (Johnston, 1995; Nicholson et al., 1997). 
It has been suggested that there is a synergistic interaction between exposure to high 
concentration of sensitising allergen and viral infection, causing a severe asthma 
exacerbation, often requiring hospitalisation (Tunnicliffe et al., 1999; Green, 2002). The 
synergistic relationship might happen because the airway epithelium is damaged as a 
consequence of both viral infection and allergic inflammation. In the presence of viral 
infection, the epithelial shedding could facilitate and enhance allergen absorption which 
then increases inflammation (Sakamoto et al., 1984). On the other hand, the epithelial 
damage as a result of pre-existing airway allergic inflammation could increase viral 
replication which leads to more severe clinical consequences (Jakiela et al., 2008).  In 
addition, several studies show that asthmatics might have impaired antiviral immune 
system which may lead to more severe and persistent viral infection and enhancement 
of airway allergic inflammatory responses (Contoli et al., 2006; Forbes et al., 2012). 
In one study by Message et al. (2008)  who investigated the responses of both 
asthmatic and non asthmatic patient toward human rhinoviruses showed that 
asthmatics had significantly more severe respiratory symptoms, reduction in lung 
functions, and increase in airway hyperresponsiveness as well as eosinophilia 
compared to non asthmatic patients. They also found that only in asthmatic patients, 
was the viral load highly associated with more severe deterioration. In asthmatic 
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patients, neutrophilic and eosinophilic inflammation was also an important determinant 
for the degree of lung function impairment (Message et al., 2008).  
Rhinovirus was identified as the most frequent cause of acute asthma exacerbation 
(Johnston, 1995). Rhinoviruses has been show to increase the histamine release, 
eosinophil recruitment and increasing the possibilities of late phase asthmatic reactions 
development in people with asthma (Gern et al., 1997; Green, 2002). Although not as 
common as rhinovirus in causing acute asthma exacerbation, influenza viruses were 
responsible for a quite high proportion of severe asthma exacerbation. Influenza A is 
the second most identified virus after rhinoviruses in adults admitted to hospital for an 
acute asthma exacerbation (Teichtahl et al., 1997).  
Influenza infection in people with asthma has been suggested to increase 
hospitalisation due to exacerbation (Glezen et al., 2000). During the influenza season, 
asthmatics which constitute nearly 79% of all high risk group in proportion had 
significantly more cases of hospitalisation and outpatient clinic visit‘s compared to non 
asthmatic healthy people (O'Brien et al., 2004).   In 2009, when the pandemic of H1N1 
emerged, asthma has even been associated more complications such as ICU 
admission (O'Riordan et al., 2010). 
I.1. IMMUNOLOGY OF VIRAL INDUCED ASTHMA EXACERBATION 
Respiratory viruses target epithelial cells lining in the airways. The injured epithelial 
cells release a plethora of inflammatory mediators including IL-1, IL-6, IL-8, IP-10, 
RANTES, GM-CSF, and eotaxin which lead to activation and migration of inflammatory 
cells such into the airway (fig 6.1) (Dougherty and Fahy, 2009). 
The nature of virus-induced asthma exacerbation is different from allergen induced 
asthma. When there is a combination of viral infection and allergen exposure in 
allergen sensitised individuals, neutrophils appear to play more important role while in 
allergen induced exacerbation, eosinophils is more dominant (Fraenkel, 1995). 
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Figure 6.1. Immunological mechanisms of viral infection in allergic individuals exposed to 
allergen which induce exacerbation of airway pathology  (Tauro et al., 2008)  
 
In experimental rhinovirus infection in asthmatic patients, there was evidence of 
increased IL-8, a neutrophil chemoattractant, as well as neutrophil influx in BAL fluid, 
sputum and nasal secretion (Message et al., 2008). The upregulation of neutrophils, 
the release of the products of activated neutrophils, and IL-8 might also involve in the 
enhancement of AHR. IL-8 has been noted to be a determinant of increasing AHR in 
viral induced-exacerbation of asthma. The level of TNF-alpha released by neutrophils 
is also correlated with the degree of AHR (Nagarkar et al., 2009). 
Eosinophils, their products and chemoattractants were also shown to be more up-
regulated following rhinovirus infection in asthmatic subjects compared to normal non 
asthmatic subjects (Heymann et al., 1995). In the asthmatic adults with rhinitis, the 
eosinophil cationic protein content in sputum was also correlated to the level of AHR 
(Grunberg, 1997). 
Macrophages also play an important role in viral infection. As the most dominant 
leucocytes in the airway, in the case of viral infection and replication, macrophages 
release some inflammatory mediators such as TNF-alpha, IL-1, IL-8, and MIP-1 alpha. 
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In addition macrophages also produce type I interferon as an antiviral agent (Laza-
Stanca et al., 2006). 
 However, some studies show that asthmatics seem to have an abnormal innate 
immune response and produce less interferon than non asthmatics in response to 
rhinovirus infection (Wark, 2005; Contoli, 2006; Contoli et al., 2006; Bullens et al., 
2008). The deficiency of interferon in asthmatics has been associated with increasing 
pathogenesis of asthma exacerbation including the increasing airway symptoms, lung 
function impairment, and increasing viral load (Contoli et al., 2006). 
T lymphocytes appears to be important in viral infection and asthma but when both 
cases occur concurrently, the balance between the typical  Th2 cytokines environment 
in asthma and Th1 predominant responses in viral infection would determine the 
severity of exacerbation.  In asthmatics, the inflammation is characterised by Th2 type 
cytokines such as IL-4, IL-5, and IL-13, while in respiratory viral infection, Th1 type 
immune response which lead to the production of IFN-gamma for viral clearance is 
more dominant (Contoli et al., 2006). 
Evidence shows that in the asthmatic environment rich in Th2 cytokines, the response 
to viral infection might skew toward Th2 response which leads to inhibition of normal 
Th1 immune response.  The Th1 deficiency would reduce the ratio between Th1 and 
Th2 cytokines production in asthmatics compared to non asthmatics (normal subjects). 
Some studies demonstrated that IFN-gamma/IL-5 ratio and IFN-gamma/IL-4 ratio is 
negatively related to asthma severity, asthma symptoms, and time needed for viral 
clearance (Papadopoulos et al., 2002; Brooks et al., 2003). Therefore, a stronger Th1 
immune response is vital to ameliorate viral induced asthma exacerbation. 
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I.2. ANIMAL MODELS OF VIRAL ASSOCIATED ASTHMA 
EXACERBATION 
Animal models are useful in investigating underlying immune responses involved in the 
interaction between respiratory viral infection and airway allergic inflammation. The 
studies on the interaction between respiratory viral infection, allergen sensitisation, and 
exposure to high concentration of sensitised allergen mostly evaluate the underlying 
mechanism of interaction between respiratory virus infection with allergen sensitisation 
or the role of respiratory viral infection in the established allergic airway inflammation. 
This chapter will only focus in the interplay between respiratory virus infection and high 
exposure of allergen in established allergen sensitisation. The term ‘exacerbation’ in 
this and subsequent chapters is defined as the worsening of allergic airway 
inflammation and respiratory function demonstrated in the animal model. 
Several animals have been exploited in the model to evaluate the co-administration of 
respiratory virus infection and high concentration of allergen administration, with mouse 
the most utilised. Some murine models have been used as a tool to investigate a range 
of different respiratory viruses, such as rhinovirus, respiratory synctial virus, 
parainfluenza virus, metapneumovirus, and influenza virus.  
Most of current our understanding on how respiratory virus infection might exacerbate 
asthma is derived from studies on the major asthma exacerbations caused by virus, 
rhinovirus (Papadopoulos et al., 2000). Bartlett et al (2008) have been successfully 
developed a model of murine model of rhinovirus exacerbation in mice sensitised and 
challenged with ovalbumin (Bartlett et al., 2008). The infection of rhinovirus during the 
ovalbumin challenge resulted in the enhancement of airway hyperresponsiveness, 
elevation in Th1 and Th2 cytokines, as well as increase of inflammatory cells influx in 
the airways particularly neutrophils, eosinophils, and lymphocytes. However, 
consideration must be given to comparisons between different viral respiratory infection 
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and airway allergic inflammation models because the genetics of the animal, the type 
of virus, the time of viral infection, the viral and allergen concentration/load may all 
contribute to the complex mechanism of interaction between respiratory viral infection 
and asthma. The studies by Barends  et al (2004) underlined the previously mentioned 
premises. Barends et al conducted a comparative study on the effect of three different 
respiratory viruses; RSV, pneumonia virus of mice (PVM), and influenza A virus during 
allergen challenge in sensitised mice (Barends et al., 2004). Both RSV and influenza A 
are identified as the trigger of asthma exacerbation in human (Teichtahl et al., 1997; 
O'Donnell and Openshaw, 1998). Both viruses also increased the effect of allergen 
sensitisation in mice by increasing Th2 type cytokines (O'Donnell and Openshaw, 
1998; Suzuki et al., 1998). Barends et al. (2004) reported that theTh1 cytokine 
expression (IFN-γ and IL-12) induced by individual virus infection was not affected by 
ovalbumin sensitisation or challenge. When Barrends et al evaluated the Th2 cytokines 
(IL-4, IL-5, and IL-13) expression in the lungs they found that RSV and PVM increased 
the production of IL-4, IL-5, and IL-13 as well as causing perivasculalitis and 
eosinophilia in OVA sensitised and challenged mice. In contrast to the two other 
viruses, influenza A has no effect on the expression of Th2 cytokines even though the 
infection was still causing eosinophilia. Different findings were reported by Marsland  et 
al. (2004) who reported that influenza infection increased the Th2 lymphocytes and 
upregulated IFN-γ (Marsland et al., 2004). Different from Barends et al. (2004) who 
administered ovalbumin challenge in the mice in the recovery phase of infection, 
Marsland et al. (2004) challenged the animal in the acute phase of infection. 
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II. AIMS 
The aims were to investigate the role of influenza infection on already established 
allergen sensitisation in mice when the allergen challenge is given during the acute 
phase of viral infection. The endpoints of the study included the enhanced early and 
late phase asthmatic reactions, inflammatory cells infiltration into the airway, airway 
hyperresponsiveness and protein leakage, and change in histological features. 
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III. METHODS 
The methods used in the studies are described in more detail in CHAPTER 2 
III.1. ANIMAL 
Six Male BALB/c mice (20-25g) per group were used for all studies 
III.1.1. SENSITISATION 
Mice were sensitised by intraperitoneal injections (0.25 ml) of the mixture of OVA (50 
μg/mouse) and Al(OH)3 (50 mg/mouse) in saline on day 0 and 5. 
III.1.2. INFLUENZA VIRUS INFECTION 
Mice were anaesthetised lightly with isoflurane and then intranasally infected with 10 
PFU in 50 µl PBS per mouse on day 13 (fig.6.2). The virus solution was inoculated 
intranasally. Each mouse was inoculated with 12.5 µL of virus stock in one nostril and 
then 12.5 µL was given to another nostril twice to give 10 pfu/50 µL of virus stock in 
total. The animal was held in upright position for 2 minutes then was put back in the 
transfer cage in prone position to facilitate the virus to spread evenly to the right and 
the left lungs. Control mice were treated the same and subjected to intranasal 
administration of sham. Sham is allantoic fluid from PBS instilled embryonated egg 
treated similarly with influenza virus infected embryonated egg. All procedures were 
conducted in class II biosafety hood/cabinet. Mice were then returned to their cage in 
mouse isolator once the infection finished.  
III.1.3. OVALBUMIN CHALLENGES 
Mice were challenged with aerosolised OVA (0.5%) or saline (in a control group) in a 
perspex box for 2 x 1 hour, with a 4 hour gap between exposures.  
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III.1.4. EARLY PHASE AND LATE PHASE DETERMINATION 
The lung function of unrestrained mice was measured as Penh using a whole body 
plethysmography system from Buxco. Values of Penh after allergen challenge were 
measured at 0, 20, 40, 60, 90 and 120 minutes, then hourly until 10 hours with a final 
reading at 19 hours after the second ovalbumin challenge. 
III.1.5. AIRWAY RESPONSIVENESS MEASUREMENTS 
Airway responsiveness in mice was measured after methacholine 
(acetyl‐β‐methylcholine chloride) provocation. Respiratory activity was recorded for 5 
min, to establish baseline value for Penh. Mice were subsequently exposed to the 
increasing doses of aerosolized methacholine dissolved in saline (1, 3, 10, 30, 100 
mg/ml). The procedures were started with preselected flow rate at 1.0 min; with 1.5 
minutes of intermittent methacholine exposures (at 25% duty: 1.5 second exposure 
followed by 4.5 seconds without exposures on a continuous cycle), and 2 min dryer 
time.  Plethysmographic data were recorded for another 5 minutes after aerosol 
administration. The Penh values measured during each 5 minutes sequence were 
averaged and are expressed for each methacholine concentration as absolute Penh 
values. Airway responsiveness measurements were performed on day 11 and 19 hours 
after the final ovalbumin exposure. 
 
Figure 6.2. Experimental protocol of influenza A (H1N1) infection in OVA model of allergic 
airway inflammation.  
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III.2. TOTAL AND DIFFERENTIAL CELL COUNTS 
After the final airway responsiveness measurements, the mice were administered a 
lethal dose of sodium pentobarbitone, the lungs were then removed and lavaged. 
Using the BAL fluid, recovered total and differential cell counts were then carried out 
using the methods described in CHAPTER 2.  
III.3. BAL FLUID PROTEIN CONTENT 
Total Protein content of BAL fluid was analysed with BCA protein assay as described in 
CHAPTER 2. 
III.4. VIRUS TITRE DETERMINATION 
The virus titre was quantitated by plaque assay with AEC immunocytochemistry as 
described previously in CHAPTER 4. 
III.5. LUNG HISTOLOGY  
Lung was stained with H and E and was analysed with histopathology scoring as 
described in CHAPTER 2. 
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IV. RESULTS 
IV.1. THE EFFECTS OF SHAM ON THE MURINE MODEL OF 
ALLERGIC AIRWAY INFLAMMATION  
The influenza virus was propagated in embryonated chicken egg. The virus stock was 
harvested, aliquoted, and kept in allantoic fluid from the egg before dilution to the 
desired concentration with PBS to be administered intranasally to infect the animals. 
Allantoic fluid contains ovalbumin, the protein used as an allergen to induce airway 
allergic inflammation in the current series of experiments. Even though ovalbumin 
content reduced as the chicken embryo develops (Sugimoto, 1999), and the virus stock 
was diluted as 1 part in 599,249 part of PBS, the virus dilution delivered in the mouse 
might still contain small traces of ovalbumin which might alter the features of the 
previously developed allergic airway inflammation model in mice. Therefore 2 groups of 
6 mice were sensitised with OVA, instilled with sham (allantoic fluid from embryonated 
egg instilled with PBS instead of influenza virus), then 1 group was challenged with 
saline and the other with ovalbumin to investigate whether the allantoic fluid content in 
the virus stock might increase the allergic inflammatory responses in the developed 
murine model.  
OVA sensitised mice instilled with sham and challenged with saline did not show any 
EAR or LAR. The airway function recorded overtime after saline challenge was not 
significantly different from mice without sham instillation (fig. 6.3). Sham instillation in 
OVA sensitised mice also did not significantly increase the inflammatory cells 
recruitment in the airway compared to un-instilled mice. 
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Figure 6.3. Mean time-course values of Penh in OVA sensitised mice that were un-instilled or 
instilled with sham and then challenged with saline. Mean changes in Penh are expressed as 
mean±S.E.M. percentage change from baseline. Data were analysed with unpaired two tailed t-
test (* P< 0.05; n=6).  
 
Early and late asthmatic responses were observed in the sham instilled mice 
challenged with OVA. The peak of EAR in sham instilled mice was not significantly 
different from un-instilled mice. The peak LAR between two groups was also not 
significantly different, 62.7±14.5% increase in baseline Penh in sham instilled mice and 
44.9±7.9% in un-instilled mice. Therefore it can be said that allantoic fluid contained 
sham did not have any significant effect on the EAR and LAR as described in figure 6.4 
 
Figure 6.4. – Mean time-course values of Penh in OVA sensitised mice that were challenged 
with 0.5% OVA. Mean changes in Penh are expressed as mean±S.E.M. percentage change 
from baseline. There was no significant different between un-instilled or sham instilled animals. 
Data were analysed with unpaired two tailed t-test (* P< 0.05; n=6). 
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Figure 6.5 represents the inflammatory cells influx in the airway of the groups mice 
instilled with sham compared to un-instilled mice. Sham did not significantly affect the 
total number of inflammatory cell in the BAL fluid as well as the individual leukocytes 
counts in all compared groups (naive vs sham, OVA/Saline vs OVA/Sham/Saline, and 
OVA/OVA vs OVA/Sham/OVA). There were no eosinophils detected in the BAL fluid in 
sham group just similar to the un-instilled group when they were challenged with saline. 
 
Figure 6.5. The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar fluid of naïve (non-sensitised), sham instilled, OVA and saline 
challenged mice. Results are expressed as mean±S.E.M. One-way Analysis of Variance 
followed by a Bonferroni post-test. ^significantly different from OVA/Sham/Saline; *significantly 
different from OVA/Saline (P<0.05; n=6 except for sham instilled animals n=4). 
 
Airways reactivity to methacholine was not affected by sham instillation as there is no 
significant different of the bronchoconstriction between un-instilled and sham instilled 
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mice. There was no significant increase in the AHR after saline challenge compared to 
that before saline challenge. However, when comparing the pre-OVA challenge and 
post-OVA challenge airway responsiveness, there was a significant increase in airway 
responsiveness in either sham instilled or un-instilled mice which challenged with OVA. 
The post-challenged airway increase in sham instilled-OVA challenged mice was not 
significantly different from the post challenged increase in un-instilled mice (fig 6.6). 
 
Figure 6.6. Mice were challenged with saline (C and D) or 0.5% OVA (E and F) on day 17. On 
day 11 and 24 h after the challenges (day 18), baseline lung function and AHR to increasing 
doses of methacholine were measured by whole body plethysmography. OVA challenge in 
sham instilled mice increased Penh levels from the Penh values before OVA exposures, while 
there is no significant increase of Penh on the saline challenged group similar to those of un-
instilled mice. Results are expressed as mean ± SEM of absolute Penh. Data were analyzed 
with unpaired two tailed t-test (*P<0.05; n=6 except for sham instilled animals (B) n=4). 
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IV.2. THE ROLE OF INFLUENZA VIRUS INFECTION IN MURINE 
MODEL OF ALLERGIC AIRWAY INFLAMMATION 
IV.2.1. EARLY AND LATE-PHASE REACTIONS 
The previous observation showed that inoculation with influenza virus in mice 
enhanced pulmonary infliltration with inflammatory cells and induced airway 
hyperresponsiveness. The time of allergen challenge inhalation was decided based on 
the dose and the time point when viral infection induced apparent inflammation without 
severe consequences such as reduction in body weight as well as increase in baseline 
respiratory functions.  
After being administered with OVA inhalation on day 4 after viral infection, EAR and 
LAR were observed (fig 6.7). Compared to sham instilled mice, the peak of EAR in 
influenza virus infected mice was not significantly increased. 
 
Figure 6.7. Early and late phase asthmatic bronchocostriction observed over 19 hours in sham 
instilled and influenza infected mice challenged with OVA 0.5%. The OVA sensitised/sham 
instilled/OVA challenged group and the OVA sensitised/ influenza A/OVA challenged group late 
asthmatic responses peaked at 7 hours and 9 hours respectively. Mean changes in Penh are 
expressed as mean±S.E.M. percentage change from baseline. Data were analysed with 
unpaired two tailed t-test (* P< 0.05; n=6).  
The influenza virus infection increased the peak and prolonged the LAR compared to 
sham instilled mice. The peak of LAR increased from 42.30±9.7% increase from 
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baseline Penh in sham instilled mice to 188.3±51.9% increase from baseline Penh in 
influenza virus infected mice. Nineteen hours after the second OVA challenge, the 
respiratory functions of the infected animals did not return to normal as in the sham 
instilled ones as depicted in figure 6.7. 
OVA sensitised-influenza infected mice but challenged with saline did not show any 
EAR or LAR (fig 6.8). So it can be said that the profound increase of EAR and LAR in 
the OVA sensitised OVA/influenza infected/OVA challenged mice was the combined 
effects of OVA challenge and virus infection.  
 
Figure 6.8.  Mean time-course values of Penh in OVA sensitised and influenza A infected mice 
that were challenged with saline or OVA 0.5%. Mean changes in Penh are expressed as 
mean±S.E.M. percentage change from baseline. Data were analysed with unpaired two tailed t-
test (* P< 0.05; OVA /influenza/OVA n=6, OVA/influenza/saline n=5). 
 
IV.2.2. TOTAL AND DIFFERENTIAL CELL COUNTS 
In OVA sensitised/influenza infected/OVA challenged mice, there was a significant 
increase in airway leucocytes counts in the BAL fluid from 25.3±2.7.105 cells/ml and 
compared to OVA sensitised/sham instilled/OVA challenged mice 14.2 ±2.61.105 
cells/ml. All individual inflammatory cells were significantly elevated with neutrophils 
being prominent. Influenza infection increased neutrophils influx in the airways; the 
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neutrophil count was 0.12±0.06.105 cells/ml in sham instilled animals and increased to 
6.2 ±1.1.105 cells/ml in influenza infected group (fig 6.9). 
 
Figure 6.9. The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar fluid of naïve (non-sensitised), OVA sensitised, sham instilled or 
influenza infected, OVA or saline challenged mice. Results are expressed as mean±S.E.M. 
Data were analysed with One-way Analysis of Variance followed by a Bonferroni post-test. 
#
significantly different from all other groups; *connected with corresponding bar is significantly 
different from each other (P<0.05; n=6 except for OVA/Influenza/Saline group n=5). 
 
In OVA sensitised/influenza infected/saline challenged mice, the inflammatory cell 
count in the BAL fluid from also increased compared to OVA sensitised/sham 
inoculated/saline challenged mice. When the individual leukocyte counts were 
observed, neutrophil is being the most increased in number in influenza infected 
animals compared to sham infected ones. Although as not as great as the increase in 
neutrophil number, lymphocyte number in OVA sensitised/influenza infected/OVA 
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challenged mice also increased significantly compared to any other groups. There was 
small number of eosinophil detected in OVA sensitised/influenza infected/saline 
challenged group but the increase was not significant compared to sham instilled group 
(fig 6.9). 
 
IV.2.3. AIRWAY RESPONSIVENESS TO METHACHOLINE 
 
Figure 6.10. Mice were challenged with saline or 0.5% OVA on day 17. On day 10 and 24 h 
after the challenges (day 18), baseline lung function and AHR to increasing doses of 
methacholine were measured by whole body plethysmography. Results are expressed as mean 
± SEM of absolute Penh. Data were analyzed with unpaired two tailed t-test (*P<0.05; n=6 
except for except for OVA/Influenza/Saline group (B) n=5). 
Airway hyperresponsiveness was induced when mice sensitised and challenged with 
OVA were provoked with methacholine with the maximum response pre- challenge 
(2.14±0.14 absolute Penh) increasing significantly to 6.9±1.1 absolute Penh post-
challenge. Influenza infection on OVA induced airway allergic inflammation further 
increased the airway responsiveness from 2.9±0.3 absolute Penh pre-infection to 
12.6±1.9 absolute Penh post-infection (fig.6.10). 
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In OVA sensitised/influenza infected/saline challenged mice, methacholine inhalation 
also significantly enhanced airway responsiveness. The airway hyperresponsiveness 
was not observed in OVA challenged/sham instilled/saline challenged animals (fig 
6.10). 
IV.2.4. PROTEIN EXUDATION IN THE AIRWAYS 
Influenza when infected concurrently with allergen challenge in sensitised mice 
significantly increased the protein level in BAL fluid (fig 6.11).  
 
Figure 6.11. Total protein content in bronchoalveolar lavage fluid of naïve (non-sensitised), 
OVA sensitised, sham instilled or influenza infected, OVA and saline challenged mice. Results 
are expressed as mean±S.E.M. Data were analysed with one-way Analysis of Variance followed 
by a Bonferroni post-test. #significantly different from all other groups; *connected with 
corresponding bar is significantly different from each other (P<0.05; n=6 except for 
OVA/Influenza/Saline group n=5). 
 
IV.2.5. INFLUENZA A (H1N1/PR8) TITRES IN THE LUNGS 
Influenza infection in the lungs was confirmed with a plaque assay. The viral titre of 
saline challenged and OVA challenged groups were not significantly different (fig 6.12). 
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Figure 6.12.  Viral titres of lungs of mice sensitised with OVA  infected with influenza A 10 pfu and 
challenged with saline or 0.5% OVA. Virus titres were determined by plaque assay on MDCK cells. Virus 
titres are expressed as mean ± SEM of pfu per sampled lungs. Data were analysed with 
unpaired two tailed t-test (* P< 0.05 OVA/Influenza/OVA n=6, OVA/Influenza/Saline n=5). 
 
IV.2.6. LUNG HISTOLOGY  
Haematoxylin and Eosin stain was used to show general morphology of the lungs. 
Marked peribronchial and perivascular inflammation were observed in OVA challenged 
mice compared to naive or sham instilled-OVA challenged mice. There was also a 
noticeable change in the features of epithelial cells in OVA challenged animals. The 
epithelium was elongated and folded (fig 6.13 C) compared to normal intact epithelium 
observed in naive or sham instilled saline challenged animals (fig 6.13 B). Influenza 
infection caused a more severe peribronchial and perivascular inflammation (fig 6.15 D 
and E).  In the lung of influenza infected animals, bronchial lumens with epithelial 
shedding or loss were also observed (fig 6.15 D and E). 
OVA challenge increased the mean pathology score from naive, or saline challenged 
animals. However, influenza infection did not significantly change the mean pathology 
score compared to sham instilled animals (fig.6.14). 
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Figure 6.13.  Histopathological changes of lungs of naive mice (A); or OVA sensitised mice which 
instilled with sham and challenged with saline (B); OVA sensitised mice which instilled with sham and 
challenged with OVA (C);  OVA sensitised mice which infected with influenza A virus and challenged with 
saline (D); or OVA sensitised mice which infected with influenza virus and challenged with OVA (E). The 
lungs were stained with haematoxylin and eosin to display general morphology (100x magnification). 
 
Figure 6.14.  The mean lung pathology score of naïve (non-sensitised), OVA sensitised, sham 
instilled or influenza infected, OVA or saline challenged mice. Results are expressed as 
mean±S.E.M. Data were analysed using one-way ANOVA, followed by post hoc Bonferroni’s 
test to determine the mean pathology score ^significantly different from all groups except 
OVA/Sham/Saline. *connected with corresponding bar is significantly different from each other 
(P<0.05; n=6, except for OVA/Influenza/Saline n=5).  
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V. DISCUSSION 
Influenza A virus is regarded as being among the most important viruses causing 
serious cases leading to morbidity and mortality in the world. How severe the 
consequence of influenza infection is determined by viral factor, host’s genetics, and 
immune system, including asthma (Abe et al., 2004). The influenza virus targets the 
epithelial cells of the respiratory system causing various symptoms in the host. Studies 
have shown that asthma might complicate the clinical condition as a result of influenza 
infection (Adkins et al., 2004). The previous experiments (CHAPTER 4) have shown 
that mouse adapted influenza A virus can infect the airway of BALB/c mice and induce 
a robust airway inflammation resulting in airway hyperresponsiveness as well as influx 
of inflammatory cells.  
V.1. THE EFFECTS OF INFLUENZA INFECTION IN ALLERGIC AIRWAY 
CELLULAR INFLAMMATION  
The influenza virus infection concurrently with allergen challenge in allergen sensitised 
mice further increased the total number of leucocytes in the BAL fluid. All types of 
individual leukocytes (macrophages, eosinophils, lymphocytes, and neutrophils) 
numbers were increased. Eosinophils as a hallmark of asthma were also increased in 
number but the increase was not as great as the number of neutrophils which has been 
increased by around 30 folds compared to the non-infected group. Some studies have 
shown that viral associated asthma exacerbation is different from acute allergen 
induced asthma exacerbation by which neutrophils are more dominant while 
eosinophils are more prominent in the allergen induced asthma (Pizzichini et al., 1998; 
Jarjour et al., 2000; de Kluijver et al., 2003). 
Human and animal studies indicate that there is a synergistic effect between allergen 
exposure and viral infection (Teichtahl et al., 1997; O'Donnell and Openshaw, 1998). In 
a human experimental study of rhinovirus, the concurrent administration of virus and 
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allergen challenge activated both eosinophil and neutrophil granulocytes (Greiff et al., 
2002). 
In OVA sensitised, influenza infected mice challenged with saline, total leucocytes 
counts were also significantly greater compared to non infected animals. There are 
some eosinophils detected in the OVA sensitised, influenza infected, saline challenged 
group but no eosinophils detected in the non infected group. However, the detected 
eosinophil number in BAL fluid of influenza infected mice was not significantly different 
from any of the uninfected animals challenged with saline. This shows that in a 
concurrent exposure of influenza infection and antigen (OVA), OVA challenge is 
important to induce eosinophil influx into the airways.  
Eosinophils are not the major response of non asthmatic subjects to viral infection 
(Barends et al., 2004). Neutrophils were quite dominant in the influenza infected group 
of mice as the proportion was increased from being none in un-infected group to 25% 
of total cells in the infected group. The greatest proportion of leucocytes subtype in 
both groups was the macrophages which in the influenza infected groups increased by 
2 folds compared to naive animals. Respiratory infection causes neutrophils and 
mononuclear cells influx into the airways for viral clearance (Ramshaw et al., 1997).  
Influenza infection has also been shown to increase the cytokines production by 
neutrophils and alveolar macrophages infiltration in the airways, which further leads to 
recruitment of additional macrophages and T lymphocytes in the pulmonary system (La 
Gruta et al., 2007). 
Lymphocytes number in influenza infected animals in both OVA and saline challenged 
groups was also increased compared to non infected animals in either OVA challenged 
or saline challenged groups. T lymphocytes have been known to be responsible for 
viral clearance by releasing IFN-γ and TNF-α, and the killing action of CD8+ cells 
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(Graham et al., 1994; Ramshaw et al., 1997).
 
 So their numbers are significantly 
increased during infection. 
Influenza A infection targets epithelial cells which release chemokines and cytokines 
including TNF-α, IL-1, MCP-1, RANTES, MIP-1, IP-10, and IL-8 upon virus induced 
lysis (Julkunen et al., 2001). The released chemokines enhance the recruitment of 
macrophages, neutrophils, and T lymphocytes to the site of infection (Ada and Jones, 
1986).  This could also underlie the enhanced cellular inflammation when influenza and 
OVA challenge were given in combination. 
A recent study by Le Goffic et al. (2011) has shown that influenza A infection leads to 
the increase of IL-33 expression (Le Goffic et al., 2011) as has been formerly 
discussed in CHAPTER 4. This cytokine could be proposed as one of the reasons to 
explain the augmentation of airway cellular inflammation when OVA challenge was 
given in the acute course of influenza infection in OVA sensitised mice. IL-33 is also a 
chemoattractant of Th2 cells to lymph nodes and site of inflammation. In the IL-33 
environment due to influenza infection, the Th2 cells will be recruited to the airways 
(Komai-Koma et al., 2007). In addition, dendritic cells maturation and their expression 
of major histocompatibility complex-II are also influenced by IL-33. The mature 
dendritic cells when introduced to naive CD4+ T cells induce the T cells production of 
IL-5 and IL-13 which both are key cytokines in asthma (Rank et al., 2009). Mast cells 
are also responsive to IL-33 as they bear ST2, the IL-33 receptor (Neill et al., 2010). 
The interaction of IL-33 and mast cells induce the expression of cytokines, 
chemokines, and inflammatory mediators including IL-8, IL-5, IL-13, IL-6, IL-1β, TNF-α, 
GM-CSF, and prostaglandin D2  (Allakhverdi et al., 2007; Iikura et al., 2007; Moulin et 
al., 2007). Eosinophils respond to IL-33 by increasing the production of IL-8, IL-6, and 
eosinophil derived neurotoxin (Chow et al., 2010).  The interplay between IL-33, IL-5, 
IL-8 and other secreted chemokines would attract circulating eosinophils and 
neutrophils into the airways where the newly recruited cells are induced to release their 
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own inflammatory mediators. The cycles will have the end result of exaggerated airway 
inflammation. 
V.2. THE EFFECTS OF INFLUENZA INFECTION ON ALLERGIC AIRWAY 
EARLY AND LATE PHASE BRONCHOCONSTRICTION  
The infection of influenza virus concurrently with allergen challenge in mice significantly 
aggravated the late asthmatic reactions compared to those in mice only sensitised and 
challenged with OVA.  The late phase reaction was magnified and prolonged.  The 
bronchoconstrictions of non-infected mice returned to normal 19 hours after the second 
OVA challenge but those of influenza virus infected allergic mice were still sustained. 
The allergen challenge is important in the development and peak enhancement of early 
and late phase reaction, as OVA sensitised mice which were infected with influenza 
virus but only challenged with saline did not show any  increase of brochoconstriction 
that could  be regarded as early and late phase asthmatic reactions.  
The potentiated late phase asthmatic reactions have also been observed in guinea pigs 
infected with human parainfluenza virus type 3 during OVA challenge. The early and 
late phase was so magnified because of the viral infection; that both phases were 
unified, and the bronchoconstrictions were elongated and persisted for up to 12 hours 
(Ford et al., 2013). In humans, there is evidence of an association between acute 
rhinovirus infection and increased level of histamine content in the BAL fluid 
immediately after allergen challenge (early phase reactions) which is sustained for 48 
hours after the challenge (late phase reactions). The histamine leakage was not seen 
in non allergic subjects (Calhoun et al., 1994).  
It has been suggested that early phase and late phase asthmatic reactions are driven 
by IgE and mast cells in atopic asthma (Fahy et al., 1997). IgE production is increased 
in some murine models of asthma (Renz et al., 1992; Hessel et al., 1995; Fernandez-
Rodriguez et al., 2008). A human experiment shows that IgE in the BAL fluid was 
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significantly increased after allergen re-exposure or challenge (Wilson et al., 2002). On 
re-exposure to allergen of sensitised animal the allergen will cross link with allergen 
specific IgE bound on high affinity IgE receptors on mast cells and initiates the 
signalling cascade which causes mast cells degranulation and release of pro-
inflammatory mediators including histamine, leukotrienes, and prostaglandin, and 
cytokines leading to early phase reactions (Edwards et al., 2009). Mast cell 
degranulation and the subsequent release of histamine, tryptase and IFN-γ are 
enhanced in acute influenza A infection (Hu et al., 2012) which might contribute to the 
increase of early (although not statistically significant) and late phase 
bronchoconstriction. 
The late phase reactions are the later outcome of the pro-inflammatory mediators 
release by degranulated mast cells. The mediators promote the recruitment of 
inflammatory cells particularly eosinophils, but also neutrophils, T lymphocytes, 
macrophages, and basophils (Bradding and Holgate, 1999). As noted all individual 
subtype of leukocytes in OVA sensitised/ influenza infected/OVA challenged group, 
were increased in number compared to non-influenza infected groups. The 
exaggerated accumulation of inflammatory cells in the lungs when OVA challenge was 
administered in the acute course of influenza infection might also play a role in the 
profound increase of late phase bronchoconstriction. The inflammatory eosinophil has 
been suggested to play a role in promoting features of allergic inflammation such as 
late phase asthmatic reactions and airway hyperresponsiveness (Busse and 
Lemanske, 2001). The significantly increased number of macrophages and neutrophils 
as the effector cells against viral infections leads to the increase production of 
prostaglandin E2, thromboxane B2, platelet activating factor, and reactive oxygen 
species, from macrophages (Folkerts et al., 1998) as well as neutrophil elastase and 
protease (Liu et al., 1999) which might contribute to the enhancement of 
bronchoconstriction. 
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V.3. THE EFFECTS OF INFLUENZA INFECTION ON ALLERGIC AIRWAY 
HYPERRESPONSIVENESS 
Airway hyperresponsiveness (AHR) is one of the asthma characteristics and has been 
robustly simulated in the developed murine model of allergic inflammation described in 
CHAPTER 5. This study has shown that influenza infection superimposed on pre-
existing allergic inflammation aggravated the airway hyperresponsiveness in the mouse 
model. The OVA sensitised, influenza infected and saline challenged animals also 
exhibited greater airway hyperresponsiveness compared to non-infected mice.  
Viral respiratory infection targets epithelial cells which will be exfoliated and damaged 
following an infection. The damaged epithelial cells loose the barrier functions which 
would expose and increase the stimulation of sub-epithelial neural systems to allergen 
or pro-inflammatory cytokines. The stimulation might lead to the release of 
neuropeptides which will activate the parasymphatic nerve ending. The activation 
causes a release of acetylcholine which stimulates the M3 receptor to cause airway 
smooth muscle contraction. This stimulation is normally inhibited by the feedback 
activation of M2 receptors, but respiratory viruses are known to decrease the functions 
and expression of M2 receptors and therefore aggravating the bronchoconstriction 
(Folkerts et al., 1998). This has been described in detail in CHAPTER 4. 
In asthma, the development of AHR is thought to be promoted by Th2 networks, 
particularly IL-13. In a recent animal study, Chang et al. (2011) reveal that the 
pathogenesis of AHR in influenza A infection might differ from OVA induced airway 
allergic inflammation(Chang et al., 2011). AHR in influenza A infection is induced 
independently of Th2 cells. The influenza virus triggers the AHR through a pathway 
requiring IL-33-NH cells- IL-13 axis as discussed in CHAPTER 4.  Hence, in this model, 
when influenza infection is combined with allergic airway inflammation, the source of 
IL-13 could be from both Th2 cells and NH cells. 
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Two studies have examined the role of influenza infection and allergen challenge in 
OVA sensitised mice with quite different results (Wohlleben et al., 2003; Marsland et 
al., 2004). Wohlleben et al. (2003) reported that influenza (H2N3) infection 1 week 
before OVA challenge reduced the airway eosinophilia and the recruitment of Th2 cells 
into the lungs compared to non infected mice. The reduction of the eosinophilia and 
Th2 recruitment were associated with the increase of IFN-γ. However, AHR was still 
significantly more exacerbated when influenza infection was given a week before 
challenge (Wohlleben et al., 2003). 
The results of this current study are more in line with Marsland et al’s report (2004). 
They developed a murine model of viral induced allergic asthma exacerbation in the 
previously sensitised host.  The influenza A (H2N3) virus was infected before allergen 
challenge in OVA sensitised mice. The allergen challenge in the acute phase of 
infection resulted in enhancement of airway hyperresponsiveness, increase in 
eosinophils and OVA specific Th2 cells in the lung. The study also revealed that during 
acute influenza virus infection allergen (OVA) challenge induced a significant increase 
of dendritic cells maturation and migration into the draining lymph node. These 
dendritic cells significantly induced the proliferation of naive T cells specific for OVA, 
which shows that the dendritic cells were carrying and presenting the allergen (OVA) to 
the naive T cells. This might be responsible for the potentiated allergic airway 
inflammation during respiratory virus infection. 
The difference in the timing of infection, OVA challenge, and the day of analysis could 
underlie the diverging results between the Wohlleben et al. (2003) and Marsland et al. 
(2004) studies. The OVA challenge and subsequent timing of analysis (day 7 and 13 
respectively) at the point of maximum IFN-γ level might explain the suppression of Th2 
responses including eosinophilia in the Wohlleben et al. (2003) study. In contrast, 
Marsland et al. (2004) reported that the highest inflammatory cell inflammation, 
including eosinophilia, which demonstrated the synergism between influenza infection 
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and OVA challenge occurred when OVA challenge was given at the same day of 
infection and analysed on day 4 after infection when the level of IFN-γ of had not risen 
to maximum.  
The highlight of both studies with regard to the current study is that the timing of viral 
and allergen exposure is fundamental in defining the results, whether the Th1 driven 
immune responses would increase or suppress the Th2 induced immune responses 
and vice versa. 
 
VI. CONCLUSION 
In conclusion, when OVA challenge was administered during acute influenza A 
infection in OVA sensitised mice, it was able to significantly exacerbate/aggravate 
allergic airway inflammation. Giving mouse adapted influenza A virus (H1N1/PR8) in 
the established murine ovalbumin model of asthma demonstrated a prominent 
increased and prolonged late phase asthmatic response, enhanced airway 
hyperresponsiveness, and significantly increased inflammatory cells influx into the 
airways with marked eosinophilia as well as neutrophilia, and protein leaking into 
bronchoalveolar fluid. This would serve as a useful model of how virus 
infectionsworsens or exacerbates asthma. This developed model will be used in 
subsequent study to evaluate the role of anti inflammatory (corticosteroid) treatment  
when viral infection occurs concurrently with allergen challenge in  airway allergic 
inflammation. 
 CHAPTER VII 
THE EFFECTS OF CORTICOSTEROIDS IN MURINE 
MODEL OF ALLERGIC AIRWAYS INFLAMMATION 
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I. INTRODUCTION 
I.1. INFLAMMATION IN ASTHMA 
Asthma is a complex disease which is characterised by a fundamental pattern of 
airway inflammation. The airway inflammation is caused by a complex cascade 
involving a variety of inflammatory cell types includes mast cell degranulation, airway 
infiltration by eosinophils and activated lymphocytes (especially Th2 cells), and 
damage of the airway epithelium. This particular type of airway inflammation has been 
thought to lead to specific clinical features of asthma including reversible airway 
obstruction and airway hyperresponsiveness (Busse and Lemanske, 2001).  
It is believed that the airway epithelium and vascular endothelium play a key role in the 
inflammatory cells recruitment by acting as a main source of inflammatory mediators in 
asthma. These include cytokines, chemokines, inflammatory enzymes, and growth 
factors (Barnes et al., 1998). The increase of inflammatory mediator production in 
asthma is a result of increasing gene transcription which is mostly regulated by nuclear 
factor k-B (NF-kB) and activator protein 1 (AP-1) (Barnes and Adcock, 2003).  
Corticosteroids, either inhaled or systemically delivered are the most effective therapy 
recommended by most if not all asthma guidelines as described in detail in CHAPTER 
1, Corticosteroids have proven to be effective in the control of asthma symptoms hence 
improve the lung function, reduce the severity and frequency of exacerbations, as well 
as preventing airway remodelling which in turn improves the quality of life of the 
asthmatic patients (Barnes, 1998). Corticosteroids work by interfering the inflammatory 
gene transcription to suppress inflammation as detailed in CHAPTER 1.  
 
 
CHAPTER VII  
 
179 
 
I.2. MECHANISM OF CORTICOSTEROIDS IN ASTHMA CONTROL 
Corticosteroids are very effective in controlling asthma because they suppress so many 
of the cascades involved in the inflammatory responses of asthma. The activation and 
recruitment of inflammatory cells, including eosinophils, T lymphocytes, dendritic cells, 
and macrophages are also reduced by corticosteroids. Mast cells activation is not 
inhibited by corticosteroid, but they reduce mast cell survival in the airways (Barnes 
and Adcock, 2003).  
One of the remarkable actions of corticosteroids is to reduce eosinophilia presumably 
by suppressing the production of certain cytokines such as IL-5 and GM-CSF which are 
responsible for the survival of eosinophils and therefore leads to their apoptosis 
(Owens et al., 1991).   
IL-5 is produced by T-cells, mast cells, basophils, and eosinophils. Apart from being 
responsible for eosinophil survival, IL-5 also regulates eosinophil generation, 
proliferation, activation, and differentiation. Gene transcription of the central mediator in 
the regulation of the eosinophil in inflammation, IL-5, is suppressed by corticosteroid 
(Robinson et al., 1993). 
Corticosteroids also have been known to inhibit gene expression of IL-4 and IL-13, both 
responsible for the allergic reaction caused by the B cells production of IgE  (Zhou et 
al., 1997). IL-4 and IL-13 which are produced by Th2 and mast cells are thought to also 
increase the expression of adhesion molecule vascular cell adhesion molecule-1 
(VCAM-1) which in turn attracts the inflammatory cells including eosinophils, 
lymphocytes, and basophils to endothelial cells (Bochner et al., 1995). Apart from IL-4 
and IL-13, increasing production of adhesion molecules including ICAM-1 is also 
regulated by IL-1 which is produced by macrophages. Corticosteroids inhibit the 
production of IL-1 (Yu et al., 1998). 
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The major target of inhaled corticosteroid is probably the epithelial cell. These cells 
along with endothelial cells, smooth muscle cells and fibroblasts are responsible for 
releasing inflammatory mediators including chemokines or chemotactic cytokines which 
regulate the recruitment or attraction of inflammatory cell into the airways (Barnes, 
1998). Chemokines particularly RANTES is an important chemoattractant for 
eosinophils and lymphocytes. Macropage inflammatory protein-1 (MIP-1 α) and 
macrophage/monocyte chemoattractant protein-3 (MCP-3) as suggested by the name 
are chemokines produced by macrophages. Corticosteroids inhibit the production of 
those mentioned chemokines (Stellato et al., 1995).  Macrophages and T lymphocytes 
produce an important cytokines in allergic inflammation, TNF-α, the production of which 
is downregulated by corticosteroids (Ying et al., 1991). The cellular effects of 
corticosteroid in asthma is displayed in figure 7.1.  
  allergen 
 
Figure 7.1. Epithelial cels produces cytokines and chemokines upon exposure to allergen. 
RANTES, eotaxin, MCP-1 and MIP-1 are responsible for the migration of leucocytes particularly 
eosinophil, T cells and macrophages. Activated macrophages also produce IL -1 and TNF-α 
which induce endothelial cells to upregulate ICAM -1 and VCAM-1 (adhesion molecules). T-cells 
also produce IL-4, IL-5, and IL-13 which upregulate the adhesion molecules and eotaxin. X = 
blocked by corticosteroids (Umland et al., 2002). 
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The effectiveness of corticosteroids in reducing airway inflammation may lead to their 
ability to reduce airway hyperresponsiveness (AHR). Even though it is not firmly 
confirmed, there are some evidences which show that eosinophils may contribute to 
the development of airway hyperresponsiveness in asthma. Eosinophil infiltration into 
the airways leads to the release of the toxic eosinophil cationic proteins (ECP) and 
major basic proteins which cause dysfunction of M2 muscarinic receptors in the 
airways. M2 muscarinic receptors are responsible for countering the 
bronchoconstriction by M3 muscarinic receptor activation through a feedback 
mechanism. M2 receptor dysfunction is one of the mechanisms involving in the 
development of airway hyprerresponsiveness.  Therefore, corticosteroids by inhibiting 
eosinophil function may reduce the airway hyperresponsiveness in asthma. Longterm 
treatment with corticosteroid has been proven to reduce airway responsiveness toward 
histamine or cholinergic agonist provocation as well as reduce the late asthmatic 
responses (Barnes, 1998). 
II. AIMS 
We have developed a murine ovalbumin model of airway allergic inflammation that 
shows inflammatory cell influx into the airways, AHR, as well as early and late 
asthmatic responses. So, it is important to determine whether corticosteroids would 
inhibit the allergic airway inflammatory response in the airway of allergic mouse model. 
Inhalation (Fluticasone Propionate) and systemically (Dexamethasone) delivered 
corticosteroids were evaluated in this study. 
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III. METHODS 
The details of the methods used in the studies are described in CHAPTER 2 
III.1. ANIMAL 
Six Male BALB/c mice (20-25g) per group were used for all studies 
III.1.1. SENSITISATION 
Mice were sensitised on day 0 and 5 by intraperitoneal injections (0.25 ml) of the 
mixture of OVA (50 μg/mouse) and Al(OH)3 (50 mg/mouse) in saline. 
III.1.2. OVALBUMIN CHALLENGES 
On day 17, mice were exposed to aerosolised OVA (0.5%) or saline (in a control group) 
inhalation challenges in a perspex box for 2 x 1 hour, with a 4 hour gap between 
exposures.  
III.1.3. PBS INSTILLATION 
Mice were anaesthetised lightly with isoflurane and then intranasally instilled with 50 µl 
PBS per mouse on day 13 (fig.7.2). Each mouse was given 12.5 µL of PBS in one 
nostril and then 12.5 µL was given to the other nostril twice to give 50 µL PBS in total. 
The animal was held in upright position for 2 minutes then was put back in the transfer 
cage. Mice were then returned to their cage once the instillation was finished.  
III.1.4. CORTICOSTEROIDS INTERVENTION 
Dexamethasone (DEX): 
Water soluble dexamethasones, 3 or 6 mg/kg in 200 µl of PBS was administered by 
intraperitoneal injection once a day for 6 day starting from day 12 of the procedure. On 
day 17, when mice were challenged with OVA, DEX was given before the first OVA 
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challenge. Control mice received a 200 µl intraperitoneal injection of PBS. Details of 
the procedures are displayed in figure 7.2.  
Fluticasone Propionate (FP): 
FP 0.25 or 0.5 mg/ml was dissolved in a mixture of saline (40%), DMSO (30%) and 
ethanol (30%). FP inhalation for 20 minutes twice a day 6 hour apart was administered 
for 6 days starting from day 12 of the procedure. On the day of OVA challenge (day 
17), FP was given before the first OVA challenge and 6 hours after the second OVA 
challenge. Control mice were given inhalation of vehicle (saline (40%), DMSO (30%) 
and ethanol (30%)) at the respective times. Details of the protocol are described in 
figure 7.2 
III.1.5. EARLY PHASE AND LATE PHASE DETERMINATION 
Measurement of the lung function of unrestrained mice was recorded as Penh using a 
Buxco system. Values of Penh after allergen challenge were recorded at 0, 20, 40, 60, 
90 and 120 minutes, then hourly until 10 hours followed by a final reading at 19 hours 
after the second ovalbumin challenge. 
III.1.6. AIRWAY RESPONSIVENESS MEASUREMENTS 
Airway responsiveness in mice was measured after methacholine 
(acetyl‐β‐methylcholine chloride) provocation. Respiratory activity was recorded for 5 
min, to establish baseline value for Penh. Mice were subsequently exposed to the 
increasing doses of aerosolized methacholine dissolved in saline (1, 3, 10, 30, 100 
mg/ml). The procedures were started with preselected flow rate at 1.0 min; with 1.5 
minutes of intermittent methacholine exposures (at 25% duty: 1.5 second exposure 
followed by 4.5 seconds without exposures on a continuous cycle), and 2 min dryer 
time.  Plethysmographic data were recorded for another 5 minutes after aerosol 
administration. The Penh values measured during each 5 minutes sequence were 
averaged and are expressed for each methacholine concentration as absolute Penh 
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values. Airway responsiveness measurements were performed on day 11 and 19 hours 
after the final ovalbumin exposure. 
 
Figure 7.2. The protocol of dexamethasone (DEX) and fluticasone propionate (FP) intervention 
in OVA model of allergic airway inflammation. DEX or PBS was given intraperitoneally once a 
day while FP or vehicle FP (30% ethanol: 30% DMSO: 40% saline) were given by aerosol 
inhalation twice a day 6 hours apart for 6 days starting from day 12  
 
III.2. TOTAL AND DIFFERENTIAL CELL COUNTS 
After the final airway responsiveness measurements, the mice were administered a 
lethal dose of sodium pentobarbitone, the lungs were then removed and lavaged. 
Using the BAL fluid, recovered total and differential cell counts were then carried out 
using the methods described in CHAPTER 2.  
III.3. BAL FLUID PROTEIN CONTENT 
Total Protein content of BAL fluid was analysed with BCA protein assay as described in 
CHAPTER 2. 
III.4. LUNG HISTOLOGY  
Lung was stained with H and E and was analysed with histopathology scoring as 
described in CHAPTER 2. 
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IV. RESULTS 
IV.1. DEXAMETHASONE (DEX) 
IV.1.1. THE EFFECTS OF DEX ON EARLY AND LATE PHASE REACTIONS 
In PBS treated mice, challenge with ovalbumin , early asthmatic bronchoconstrictions 
(EAR) were observed 2 hours after the second OVA challenge (40.3 ±12.3% increase 
from baseline Penh). Both doses of DEX did not affect this EAR. Mice treated with 3 or 
6 mg/kg DEX also displayed the EAR at 1 hour after OVA challenge (45.7±9.7% and 
33.9±7.6% respectively). Corticosteroid did not affect the EAR. Penh values in mice in 
PBS treated group were then gradually restored towards baseline and then increased 
again peaking at hour 7 (63.6±5.9%). This is regarded as late asthmatic 
bronchoconstriction (reactions) (LAR). Treatment with DEX 6 mg/kg significantly 
attenuated the LAR (22.7±6.5%), but 3 mg/kg DEX did not. Penh values in all groups 
returned to baseline 24 hours after the first OVA challenge or 19 hours after the second 
OVA challenge. The EAR and LAR of DEX and vehicle treated mice were displayed in 
figure 7.3. 
 
Figure 7.3. Mean time-course values of Penh in OVA sensitised and challenged mice and 
treated with PBS or DEX (3 or 6 mg/kg) for 6 days. Early and late phase asthmatic 
bronchoconstriction were observed around 0-3 hours and 3-10 hours respectively  after 
challenge in mice which treated with PBS or DEX 3 mg/kg. Results are expressed as 
mean±S.E.M. percentage of Penh change from baseline. Data were analysed with unpaired two 
tailed t-test (* P< 0.05; n=6).  
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IV.1.2. THE EFFECTS OF DEX ON AIRWAY RESPONSIVENESS TO 
METHACHOLINE 
Figure 7.4 displayed the airway responsiveness of OVA sensitised and OVA 
challenged mice which were treated with DEX 3 and 6 mg/kg or PBS. The PBS treated 
mice show a significant increase in Penh values 24 hours after OVA challenge when 
provoked with methacholine compared to those before OVA challenge. DEX 6 mg/kg 
attenuated the airway hyperresponsiveness but not DEX 3 mg/kg.  
 
Figure 7.4. Mice were sensitised and challenged with OVA and treated with DEX (6 mg/kg or 3 
mg/kg) or vehicle (PBS) for 6 days. A day before administration of DEX or vehicle, and 24 h 
after the challenges, baseline lung function and responses to increasing doses of methacholine 
was measured by whole body plethysmography . Results are expressed as mean ± SEM of 
absolute Penh. Data were analysed with unpaired two tailed t-test (* P< 0.05; n=6).   
 
IV.1.3. THE EFFECTS OF DEX ON TOTAL AND DIFFERENTIAL CELL COUNTS 
OVA sensitisation and challenge increased the total inflammatory cell numbers 
compared to either naive or saline challenged animals. There was a significant 
reduction in total inflammatory cells count in the bronchoalveolar lavage fluid (BALF) in 
mice treated with 3 and 6 mg/kg of DEX compared to PBS treated mice (14.2±2.6.105 
cells/ml to 7.3±1.4.105 cells/ml and 4.2 ±0.8.105 cells/ml respectively). A significant 
reduction of eosinophil number was also observed in DEX treated mice compared to 
PBS group (7.6±1.7.105 cells/ml to 1.1±0.8.105 cells/ml and 0.2 ±0.1.105 cells/ml 
respectively) as shown in figure 7.5. No eosinophils or neutrophils detected in naive or 
saline challenged animals. 
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Figure 7.5. The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar lavage fluid of naive mice and OVA challenged treated with PBS or 
DEX (3 mg/kg or 6 mg/kg) mice. Results are expressed as mean±S.E.M. Data were analysed 
with One-way Analysis of Variance followed by a Bonferroni post-test #significantly different 
from all other groups; *connected with corresponding bar is significantly different from each 
other (P<0.05; n=6).  
 
IV.1.4. THE EFFECTS OF DEX ON PROTEIN EXUDATION 
OVA challenged and vehicle treated mice displayed significant increase in protein 
content in BALF compared to the level of protein content in naive mice (fig 7.6). 
However, the high dose of DEX (6 mg/kg) did not significantly reduce the protein 
concentration. Even so, the level of protein in DEX treated mice were at similar level 
compared to saline challenged mice (0.19±0.07 and 0.18±0.05 respectively). 
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Figure 7.6. Total protein content in bronchoalveolar lavage fluid of naïve mice and mice 
sensitised and challenged with OVA and treated with DEX (3 or 6 mg/kg) or vehicle (PBS) for 7 
days. Results are expressed as mean±S.E.M. Data were analysed with One-way Analysis of 
Variance followed by a Bonferroni post-test (*P<0.05; n=6).  
 
IV.1.5. THE EFFECTS OF DEX ON LUNG HISTOLOGY  
Marked peribronchial and perivascular inflammation as well as folding and elongation 
of epithelial cells were observed in OVA challenged/vehicle (PBS) treated mice 
compared to naive mice (fig 7.7.B). The mean pathological score of vehicle treated 
mice was also significantly increased compared to naive mice (fig 7.8). Treatment with 
DEX (6 mg/ml) attenuated the peribronchial and perivascular inflammation (fig 7.7.C). 
Although there is a trend of mean pathological score reduction in DEX (6 mg/kg) 
treated group, the reduction was not statistically significant compared to the vehicle 
treated mice. 
 
Figure 7.7.  Histopathological changes of lungs of naive mice (A) or OVA sensitised and challenged mice 
which were treated with vehicle DEX (PBS) (B) or DEX (6 mg/kg)(C). The lungs were stained with 
haematoxylin and eosin to display general morphology (100x magnification). 
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Figure 7.8. The mean lung pathology score of naïve, OVA sensitised and challenged mice 
which were treated with PBS (Vehicle DEX) or DEX 6 mg/kg. Results are expressed as 
mean±S.E.M. Data were analysed using one-way ANOVA, followed by post hoc Bonferroni’s 
test to determine the mean pathology score (*P < 0.05; n=6).  
 
IV.2. FLUTICASONE PROPIONATE (FP) 
IV.2.1. THE EFFECTS OF FP ON EARLY AND LATE PHASE REACTIONS 
 
Figure 7.9. Mean time-course values of Penh in OVA sensitised and challenged mice that were 
treated with FP (0.25 or 0.5 mg/ml) or vehicle (saline/DMSO/ethanol (40%/30%/30)) for 6 days. 
Mean changes in Penh are expressed as mean±S.E.M. percentage change from baseline. Data 
were analysed with unpaired two tailed t-test (* P< 0.05; n=6).  
 
The vehicle treated mice displayed a significant increase of Penh at 7 hour after OVA 
challenge which was regarded as the LAR (46.8 ±9.6% increase from baseline Penh). 
FP treatment did not significantly change EAR compared to vehicle 
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(saline/DMSO/ethanol (40%/30%/30%)). Treatment with 0.25 mg/ml FP did not 
attenuated the LAR (38.9 ±10.9% increase from baseline Penh). Therefore the higher 
dose (0.5 mg/ml) was delivered which was significantly reduced the LAR (22.3 ±6.0% 
increase from baseline Penh) (fig 7.9). 
 
IV.2.2. THE EFFECTS OF FP ON AIRWAY RESPONSIVENESS TO 
METHACHOLINE 
 
Figure 7.10. Mice were sensitised and challenged with OVA and treated with FP (0.5 mg/ml or 
0.25 mg/ml) or vehicle (saline/DMSO/ethanol (40%/30%/30)) for 6 days. A day before 
administration of FP or vehicle, and 24 h after the challenges, baseline lung function and AHR 
to increasing doses of methacholine was measured by whole body plethysmography . Results 
are expressed as mean ± SEM of absolute Penh. Data were analysed with unpaired two tailed t-
test (* P< 0.05; n=6).   
Mice sensitised and challenged with OVA and treated with vehicle 
(saline/DMSO/ethanol (40%/30%/30)) showed a significant increase in airway 
responsiveness when provoked with methacholine (maximum response from absolute 
Penh 1.9±0.3 before OVA challenge to absolute Penh 7.1±0.8 after vehicle treatment 
and OVA challenge). The airway function responses to the highest dose of 
methacholine in mice treated with the highest dose of FP (0.5 mg/ml) before OVA 
challenge was not significantly different from those after OVA challenge. Administration 
of FP 0.5 mg/ml b.i.d for 7 days completely abolished the airway hyperresponsiveness 
induced by OVA challenge and provoked by methacholine, but not by administration of 
FP 0.25 mg/ml (Fig.7.10).  
 
CHAPTER VII  
 
191 
 
IV.2.3. THE EFFECTS OF FP ON TOTAL AND DIFFERENTIAL CELL 
COUNTS 
FP 0.5 mg/ml significantly decreased BALF total inflammatory cell numbers from 
15.1±1.4x105cells/ml in vehicle treated mice to 4.6±0.7.105cells/ml. Treatment with 0.5 
mg/ml FP also significantly reduced eosinophil influx in the airways from 
6.6±0.6x10
5
cells/ml in vehicle treated group to 0.6±0.3.10
5
cells/ml. FP 0.25 mg/ml was 
not sufficient to significantly reduce the level of inflammatory cell accumulation. The 
effects of FP on total and differential cells are displayed in figure 7.11.  
 
Figure 7.11. The number of total cells, macrophages, eosinophils, lymphocytes and neutrophils 
found in the bronchoalveolar fluid of OVA challenged mice treated with FP (0.25 and 0.5 mg/ml) 
or vehicle (saline/DMSO/ethanol (40%/30%/30)) for 6 days. Results are expressed as 
mean±S.E.M. Data were analysed with One-way Analysis of Variance followed by a Bonferroni 
post-test 
#
significantly different from all other groups; *connected with corresponding bar is 
significantly different from each other (P<0.05; n=6).  
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IV.2.4. THE EFFECTS OF FP ON PROTEIN EXUDATION 
The increase in BALF protein content after OVA sensitication and challenge in vehicle 
treated mice was not significant compared to naive mice. Treatment with FP 0.5 mg/ml 
did not significantly reduce protein content (fig.7.12). 
 
Figure 7.12. Total protein content in bronchoalveolar lavage fluid of naïve, OVA sensitised and 
OVA challenged mice which were treated with FP 0.5 mg/ml or vehicle (saline/DMSO/Ethanol 
(40%/30%/30)) for 7 days. Results are expressed as mean±S.E.M. One-way Analysis of 
Variance followed by a Bonferroni post-test (P<0.05; n=6). 
 
IV.2.5. THE EFFECTS OF FP ON LUNG HISTOLOGY 
OVA sensitisation and challenge in vehicle treated mice caused a significant 
peribronchial and perivascular inflammation (fig 7.13.B) compared to naive mice 
(fig.7.13.A). Treatment with FP 0.5 mg/ml for 7 days reduced the inflammation 
(fig.7.13.C). Epithelial cells were also elongated and folded in the bronchial lumen of 
vehicle treated mice whereas in mice treated with FP 0.5 mg/ml, epithelial cell were 
intact and normal in shape. The mean pathology score of OVA sensitised and 
challenged mice which treated with vehicle was significantly higher than naive mice. 
The mean pathology score of FP 0.5 mg/ml treated mice was significantly lower than 
that of the vehicle treated mice (fig 7.14). 
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Figure 7.13.  Histopathological changes of lungs of naive mice (A) or OVA sensitised and 
challenged mice which were treated vehicle (saline/DMSO/Ethanol (40%/30%/30)) (B) or FP 
(0.5 mg/ml) (C). The lungs were stained with haematoxylin and eosin to display general 
morphology (100x magnification). 
 
Figure 7.14. The mean lung pathology score of naïve, OVA sensitised and challenged mice 
which were treated with FP (0.5 mg/ml) or vehicle (saline/DMSO/Ethanol (40%/30%/30)). 
Results are expressed as mean±S.E.M. Data were analysed using one-way ANOVA, followed 
by post hoc Bonferroni’s test to determine the mean pathology score. 
#
Significantly different 
from all other groups (P < 0.05; n=6).  
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V. DISCUSSION 
A murine model of airway allergic inflammation which simulates most features of 
human asthma including increasing airway hyperresponsiveness, infliltration of 
inflammatory cells into the airways  which elicit Th2 skewed inflammation with 
eosinophilia, protein exudation and accumulation in BALF, and showing early as well 
as late phase asthmatic bronchoconstriction has been developed.  
Most asthma guidelines recommend treatment with corticosteroid and beta agonist for 
asthma controller and reliever particularly for mild and moderate asthma. Inhaled 
corticosteroid is now the first choice for asthma management as it is convenient to use, 
cost effective, and has fewer side effects compared to the systemic corticosteroid 
(Barnes, 1998; GINA, 2012). Due to their side effects, systemic corticosteroids are now 
only administered for severe or difficult to control asthma (Schäcke et al., 2002). 
Although inhaled or systemic corticosteroids have been proven to be the most effective 
therapy of asthma, only a few identified studies have investigated the anti inflammatory 
and immunomudulation properties of corticosteroids together with their effects on 
functional parameters such as EAR, LAR, and AHR on animal models of airway allergic 
inflammation. Most studies did not measure the effect of corticosteroids in the EAR and 
LAR as endpoints, the studies commonly only investigating airway 
hyprerresponsiveness to methacholine. This reduces the value of the animal models to 
reflect and correlate treatment in the clinic (Stevenson and Birrell, 2011). The 
availability of non invasive whole body plethysmography to measure Penh as a 
reflection of airway function in conscious unrestrained animal has allowed the study to 
include the monitoring the airway function overtime to investigate the early and late 
phase responses to antigen challenge. 
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Corticosteroids, both DEX and FP, did not inhibit early asthmatic phase 
bronchocostriction. Early phase bronchoconstriction responses have been known to be 
not affected by corticosteroid. Studies in human and animal have shown this 
insensitivity (Evans, 2009; Ishmael, 2011). Mediators released from mast cells 
activation and degranulation are believed to be the main cause of the cascade which 
leads to early phase bronchoconstriction.  Corticosteroids do not inhibit mast cells 
activation (Schleimer et al., 1983; Liu et al., 2001) hence are not effective in reducing 
the early phase bronchoconstriction. This is one of the reasons why corticosteroid is 
recommended to be coupled with β-adrenoreceptor drugs in mild and moderate 
persistent asthmatics (GINA Report, 2012), the bronchodilator action of the later drug 
effectively reducing broncoconstriction in the EAR. 
The late asthmatic bronchocostriction responses in vehicle treated groups were 
attenuated significantly by high dose of both corticosteroids. This finding is in line with 
studies in human and in animal models (Parameswaran et al., 2000; Evans, 2009). The 
nature of the inflammatory processes during late phase reactions is different from those 
of early phase reactions. Activation and accumulation of inflammatory cells particularly 
eosinophils are essential in the development of late phase reactions (Weersink et al., 
1994). The accumulation of eosinophils in the airways is believed to be regulated by IL-
13, IL-5, and GM-CSF which are also released by mast cells. The mentioned cytokines 
are inhibited by corticosteroids which therefore inhibit late phase bronchoconstriction 
(Umland et al., 2002).  
Similar to previous studies in human or animals (Trifilieff et al., 2000; Singer et al., 
2002), both corticosteroids (DEX and FP) are confirmed in this study to significantly 
reduce the total cell number in bronchoalveolar lavage compared to vehicle treated 
groups of mice in dose dependent manner. The individual numbers of eosinophils and 
macrophages in the lavage fluids were also reduced. Inflammatory cells including 
eosinophils, T lymphocytes, and dendritic cells are known to be sensitive to 
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corticosteroids which inhibit their migration into the airway as well as reducing their 
survival by inhibiting their regulators including chemokines, cytokines, and adhesion 
molecules (Pitzalis et al., 2002).  
The administration of the highest dose of both corticosteroids also significantly reduced 
methacholine-induced airway hyperresponsiveness.  Similar findings on corticosteroids 
inhibiting airway hyperresponsiveness have also been reported (Gauvreau et al., 2000; 
Inman et al., 2001; Vanacker et al., 2002). The exact mechanism on how corticosteroid 
inhibits airway hyperresponsiveness is not clear. However, there is an established 
relationship between airway inflammation and airway hyperresponsiveness in allergic 
asthma (Meurs et al., 2008). Eosinophils have been thought to indirectly play a role in 
airway hyprresponsiveness through the production of MBP (Major Basic Proteins). 
MPB is toxic to the epithelial cells in vitro (Rothenberg, 1998). MBP may also causes 
dysfunction in muscarinic M2 receptors resulting in increased smooth muscle reactivity 
(Jacoby et al., 1993). 
The pathophysiology of AHR is quite complex and only partially understood. However, 
it is believed that there are two fundamental elements of AHR which are the variable 
and persistent types (Meurs et al., 2008). This study only reveals variable AHR induced 
by acute allergen challenge as there is no noticeable structural change in the airway or 
airway remodelling which will cause the persistent element. Therefore the persistent 
element of AHR as seen in clinic is not reflected in this model.  
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VI. CONCLUSION 
In conclusion, administration of corticosteroids (DEX and FP) inhibited airway 
inflammation by attenuating late asthmatic bronchocostriction, reducing the 
inflammatory cell accumulation in the airways, and reducing airway 
hyperresponsiveness in the murine model of ovalbumin induced airway inflammation. 
This shows that the model is sensitive to corticosteroids and closely mimics the 
features of human asthma. Therefore this corticosteroids intervention model would be 
an effective model to be further developed and used in subsequent studies of viral 
associated exacerbation in allergic airway inflammation.   
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I. INTRODUCTION 
Classical features of allergic asthma are airway hyperreactivity and airway 
inflammation which are orchestrated by allergen specific Th2 cells in combination with 
eosinophilia as a hallmark (Robinson et al., 1992). Although allergen specific Th2 cells 
and eosinophilia are marking the inflammation in allergic asthma, the major culprit of 
asthma exacerbation is actually microbial infection particularly respiratory virus 
infection (Traves and Proud, 2007). Respiratory viral infection is able to exacerbate 
asthma in almost all asthmatics. As a result, the asthma symptoms are often 
precipitated, becoming severe, and requiring hospitalisation. The most common cause 
of virus induced asthma exacerbation is rhinovirus  (Message and Johnston, 2001). 
Influenza is also a common cause of asthma exacerbation and has been associated 
with significant number of morbidity and mortality particularly during influenza H1N1 
pandemic in 2009 (Jain et al., 2009).  
Influenza on its own causes a substantial morbidity and mortality from severe 
pneumonia which leads to acute lung injury and acute respiratory distress syndrome 
(ARDS). A study showed that ARDS is the most important cause of patient death 
(Szretter et al., 2007). One proposed mechanism for ARDS is influenza virus induced 
cell death in lung parenchyma and epithelial cells apoptosis (Yang et al., 2011). Other 
important reason for the severe consequence of influenza virus infection is 
exaggerated immune response known as cytokine storm (Tyburski et al., 2001; Li et 
al., 2012) .  In some patients the appropriate immune response will clear the virions as 
well as inhibit viral replication. However, the inflammation from overreacted and 
uncontrolled immune response may lead to an unwanted more severe disease process 
(Lee et al., 2011). 
It has been estimated that in the UK, the cost of patients with asthma exacerbation  
were 3.5 times higher compared to asthmatic without exacerbation (Hoskins et al., 
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2000). Viral associated asthma exacerbations account for around 80% of asthma 
exacerbation cases in children and between 46% and 76% cases in adults (Johnston, 
1995; Nicholson et al., 1997). The exact cost of asthma exacerbation is not known. 
However, from the facts mentioned, the approximate figure of virus induced asthma 
exacerbation’s cost is quite significant.  
I.1. THERAPEUTIC OPTIONS 
Asthma exacerbation could be life threatening and has been associated with 
emergency care and hospital admission, therefore any available strategies of 
prevention and effective treatment of virus induced asthma exacerbation is a major 
necessity. Several therapeutic options have the potential to prevent or to reduce the 
severity of viral associated asthma exacerbations. The interventions include vaccines 
and monoclonal antibodies for prevention, anti-inflammatory agents such as 
corticosteroids, and also antiviral treatments as well as interferon (Holt and Sly, 2012). 
In this chapter, the focus will be given to corticosteroids, the anti-inflammatory agents. 
I.1.1. SYSTEMIC CORTICOSTEROIDS 
Systemic corticosteroids have been known as a first choice treatment for acute 
exacerbation of asthma (GINA Report, 2012). Their place as a mainstay therapy for 
asthma have been replaced by inhaled corticosteroids (ICS) because long use of oral 
corticosteroid treatment can lead to serious unwanted side effects such as growth 
retardation, hypertension, adrenal suppression, Cushing syndrome, and osteoporosis 
(Covar et al., 2000). Therefore, long term therapy with oral corticosteroid is not 
recommended unless for patients with severe disease uncontrolled with ICS and 
bronchodilator or patients who are not capable of using ICS (National Asthma 
Education and Prevention Program (2002). Short term use of oral corticosteroids is 
also only considered in an emergency setting requiring immediate control of asthma 
exacerbation (Scarfone et al., 1993).  
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Studies have shown that the early systemic corticosteroid administration in acute 
exacerbation of asthma might offer some clinical advantages.  In 2 randomised clinical 
trials, the intervention of systemic prednisolone in early acute asthma exacerbation 
reduced the number of hospital admission compared to placebo (Tal et al., 1990; 
Scarfone et al., 1993). Oral prednisolone given at the onset of asthma exacerbation 
also led to improved clinical status and respiratory functions as opposed to the 
deteriorating status of placebo treated group (Harris et al., 1987).  
Some studies showed the benefit of giving corticosteroid in respiratory viral infection 
associated exacerbations. The clinical conditions because of virus induced bronchiolitis 
also seem to be responsive to systemic corticosteroid if appropriate and sufficient dose 
is given (Weinberger, 2003). Oral corticosteroid has also played a role in preventing 
asthma exacerbation. Brunette et al (1988) investigated the role of oral prednisone in 
children with 7 times hospitalisation for acute virus infection induced exacerbations in 
average (Brunette et al., 1988). Prednisolone treatment for one year given at the onset 
of viral respiratory infection has made a 90% reduction in the number of 
hospitalisations compared to placebo treated group. Other study by the same 
investigators showed that giving systemic corticosteroid in early onset of respiratory 
viral infection in asthmatics prevented the symptoms from progressing to severe acute 
exacerbation of asthma which require hospitalisation (Storr et al., 1987). The studies 
define the role of early systemic corticosteroid intervention in acute asthma which leads 
to shorter hospital stay, reducing the probability of emergency hospital care, and 
preventing the worsening of exacerbations for patients requiring emergency care. At 
present, the asthma treatment guidelines agree on using systemic corticosteroid along 
with β2-agonists, anticholinergic drugs, and adequate oxygenation as the main 
intervention for acute asthma in emergency departments (GINA Report, 2012; National 
Asthma Education and Prevention Program, 2002; NHLBI/WHO, 2002). 
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I.1.2. INHALED CORTICOSTEROID 
Consideration of the adverse effects of systemic corticosteroids has led to the 
development of inhaled corticosteroids (ICS). The inhaled administration means the 
direct delivery of the corticosteroid into the inflamed lungs. The direct administration 
has also made the lower dose and therefore less systemic adverse effects possible.  
Currently ICS has been regarded as first line therapy for all level of persistent asthma 
with the addition of bronchodilator in patient with moderate and severe diseases 
(National Asthma Education and Prevention Program, 2002).   
Some studies have reported the role of ICS in reducing the risk of asthma exacerbation 
(Juniper et al., 1990; Dahl et al., 1993). In one study, asthmatics were treated with 
high, moderate, and low dose budesonide. The rate of asthma exacerbation was 
reduced by 50% in the group treated with high dose of budesonide. The benefit of 
budesonide treatment was in a dose response relationship (Tattersfield et al., 1999). 
Another study reported that treatment with budesonide in newly diagnosed mild 
persistent asthmatics was able to reduce the number of exacerbations by 25% 
compared to placebo treated patients (Pauwels et al., 2003). The OPTIMA study also 
showed a greater benefit of ICS in reducing the risk of asthma exacerbation by 
reducing the risk of annual exacerbation from 0.77 per patient to 0.29 per patient when 
given to ICS naive patients (O'Byrne et al., 2001). 
The role of ICS in exacerbation of asthma is still debated. However, a meta analysis 
which was conducted to compare the use of ICS to systemic corticosteroid or 
combination of ICS and systemic corticosteroid to combination of placebo and systemic 
corticosteroid found that ICS has additional benefit to systemic corticosteroid in the 
acute asthma exacerbation in the emergency setting (Rodrigo, 2006). The combination 
of ICS and bronchodilator (salbutamol) in the same setting also showed a greater level 
of bronchodilation compared to salbutamol alone (Rodrigo, 2005). Based on the 
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mentioned meta analyses, some guidelines including Global Initiative for Asthma 
(2012) suggested that the use of ICS in acute exacerbation of asthma could be an 
effective part of acute asthma exacerbation therapy. However, other guidelines such as 
the National Heart, Lung, and Blood Institute (NHLBI) do not list ICS as part of acute 
asthma exacerbation therapy (NHLBI, 2007). 
I.2. THE NATURE OF INFLAMMATION IN VIRUS-INDUCED ASTHMA 
EXACERBATION AND THE ROLE OF CORTICOSTEROIDS 
Despite some evidence that corticosteroids have benefit in exacerbation of asthma as 
well as being listed as part of therapy in acute exacerbation of asthma, some might 
argue that there is a reduced efficacy of corticosteroid in virus-induced exacerbation of 
asthma. In a human experimental Rhinovirus infection, treatment with prednisolone or 
beclomethasone before challenge as prophylactic were effective in reducing nasal 
obstruction, nasal mucus, and level of intranasal kinin, but the effects ceased when the 
treatments were stopped (Farr et al., 1990). In other human experimental RV infection, 
the administration of inhaled budesonide in mild asthmatic during the infection was able 
to improve lung functions and reduced the number of eosinophil but not the total 
inflammatory cells in the airways (Grunberg et al., 2001). In children with asthma, the 
administration of oral corticosteroid in an early course of acute viral respiratory infection 
reduced the duration and the level of severity of asthma exacerbation, but did not 
alleviate the cold symptoms (Brunette et al., 1988).  
The use of corticosteroid in the case of ARDS because of influenza infection is still in 
debate. There is evidence that giving corticosteroid in H1N1 induced ARDS improve 
the oxygenation and reduce the mortality rate (Confalonieri et al., 2010; Quispe-Laime 
et al., 2010). The administration of corticosteroid in H1N1 induced ARDS has justified 
reasons as the ARDS in pandemic H1N1 2009 was largely due to uncontrolled lung 
and systemic inflammation  rather than excessive viral infection (Annane, 2011). Hence 
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the use of anti inflammatory corticosteroids in this case is rational. However, WHO 
does not recommend the use high dose corticosteroids in severely ill H1N1 infected 
patient considering the unwanted serious outcome that might come from opportunistic 
infection, enhancement of viral replication, and inhibition of viral clearance (WHO, 
2009). 
There are differences between allergen and virus induced exacerbation of asthma. One 
distinct different between the two is the effectiveness of corticosteroids, as they are 
less effective in the virus-induced exacerbations   (Farr et al., 1990; Grunberg et al., 
2001; FitzGerald et al., 2004; Harrison et al., 2004). It has been mentioned that viral 
infection may act synergistically with allergic airway inflammation worsening the 
symptoms, the outcomes and hence the severity of asthma exacerbation (Contoli et al., 
2005). One of the proposed mechanisms of the enhancement of the severity is that the 
immune system responds to viral infection by attracting  neutrophils. The neutrophilia in 
combination with allergen induced eosinophilia increases the severity of the 
inflammation (Liu et al., 1999). While eosinophil number is also significantly increased 
in asthma exacerbations, neutrophils seem to a play more prominent role in virus-
induced asthma exacerbation  (Pizzichini et al., 1998; de Kluijver et al., 2003; Wark, 
2005)  
 One of the well known clinical benefits of corticosteroids to reduce the allergic airway 
inflammation appears to be through reducing the number and activity of eosinophils 
(Gibson et al., 2000). However, corticosteroids do not seem to have effect in reducing 
the number of neutrophils and their survival (Cox, 1995). Therefore, some might say, 
corticosteroids, the potent anti-inflammatory agents do not fully ameliorate 
inflammation and seems to only have a partial protection in virus induced asthma 
exacerbation. 
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II. AIMS 
The studies aim to determine the role of systemic and inhaled corticosteroids in the 
established murine model of allergic airway inflammation when challenged with the 
allergen (ovalbumin) during acute influenza infection. The endpoints include airway cell 
inflammation, early and late phase asthmatic reactions, and airway 
hyperresponsiveness. The studies would investigate whether the effective dose of 
corticosteroids in murine model of ovalbumin induced allergic airway inflammation were 
still able to reduce the inflammation during viral exacerbations. 
III. METHODS 
The methods used in the studies are described in more detail in CHAPTER 2 
III.1. ANIMAL 
Six Male BALB/c mice (20-25g) per group were used for all studies 
III.1.1. SENSITISATION 
Mice were sensitised by intraperitoneal injections (0.25 ml) of the mixture of OVA (50 
μg/mouse) and Al(OH)3 (50 mg/mouse) in saline or saline on day 0 and 5. 
III.1.2. INFLUENZA VIRUS INFECTION 
Mice were anaesthetised lightly with isoflurane and then intranasally infected with 10 
pfu in 50 µl PBS per mouse on day 13 (fig.8.1). Each mouse was given 12.5 µL of virus 
stock in one nostril and then 12.5 µL was given to the other nostril twice to give 10 
pfu/50 µL virus stock in total. The animal was held in upright position for 2 minutes then 
was put back in the transfer cage in prone position to facilitate the virus to spread 
evenly to the right and the left lungs. Control mice were treated the same and 
subjected to intranasal administration of sham. Sham is allantoic fluid from PBS 
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instilled embryonated egg treated similarly with influenza virus infected embryonated 
egg. All procedures were conducted in class II biosafety hood/cabinet. Mice were then 
returned to their cage in the mouse isolator once the infection was finished.  
III.1.3. CORTICOSTEROIDS INTERVENTION 
Dexamethasone (DEX): 
Water soluble dexamethasone, 6 mg/kg in 200 µl of PBS was administered by 
intraperitoneal injection once a day for 6 days starting from day 12 of the procedure. 
On day 17, when mice were challenged with OVA, DEX was given before the first OVA 
challenge. Control mice received a 200 µl intraperitoneal injection of PBS. Details of 
the procedures are displayed in figure 8.1.  
Fluticasone Propionate (FP): 
FP 0.5 mg/ml was dissolved in a mixture of saline (40%), DMSO (30%) and ethanol 
(30%). FP inhalation for 20 minutes twice a day 6 hour apart was administered for 6 
days starting from day 12 of the procedure. On the day of OVA challenge (day 17), FP 
was given before the first OVA challenge and 6 hours after the second OVA challenge. 
Control mice were given inhalation of vehicle (saline (40%), DMSO (30%) and ethanol 
(30%)) at the respective times. Details of the protocol are described in figure 8.1. 
III.1.4. OVALBUMIN CHALLENGES 
Mice were challenged with aerosolised OVA (0.5%) or saline (in a control group) 
inhalation challenges in a perspex box for 2 x 1 hour, with a 4 hour gap between 
exposures.  
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III.1.5. EARLY PHASE AND LATE PHASE DETERMINATION 
The lung function of unrestrained mice was measured as Penh using a whole body 
plethysmography system from Buxco. Values of Penh after allergen challenge were 
measured at 0, 20, 40, 60, 90 and 120 minutes, then hourly until 10 hours with a final 
reading at 19 hours after the second ovalbumin challenge.  
III.1.6. AIRWAY RESPONSIVENESS MEASUREMENTS 
Airway responsiveness in mice was measured after methacholine 
(acetyl‐β‐methylcholine chloride) provocation. Respiratory activity was recorded for 5 
min, to establish baseline value for Penh. Mice were subsequently exposed to the 
increasing doses of aerosolized methacholine dissolved in saline (1, 3, 10, 30, 100 
mg/ml). The procedures were started with preselected flow rate at 1.0 min; with 1.5 
minutes of intermittent methacholine exposures (at 25% duty: 1.5 second exposure 
followed by 4.5 seconds without exposures on a continuous cycle), and 2 min dryer 
time.  Plethysmographic data were recorded for another 5 minutes after aerosol 
administration. The Penh values measured during each 5 minutes sequence were 
averaged and are expressed for each methacholine concentration as absolute Penh 
values. Airway responsiveness measurements were performed on day 11 and 19 hours 
after the final ovalbumin exposure. 
  
Figure 8.1. The protocol of DEX or FP interventions given in the acute course of influenza A  
infection in OVA model of allergic airway inflammation. DEX or PBS was given int raperitoneally 
once a day while FP or vehicle FP (30% ethanol: 30% DMSO: 40% saline) were given by 
aerosol inhalation twice a day 6 hours apart for 6 days starting from day 12  
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Figure 8.2. The protocol of DEX or FP interventions given in the acute course of influenza A 
infection. DEX or PBS was given intraperitoneally once a day while FP or vehicle FP (30% 
ethanol: 30% DMSO: 40% saline) were given by aerosol inhalation twice a day 6 hours apart for 
6 days starting from day 12 
 
III.2. TOTAL AND DIFFERENTIAL CELL COUNTS 
After the final airway responsiveness measurements, the mice were administered a 
lethal dose of sodium pentobarbitone, the lungs were then removed and lavaged. 
Using the BAL fluid, recovered total and differential cell counts were then carried out 
using the methods described in CHAPTER 2.  
III.3. BAL FLUID PROTEIN CONTENT 
Total Protein content of BAL fluid was analysed with BCA protein assay as described in 
CHAPTER 2. 
III.4. VIRUS TITRE DETERMINATION 
The virus titre was quantitated by plaque assay with AEC immunocytochemistry as 
described previously in CHAPTER 4. 
III.5. LUNG HISTOLOGY  
Lung was stained with H and E and was analysed with histopathology scoring as 
described in CHAPTER 2. 
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IV. RESULTS 
IV.1. THE EFFECTS OF SYSTEMIC CORTICOSTEROID (DEX) ON 
INFLUENZA ASSOCIATED EXACERBATION OF MURINE AIRWAY 
ALLERGIC INFLAMMATION 
 
IV.1.1. THE EFFECTS OF DEX ON EARLY AND LATE PHASE REACTIONS 
OVA challenge induced early phase reactions in both vehicle (PBS) and DEX treated 
group. The EAR for both vehicle treated and DEX treated groups peaked on 2 hours 
after the second OVA challenge (61.9 ±20.9% and 78.7 ±20.5% increase from baseline 
Penh respectively). Late phase responses were clearly demonstrated in vehicle treated 
group and peaked (194.6 ±36.01% increases from baseline Penh) on the 8th hour after 
the second OVA challenge. The bronchoconstrictions were sustained and did not 
return to normal baseline 19 hours after OVA challenge.  
DEX reduced the peak of the LAR (46.5 ±19.02% increase from baseline Penh) on 8 
hours after OVA challenge. However, after the greatest reduction of the change from 
baseline Penh on 7 hours after OVA challenge, the level of bronchocostriction was 
gradually increased up to the last observation time point i.e. 10 hours after the second 
OVA challenge. Ten hours after the last OVA challenge, the change from baseline 
Penh of vehicle and DEX treated animals were not significantly different. Nineteen 
hours after the second OVA challenge Penh did not return to baseline and the increase 
in baseline Penh was greater (although not statistically significant) compared to those 
on hour 10 when the mice were last observed as depicted on figure 8.3. Change from 
baseline Penh at 19 hour were no significantly different between vehicle treated and 
DEX treated group. 
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Figure 8.3. Mean time-course values of Penh in OVA sensitised, influenza infected, and OVA 
challenged mice and treated with PBS or DEX (6 mg/kg) for 6 days. Mean changes in Penh are 
expressed as mean±S.E.M. percentage change from baseline. Data were analysed with 
unpaired two tailed t-test (* P< 0.05; n=6).  
 
IV.1.2. THE EFFECTS OF DEX ON AIRWAY RESPONSIVENESS 
 
Figure 8.4. Mice were OVA sensitised, influenza infected, challenged with OVA and 
treated with DEX (6 mg/kg) or vehicle (PBS) for 6 days. A day before administration of 
DEX or vehicle, and 24 h after the challenges, baseline lung function and AHR to 
increasing doses of methacholine was measured by whole body plethysmography. 
Results are expressed as mean ± SEM of absolute Penh. Data were analyzed with 
unpaired two tailed t-test (*P<0.05; n=6). 
 
The OVA challenge in the acute course of influenza infection induced airway 
hyperresponsiveness. The absolute Penh by methacholine provocation was enhaced 
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significantly compared to those read before the influenza infection and OVA challenge. 
There was still a significantly increased airway responsiveness to methacholine after 
DEX (Fig. 8.4). 
IV.1.3. THE EFFECTS OF DEX ON TOTAL AND DIFFERENTIAL CELL 
COUNTS 
Influenza virus infection and OVA challenge increased the total cell counts significantly 
(Fig. 8.5) in vehicle treated animals compared to naive animal. Treatment with DEX 
significantly reduced the influx of inflammatory cells recovered in bronchoalveolar fluid 
from 28.6±3.6.105 cells/ml in vehicle treated group to 14.3=5±2.7.105 cells/ml in DEX 
treated group. The macrophages and neutrophil counts were not affected by DEX. 
However, eosinophil and lymphocyte numbers were significantly attenuated by DEX. 
Lymphocyte number was reduced from 1.5±0.2.105 cells/ml in vehicle treated animal to 
0.3±0.1.105 cells/ml in DEX treated animal, while the eosinophil number was reduced 
from 9.3±1.6.105 cells/ml to 0.06±0.02.105 cells/ml respectively. 
 
Figure 8.5. Broncholaveolar lavage total and differential cells number (macrophages, 
eosinophils, lymphocytes and neutrophils) of naïve (non-sensitised) and OVA sensitised, 
influenza infected, OVA challenged mice which were treated with PBS or DEX (6 mg/kg) for 6 
days. Values represent mean±S.E.M. Data were analysed with One-way Analysis of Variance 
followed by a Bonferroni post-test. 
#
significantly different from all other groups; *connected with 
corresponding bar is significantly different from each other (P<0.05; n=6 )   
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The percentage of each subtype of leucocytes in the total inflammatory cells recovered 
in BALF was also observed. The DEX treatment significantly altered the proportion of 
macrophages, eosinophil, and lymphocyte. However, it did not change the proportion of 
neutrophils from the total leucocytes influx (Fig 8.6). 
 
Figure 8.6. The percentage of macrophages, eosinophils, lymphocytes and neutrophils found in 
the bronchoalveolar fluid of naïve AND OVA sensitised, influenza infected, OVA challenged 
mice which were treated with PBS or DEX for 6 days. Results are expressed as mean±S.E.M. 
Data were analysed with One-way Analysis of Variance followed by a Bonferroni post-test 
(*P<0.05; n=6).  
 
IV.2. THE EFFECTS OF SYSTEMIC CORTICOSTEROID (DEX) ON 
THE ACUTE COURSE OF INFLUENZA INFECTION IN SALINE 
SENSITISED AND NON-CHALLENGED MICE 
The reading of Penh (airway resistance) in these groups of mice was not conducted as 
saline challenged mice did not show any significant change in Penh to be regarded as 
EAR and LAR. 
IV.2.1. THE EFFECTS OF DEX ON AIRWAY RESPONSIVENESS 
The maximum airway responsiveness was increased significantly from 3.5±0.9 
absolute Penh before mice were infected with influenza virus to 8.7±0.7 absolute Penh 
after infection. DEX treatment did not reduce the increasing AHR (fig 8.7).  
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Figure 8.7. Mice were saline sensitised, influenza infected, and treated with DEX (6 mg/kg) or 
vehicle (PBS) for 6 days. A day before administration of DEX or vehicle, and 24 h after the 
challenges, baseline lung function and AHR to increasing doses of methacholine was measured 
by whole body plethysmography. Results are expressed as mean ± SEM of absolute Penh. 
Data were analyzed with unpaired two tailed t-test (*P<0.05; n=6).   
 
IV.2.2. THE EFFECTS OF DEX ON TOTAL AND DIFFERENTIAL CELL 
COUNTS 
 
Figure 8.8. Broncholaveolar lavage total and differential cells number (macrophages, 
eosinophils, lymphocytes and neutrophils) of naïve and saline sensitised, influenza infected, 
and treated with PBS or DEX for 6 days. Results are expressed as mean±S.E.M. Data were 
analysed with One-way Analysis of Variance followed by a Bonferroni post-test. 
#
significantly 
different from all other groups (P<0.05; n=6). 
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Influenza Infection increased the total inflammatory cells influx into the airway. The 
number of macrophage, lymphocyte, and neutrophil were significantly greater than 
those in naive animals. The increase in the total cell count, macrophage count, 
lymphocyte count, and neutrophil count were not affected by DEX (fig 8.8).  
 
IV.2.3. THE EFFECTS OF DEX ON PLASMA EXUDATION/PROTEIN 
LEAKAGE 
OVA sensitisation, OVA challenge, influenza infection, and DEX treatment, when all 
given concurrently enhanced protein content in BALF. However, influenza infection per 
se did not increase the protein level significantly compared to naive mice (Fig 8.9).  
 
Figure 8.9. Total protein content in bronchoalveolar lavage fluid of naïve, naïve (non-sensitised) 
and OVA sensitised, influenza infected, OVA challenged mice which were treated with PBS or 
DEX (6 mg/kg) for 6 days. Results are expressed as mean±S.E.M. Data were analysed with 
One-way Analysis of Variance followed by a Bonferroni post-test. 
#
significantly different from all 
other groups, s^ignificantly different from naive mice (P<0.05; n=6). 
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IV.2.4. THE EFFECTS OF DEX ON VIRAL TITRES 
OVA sensitisation and challenge did not significantly increase the viral titre. Treatment 
with DEX did not affect viral titre in either saline sensitised or OVA sensitised and 
challenged animals (fig. 8.10). 
 
Figure 8.10.  Viral titres of lungs of mice sensitised with OVA infected with influenza A, 
challenged with OVA and treated with DEX (6mg/kg) or PBS for 6 days. Virus titres were 
determined by plaque assay on MDCK cells. Virus titres are expressed as mean ± SEM of pfu 
per sampled lungs. Data were analysed with one-way Analysis of Variance, followed by post 
hoc Bonferroni’s test to determine the difference in viral titres.  
 
IV.2.5. THE EFFECTS OF DEX LUNG HISTOLOGY 
Figure 8.11 displays change in lung histological features of mice when they infected 
with influenza virus and challenged with OVA compared to naive mice. The lung from 
mice which were infected with influenza virus alone and treated with vehicle DEX 
(PBS) showed a distinct peribronchial and perivascular inflammation as well as 
epithelial loss or shedding (fig 8.11.B). Treatment with DEX did not significantly change 
the lung histological features (fig.8.11.C). Lungs of OVA sensitised, influenza infected 
and OVA challenged mice display a more severe perivascular and peribronchial 
inflammation (fig 8.11.D) compared to the non challenged mice (fig 8.11.B and C). DEX 
slightly reduced the density of inflammatory cells around bronchioles and lung blood 
vessel (fig 8.11 E). 
CHAPTER VIII  
 
216 
 
 
Figure 8.11.  Histopathological changes of lungs of naive mice (A); or saline sensitised/influenza infected 
mice which were treated with PBS (vehicle DEX) (B );  Saline sensitised/influenza infected mice which 
were treated with DEX (C);  OVA sensitised/influenza infected mice which were treated with PBS (D); or 
OVA sensitised/influenza infected mice which were treated with DEX (E). The lungs were stained with 
haematoxylin and eosin to display general morphology (100x magnification). 
 
Influenza infection increased the mean pathological scores compared to naive animals. 
However, DEX treatment or OVA sensitisation and challenge did not significantly alter  
the mean pathology scores compared any other groups (fig. 8.12).  
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Figure 8.12. The mean lung pathology score of naïve or saline sensitised mice which were 
treated with PBS (Vehicle DEX) or DEX 6 mg/kg or OVA sensitised and challenged mice which 
were treated with PBS or DEX 6 mg/kg. Results are expressed as mean±S.E.M. Data were 
analysed using one-way ANOVA, followed by post hoc Bonferroni’s test to determine the mean 
pathology score. *significantly different from all other groups (P<0.05; n=6).  
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IV.3. THE EFFECTS OF INHALED CORTICOSTEROID (FP) ON 
INFLUENZA ASSOCIATED EXACERBATION OF MURINE AIRWAY 
ALLERGIC INFLAMMATION 
IV.3.1. THE EFFECTS OF FP ON EARLY AND LATE PHASE REACTIONS 
When the OVA sensitised and influenza infected animals were challenged with OVA, 
the EAR was observed on both vehicle treated and FP treated mice. The EAR of the 
vehicle treated mice peaked 1.5 hour after the last OVA challenge (107.6  ±18.9% 
increase from baseline Penh), while the EAR of FP treated animals peaked 2 hours 
after the challenge (59.7±33.6% increase from baseline Penh) (fig 8.13). 
 
Figure 8.13 Mean time-course values of Penh in OVA sensitised, influenza infected, and OVA 
challenged mice and treated with vehicle (saline/DMSO/Ethanol (40%/30%/30)) or FP (0.5 
mg/ml) for 6 days. Mean changes in Penh are expressed as mean±S.E.M. percentage change 
from baseline. Data were analysed with unpaired two tailed t -test (* P< 0.05; n=6).  
 
The peak of LAR in vehicle treated mice was detected 8 hours after the last OVA 
challenge in vehicle treated mice (160.3±36.9% increase from baseline Penh). There 
was no LAR peak detected in mice treated with FP, hence FP attenuated the LAR. 
Nineteen hours after the last OVA challenge, the baseline airway functions did not 
return to baseline on either vehicle treated or FP treated mice. However, the baseline 
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airway functions of FP treated mice were significantly lower compared to vehicle 
treated mice (fig 8.13). 
 
IV.3.2. THE EFFECTS OF FP ON AIRWAY RESPONSIVENESS 
There was a marked increase in airway responsiveness when OVA challenge and 
influenza infection were given simultaneously in OVA sensitised animals. FP did not 
significantly reduce the airway responsiveness induced by viral infection and allergen 
challenge at 24 hours (fig 8.14). 
 
Figure 8.14. Mice were OVA sensitised, influenza infected,  challenged with OVA and treated 
with FP (0.5 mg/ml)or vehicle (saline/DMSO/ethanol (40%/30%/30)) for 6 days. A day before 
administration of FP or vehicle, and 24 h after the challenges, baseline lung function and AHR 
to increasing doses of methacholine was measured by whole body plethysmography. Results 
are expressed as mean±S.E.M of absolute Penh. Data were analyzed with unpaired two tailed t -
test (*P<0.05; n=6).  
 
IV.3.3. THE EFFECTS OF FP ON TOTAL AND DIFFERENTIAL CELL 
COUNTS 
Influenza infection and OVA challenge in OVA sensitised mice increased the total 
inflammatory cells recovered in BAL fluid compared to naive animal. The macrophage, 
eosinophil, lymphocyte, and neutrophil number were also significantly greater than 
naive. FP treatment significantly reduced the total leukocytes count. The numbers of all 
individual cells were also attenuated by FP (Fig 8.15).  
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FP also significantly affected the proportion of individual leukocyte subtypes particularly 
macrophages and eosinophils in total influx of inflammatory cells in BAL fluid. The 
proportion of lymphocytes and neutrophils were not altered by FP (fig 8.16).  
 
Figure 8.15. Broncholaveolar lavage total and differential cells number (macrophages, 
eosinophils, lymphocytes and neutrophils) of naïve (non -sensitised) and OVA sensitised, 
influenza infected, OVA challenged and treated with Vehicle (saline/DMSO/ethanol 
(40%/30%/30) or FP (0.5 mg/ml) for 6 days. Values represent mean±S.E.M. Data were 
analysed with One-way Analysis of Variance followed by a Bonferroni post-test. 
#
significantly 
different from all other groups; *connected with corresponding bar is significantly different from 
each other (P<0.05; n=6)   
 
Figure 8.16. The percentage of macrophages, eosinophils, lymphocytes and neutrophils found 
in the bronchoalveolar fluid of naïve AND OVA sensitised, influenza infected, OVA challenged 
and t reated with vehicle (saline/DMSO/ethanol (40%/30%/30)) or FP (0.5 mg/ml) for 6 days 
mice. Results are expressed as mean±S.E.M. Data were analysed with One-way Analysis of 
Variance followed by a Bonferroni post-test (*P<0.05; n=6).  
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IV.4. THE EFFECTS OF INHALED CORTICOSTEROID (FP) ON THE 
ACUTE COURSE OF INFLUENZA INFECTION IN SALINE 
SENSITISED AND UNCHALLENGED MICE 
Observation of the airway functions (Penh) overtime to determine AER and LAR was 
also not performed in these groups of animal for the same reasons as per the DEX 
treated mice. 
IV.4.1. THE EFFECTS OF FP ON AIRWAY RESPONSIVENESS 
The airway responsiveness increased by influenza virus infection was not reduced by 
FP as described on figure 8.17. 
 
Figure 8.17. Mice were saline sensitised, influenza infected, and treated with FP (0.5 mg/ml) or 
vehicle (saline/DMSO/ethanol (40%/30%/30)) for 6 days. A day before administration of FP or 
vehicle, and 24 h after the challenges, baseline lung function and AHR to increasing doses of 
methacholine was measured by whole body plethysmography . Results are expressed as 
mean±S.E.M of absolute Penh. Data were analyzed with unpaired two tailed t -test (*P<0.05; 
n=6).  . 
IV.4.2. THE EFFECTS OF FP ON TOTAL AND DIFFERENTIAL CELL 
COUNTS 
FP treatment did not significantly reduce the increasing total cell counts induced by 
influenza virus infection (fig 8.18). The individual inflammatory cells subtype number 
was also not affected by FP treatment except for lymphocytes which reduced from 
0.3±0.1.105 cells/ml in vehicle treated mice to 0.99±0.07.105 cells/ml in FP treated 
mice. 
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Figure 8.18. Broncholaveolar lavage total and differential cells number (macrophages, 
eosinophils, lymphocytes and neutrophils) of naïve and saline sensitised, influenza infected, 
and treated with vehicle (saline/DMSO/ethanol (40%/30%/30)) or FP (0.5 mg/ml) for 6 days. 
Results are expressed as mean±S.E.M. Data were analysed with One-way Analysis of Variance 
followed by a Bonferroni post-test. 
#
significantly different from all other groups (P<0.05; n=6). 
 
IV.4.3. THE EFFECTS OF FP ON PLASMA EXUDATION/PROTEIN 
LEAKAGE 
 
Figure 8.19. Total protein content  in bronchoalveolar lavage fluid of naïve (non-sensitised) and 
OVA sensitised, influenza infected, OVA challenged mice which were treated with vehicle 
(saline/DMSO/ethanol (40%/30%/30)) or FP (0.5 mg/ml) for 6 days. Results are expressed as 
mean±S.E.M. Data were analysed with One-way Analysis of Variance followed by a Bonferroni 
post-test.
 #
significantly different from all other groups (P<0.05; n=6). 
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Protein level in the BAL fluid from OVA sensitised, OVA challenged, influenza infected, 
and FP treated animals was significantly higher than any other groups (fig 8.19).  
IV.4.4. THE EFFECTS OF FP ON VIRAL TITRES 
OVA sensitisation and challenge did not significantly change viral titre compared to 
saline sensitised and non challenged animal. Treatment with FP did not have any 
significant effect on influenza virus titre (Fig 8.20).   
 
Figure 8.20.  Viral titres of lungs of mice sensitised with OVA  infected with influenza A, 
challenged with OVA and treated with vehicle (saline/DMSO/ethanol (40%/30%/30)) or FP (0.5 
mg/ml) for 6 days. Virus titres were determined by plaque assay on MDCK cells. Virus titres are 
expressed as mean ± SEM of pfu per sampled lungs. Data analysed for each differential cell  
type and total count using one-way ANOVA, followed by post hoc Bonferroni’s test to determine 
the difference in viral titres. 
 
IV.4.5. THE EFFECTS OF FP LUNG HISTOLOGY 
Marked peribronchial and perivascular inflammation were observed in influenza 
infected mice (fig 8.21.B, C, D, and E) compared to naive animals. In the mice which 
OVA sensitised, influenza virus infected, and challenged with OVA there is an evidence 
of epithelial cells elongation and folding (fig 8.21.D and E). OVA sensitisation and 
challenge caused denser accumulation of cells in peribronchial and perivascular area 
(fig 8.21.E).  Treatment with FP reduce the density of the inflammatory cells 
accumulation in OVA sensitised and OVA challenged group (fig 8.21.E) but did not 
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significantly change the general histological appearance of the lungs from influenza 
infected mice which only sensitised with saline (fig 8.21.C).  
 
Figure 8.21.  Histopathological changes of lungs of naive mice (A); or saline sensitised/influenza infected 
mice which were treated with vehicle FP (B );  Saline sensitised/influenza infected mice which were treated 
with FP (C);  OVA sensitised/influenza infected mice which were treated with vehicle FP (D); or OVA 
sensitised/influenza infected mice which were treated with FP (E). The lungs were stained with 
haematoxylin and eosin to display general morphology (100x magnification). 
 
Influenza infection increased the mean pathology score compared to naive mice. 
Treatment with FP 0.5 mg/ml significantly reduced the mean pathology score in OVA 
challenge, influenza infected, and OVA challenged animals but did not change the 
score of the animals which were only sensitised with saline (fig 8.22).  
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Figure 8.22. The mean lung pathology score of naïve or saline sensitised mice which were 
treated with vehicle (saline/DMSO/ethanol (40%/30%/30)) or FP (0.5 mg/ml) or OVA sensitised 
and challenged mice which were treated with vehicle (saline/DMSO/Ethanol (40%/30%/30)) or 
FP (0.5 mg/ml) for 6 days. Results are expressed as mean±S.E.M. Data were analysed using 
one-way ANOVA, followed by post hoc Bonferroni’s test to determine the mean pathology 
score. 
#
significantly different from all other groups; *connected with corresponding bar is 
significantly different from each other (P<0.05; n=6).  
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V. DISCUSSION 
Currently, corticosteroids either inhaled or systemically administered are the mainstay 
of asthma therapy. Corticosteroid is a potent anti inflammatory agent which can 
attenuate the inflammation in asthmatics via their genomic or non-genomic actions. In 
the case of asthma exacerbation, particularly viral associated asthma exacerbation, 
theoretically corticosteroids should be effective in reducing the inflammation from the 
interplay between allergic inflammation and respiratory viral infection. Therefore, 
corticosteroids have been commonly prescribed in the case of viral induced asthma 
exacerbation both in general practice or emergency setting. However, in reality, the 
benefit of corticosteroid in the case of asthma exacerbations induced by respiratory 
viral infection is still controversial as described in the introduction section.  
In this series of experiments, the role of both systemic (DEX) and inhaled (FP) 
corticosteroid in the course of acute influenza infection of mice with allergic airway 
inflammation when they are challenged with allergen were determined.  
V.1. THE EFFECTS OF CORTICOSTEROIDS ON THE INFLAMMATORY 
CELLS INFLUX INTO THE AIRWAYS 
OVA challenge in acute influenza infection on OVA sensitised mice in which they were 
treated with the vehicle of corticosteroid led to a very significant inflammatory cells 
influx into the airways. This is consistent with our results in CHAPTER 6. DEX 
significantly reduced the total inflammatory cell. DEX reduced the individual number of 
lymphocytes and eosinophils. Eosinophil number was almost completely abrogated by 
DEX. The number of macrophages and neutrophils though were not affected by DEX.  
Influenza infection alone in saline sensitised and non-challenged mice also increased 
the total inflammatory cells counts. The number of macrophages, lymphocytes, and 
neutrophils were higher than those numbers in naive animals.  The treatment of DEX 
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did not reduce the total inflammatory cells count or the individual count of inflammatory 
cells subtype i.e. macrophages, neutrophils, and lymphocytes. 
Influenza infection targets the epithelial cells which line the airways. In the course of 
acute influenza infection, the infected epithelial cells become necrotic, lysed, and 
release a range of cytokines and chemokines such as TNF-α, IL-1, MCP-1, RANTES, 
MIP-1, IP-10, and IL-8 (Julkunen et al., 2001). The release of the inflammatory 
mediators by necrotic epithelial cells promotes the extravasation of macrophages, 
neutrophils, and T lymphocytes from peripheral blood trough the endothelial-epithelial 
barrier to the infected tissue in the airways (Ada and Jones, 1986). Macrophages have 
an essential role as both killing the virus and secreting inflammatory mediators which 
further recruit inflammatory cells into the lungs. Macrophages and neutrophils also act 
as phagocytes to the virus infected apoptotic cells (Hashimoto et al., 2007). Hence, 
along with neutrophils, macrophages have a role in viral clearance (Watanabe et al., 
2005).  
In acute viral-infected allergic mice, allergen challenge exaggerates the migration of 
inflammatory cells into the airways as there is a synergism between the two as 
discussed in CHAPTER 6.  The administration of DEX reduced the number of 
eosinophils in BAL fluid.  Eosinophilia is the hallmark of asthma. Eosinophils are known 
to be sensitive to corticosteroid. The pharmacologic characteristic of corticosteroid in 
the treatment of asthma includes the action of the anti-inflammatory agent in the 
inhibition of eosinophil recruitment, reduction of the number of eosinophil including their 
secretary products (Birrell et al., 2003) and induction of eosinophil apoptosis 
(Anderson, 1996).  
Schleimer (2004) in his review argues that corticosteroids, while effective in reducing 
inflammation as a result of activated adaptive immune responses, they have a 
minimum effect on innate immune responses which usually triggered by infection. 
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Macrophages and neutrophils are essential effector cells in the innate immune 
responses. The function of macrophages as phagocytes is increased by corticosteroid 
(Heasman et al., 2003). Systemic corticosteroids are also known to significantly 
increase the number neutrophils and increase their survival (Schleimer, 2004).  The 
action of sparing innate immune response by corticosteroids might be the reasons why 
DEX had a minimal effect in the reduction of macrophages and neutrophils in either 
OVA sensitised/influenza infected/OVA challenged mice or saline sensitised/influenza 
infected/non-challenged mice. 
Similar to DEX, in acute influenza infection of saline sensitised and un-challenged 
mice, FP treatment did not reduce the total cell count. However, different from DEX, FP 
reduced the number of lymphocytes significantly compared to vehicle treated animals. 
Treatment of FP in OVA sensitised/influenza infected/OVA challenged mice also 
reduced the total inflammatory cells count significantly compared to the cells count in 
vehicle treated animals. Different from DEX though, the number of all individual 
subtypes of leukocytes was significantly lower in FP treated group than those in vehicle 
treated group.  However, when compared the effects of the DEX and FP treatments on 
the proportion of individual subtypes of leukocytes recovered in BAL fluid of OVA 
sensitised, influenza infected, and OVA challenged groups were quite similar with the 
increased proportion of macrophages and the reduced proportion of eosinophils 
compared to vehicle treated groups. 
Corticosteroids have been proposed to largely act on reducing the migration and 
accumulation of inflammatory cells in the airway by reducing the production of 
chemokines/chemoattractant and inhibiting the upregulation of some particular 
adhesion molecules (Schleimer, 2004). Therefore, Schleimer (2004) also propose that 
corticosteroids primarily affect the production of chemoattractants and not the 
leukocytes responses to their chemoattractants. And in this study, FP effects on the 
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reduction of the inflammatory cells chemoattractants might be larger than those of 
DEX.  
Corticosteroids, even though almost similar in their molecular structures have a varied 
rank of potency. FP has a relatively higher affinity for the glucocorticoid receptor (GR) 
compared to DEX (Johnson, 1998). The rate of dissociation of the FP-GR complex is 
also slower than DEX. The GR-FP profile is associated with a relatively high anti-
inflammatory activity. The FP-GR interacts with glucocorticoid response element on 
target genes at significantly lower concentration than DEX (EC50 FP = range 0.01 to 0.1 
nmol/L and EC50 DEX = 3 nmol/L respectively) (Adcock et al., 1999). To the best of my 
knowledge, there are no study to find the direct comparison between FP and DEX 
effect on every chemoattractant for the individual leucocytes, but there are some 
reference that showed FP is more potent compared to DEX in inhibiting human T-
lymphocytes migration and proliferation. FP is also more potent in inhibiting the 
production of IL-5 and IL-4 from Th2 lymphocytes (Johnson, 1998). So, FP may be 
more potent in reducing the number of inflammatory cells in the lungs compared to 
DEX in OVA sensitised/influenza infected/OVA challenged animals. However, FP was 
not effective in attenuating the inflammatory cell influx in the lungs of the animals which 
only infected with influenza virus. 
V.2.  THE EFFECTS OF CORTICOSTEROIDS ON EARLY AND LATE 
PHASE ASTHMATIC RESPONSES 
The allergic cascade initiated by re-exposure of allergen has been known to cause 
early and late phase bronchoconstriction. Previous series of experiments (CHAPTER 
6) highlighted interesting findings demonstrating that influenza virus infection when 
occurs concomitantly with allergen exposure/challenge in allergen sensitised mice 
profoundly accentuate the brochoconstriction particularly late phase asthmatic 
response. Late phase asthmatic reaction was also prolonged and the lung functions did 
not return to baseline 19 hours after the second (24 hours after the first) allergen 
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challenge. Mice treated with vehicle corticosteroids also had a significant increase in 
late phase asthmatic bronchoconstriction. The bronchoconstriction still persisted 19 
hours after the second OVA challenge. This was a measure of exacerbation. Neither 
DEX nor FP reduced early phase asthmatic reactions.  
The number of mast cells in airway smooth muscle (Brightling et al., 2002) and within 
the epithelial layer (Balzar et al., 2011) of asthmatics is higher than that in their healthy 
counterpart.  After allergen challenge, mast cells in the allergic airways are rich in 
allergen specific IgE. They degranulate and release inflammatory mediators such as 
prostaglandin, leukotrienes, and histamine which contribute to early phase 
brochoconstriction (Edwards et al., 2009).  Influenza A infection has also been noted to 
induce mast cells proliferation and activation. In the acute phase of influenza infection, 
mast cells when degranulated have been suspected to have a significant contribution 
on the lung injury by releasing histamine, tryptase and IFN-γ ((Hu et al., 2012). 
Inhaled corticosteroid (Budesonide) has been known to selectively reduce the number 
of mast cells in the smooth muscle and epithelium of asthmatic’s airways but not sub-
mucosal mast cells (James et al., 2012). FP was also able to reduce the number of 
mast cell in COPD patients after 3 months treatment (Gizycki et al., 2002). 
Nonetheless, corticosteroid has failed to inhibit the activation and release of histamine 
from degranulated mast cells (Liu et al., 2001). Therefore, this could explain why 
corticosteroid has a minimum effect in inhibiting early phase bronchoconstrictions in 
this study. 
Late phase reaction was sensitive to FP. Mice treated with FP had the late phase 
bronchoconstriction completely abrogated. Mice treated with FP also had significantly 
lower baseline lung functions 19 hours after the second OVA challenge compared to 
vehicle treated mice. 
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The effects of DEX on the late phase bronchoconstrictions were slightly different from 
FP. DEX was able to reduce the peak of late phase bronchoconstriction. However, 
starting from hour 7 after the second OVA challenge, the mice beginning to have 
ongoing increase of bronchoconstriction up to hour 10 when the observation was 
paused. The next day (19 hours after the second OVA challenge) there was no 
significant reduction of bronchoconstriction and the increase of baseline Penh was not 
significantly different from vehicle treated mice. It is interesting because, anything could 
happen in 10-19 hour when the Penh reading was paused. The late phase 
bronchoconstriction might just have been delayed and not completely attenuated by 
DEX. 
Late phase bronchoconstriction has been known as the continuing consequences of 
mast cells degranulation. Mast cells generate a variety of chemokines which attracts 
Th1 and Th2 lymphocytes, eosinophils and neutrophils into the airway. The migrated 
Th2 lymphocytes also produce Th2 specific cytokines including IL-5 which is important 
for eosinophil differentiation, proliferation, activation, and survival (Renauld, 2001). 
Mast cells also produce a range of Th2 cytokines including IL-4 and IL-13 which 
contribute to the increasing production of chemokines from epithelial and airway 
smooth muscle cells.  IL-13 is recognized to highly contribute to the increase of airway 
hyperresponsiveness in asthma (Leigh et al., 2004; Yang et al., 2004). The 
inflammatory cells influx into the airway, particularly the Th2 lymphocytes has been 
thought to have an important role in the development of the late asthmatic responses. 
The difference of the relative potency between DEX and FP in the inhibition of T 
lymphocytes proliferation and migration as well as IL-4 and IL-5 secretion might 
contribute in their differences in the abolishment of late phase brochoconstriction in this 
study. This seems to be associated with the effectiveness of DEX and FP in reducing 
the influx of inflammatory cells into the airways.  
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As noted, the levels of circulating alveolar macrophages and neutrophils as part of the 
innate immune response effector cells toward respiratory viral infection seem to be 
spared by corticosteroid (Schleimer, 2004). The accumulated macrophages can also 
be a source of inflammatory cytokines by their ability to secrete IL-1, TNF-α, and IL-8 
which lead to the amplifications of inflammation in the airways by triggering the 
activation and further recruitment of inflammatory cells into the infected sites (Julkunen 
et al., 2000). Macrophages infected with respiratory virus in vitro were capable of 
producing prostaglandine E2, thromboxane B2, platelet activating factor, and reactive 
oxygen species, which might contribute to the enhancement of bronchoconstriction 
(Folkerts et al., 1998). Neutrophils were also capable of secreting inflammatory 
mediators, elastase, and protease (Liu et al., 1999). Protease produced by neutrophils 
can activate eosinophils (Liu et al., 1999). Eosinophils were sensitive to corticosteroid 
treatment. However, there is a study which reported that neutrophils take up and store 
the eosinophil cationic protein released by eosinophils (OrdoÑEz et al., 2000).  
DEX seems to have a minimal effect to reduce the increased number macrophages 
and neutrophils induced by influenza infection. This might lead to the persistent airway 
bronchoconstriction, 19 hours after OVA challenge even after DEX treatment. FP 
treatment though was capable of reducing the number of macrophages and neutrophis 
in mice, which might lead to the significant reduction of airway bronchoconstrictions 
observed 19 hours after OVA challenge. 
V.3. THE EFFECTS OF CORTICOSTEROIDS ON AIRWAY 
HYPERRESPONSIVENESS 
Similar with the result of the study to develop a model of virus infection-induced asthma 
exacerbation described in CHAPTER 6; OVA sensitised, influenza infected, and OVA 
challenged mice had a very significant increase in airway hyperresponsiveness after 
they were treated with the vehicle of corticosteroids, compared to the airway 
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responsiveness read before any of the interventions. DEX did not significantly reduce 
the increase in airway hyperresponsiveness and neither did FP.   
The augmentation of airway hyperresponsiveness after influenza infection was also 
observed in mice which were only saline sensitised and not given any challenge. 
Neither DEX nor FP significantly reduced the increase of airway hyperresponsiveness. 
The hypothesis of possible causes of the enhancement of airway responsiveness in 
influenza infection alone; OVA allergic airway inflammation model; and OVA challenge 
in influenza infected in OVA sensitised mice have been discussed CHAPTER 4, 5, and 
6.  In the OVA allergic inflammation model, Th-2 cytokine, IL-13 has been thought to 
play a significant role in the development of airway hyperresponsiveness (Bousquet et 
al., 2000). The airway hyperresponsiveness induced by influenza infection is shown to 
have a different mechanism from OVA induced airway hyperresponsiveness as it 
requires IL-33-IL-13 axis to develop as described in CHAPTER 4 and 6.    
IL-33 expression in the lung is profoundly augmented by influenza A infection (Le 
Goffic et al., 2011). The cells which are responsible for the up regulation of IL-33 
include epithelial cells, macrophages, and airway smooth muscle cells. IL-33 is an 
‘alarmin’ or a danger signal released when cells undergoing apoptosis or necrosis 
(Borish and Steinke, 2011). In the case of influenza virus infection, IL-33 could be 
released by the infected epithelial cells which undergo apoptosis or necrosis. 
Recently, it has been noted that there is a new comer in innate immune response, the 
natural helper (NH) cells which bear ST2 receptor and is responsive to IL-33. In 
response to IL-33, NH cells are capable of producing IL-5 and large amounts of IL-13. 
IL-33 also plays a role in the activation and proliferation of NH cells (Oboki et al., 2011). 
DEX has been reported to significantly reduce the IL-33 induced NH cell accumulation 
in the lung (Kabata et al., 2013). However, in the same study, it was reported that 
administration of IL-33 in OVA induced allergic airway inflammation in mice significantly 
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reduced the sensitivity of NH cells to DEX. Thus, the production of IL-5 and IL-13 by 
NH cells was also resistant to DEX. The important player in the induction of 
corticosteroid resistance is thymic stromal lymphopoietin (TSLP) (Kabata et al., 2013) 
which has been noted to be upregulated in asthma (Borish and Steinke, 2011).  In 
asthma, TSLP plays an important role in the Th2 differentiation (Oboki et al., 2011).  
Airway smooth muscle cells are also known to release TSLP both in vivo and in vitro 
(Redhu et al., 2011).  
To the best of my knowledge, the study of NH cells sensitivity to FP has not been 
reported. Nevertheless, NH cells insensitivity to corticosteroid in the presence of TSLP 
might contribute to the insensitivity of the increased airway hyperresponsiveness to 
either DEX or FP in this model. 
The enhancement of AHR induced by influenza infection alone without OVA 
sensitisation or challenge was also refractory to the treatment of DEX and FP.  TNF-α 
is also worth to be considered as a reason which underlie the mechanism of the AHR 
insensitivity to corticosteroid. TNF-α is one of significantly identified cytokines in allergic 
airway inflammation as an inducer of AHR (Thomas and Heywood, 2002). TNF-α is 
also found in BAL fluid during acute viral respiratory infection (Folkerts et al., 1998). IL-
33 in the airways has been up-regulated by TNF-α in a dose dependent manner. IFN-γ 
which is abundantly released in the course of viral infection, synergistically work with 
TNF-α to increase the level of IL-33. The TNF-α stimulated IL-33 was resistant to DEX 
(Prefontaine et al., 2009). 
Apart from the IL-33 - IL-13 - NH cells axis previously discussed, a physical mechanism 
might also underlie the corticosteroid insensitivity. Respiratory tract epithelial cells are 
the first target of influenza virus infection.  In addition, influenza infection leads to 
epithelial cells lysis, necrosis and apoptosis (Hashimoto et al., 2007). The epithelial 
shedding might alter the permeability and the barrier function of epithelial cells which 
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increases the access of methacholine to the smooth muscle cells and increase the 
AHR.  If the infection persists and the repair mechanism’s rate is slower than the cell 
lysis, the integrity of airway epithelial cells would be further destroyed. Corticosteroid 
has been shown to suppress the early state of epithelial cells migration and 
proliferation in the repair process (Dorscheid et al., 2006) which might contribute to the 
insensitivity of the AHR to corticosteroid treatments.  
V.4. THE EFFECTS OF CORTICOSTEROIDS ON AIRWAY PROTEIN 
EXUDATION 
Influenza virus infection when given simultaneously with OVA challenge in OVA 
sensitised mice increased the protein content recovered in BAL fluid even though not 
statistically significant. Interestingly, treatment with DEX or FP which was expected to 
reduce the protein level, in fact significantly increased the level of protein in BAL fluid 
compared to vehicle treated mice.  
Asthma associated protein leakage has been thought to originate from capillary 
leakage because of the loose intracellular gaps (McDonald, 1994). In influenza 
infection, this condition is worsened by the epithelial shedding due to viral infection 
which also alters the permeability of epithelial-capillary barrier and allows plasma 
extravasation (Bozanich et al., 2008).  
Corticosteroids are capable of reducing the increased capillary permeability and 
plasma leakage into the respiratory lumen in asthma (Nocker et al., 1999). In rat 
sensitised with OVA, DEX reduced the protein leakage (Damazo et al., 2001). In 
previous studies discussed in CHAPTER 7, DEX and FP also slightly reduced the 
enhanced protein content recovered in BAL fluid even though not statistically 
significant. However, when viral infection which given concurrently with antigen 
challenge is treated with corticosteroid, the protein originating from cell lysis, necrosis, 
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and apoptosis might becoming more accumulated as a result of viral infection and 
corticosteroid induced apoptosis.   
The proteins can also originate from the increased release of inflammatory proteins. 
The airway lining fluid is known to contain some major antimicrobial component to 
protect it from infection (Travis et al., 1999). Influenza infection activates the innate 
immune system such as collectins and defensin to restrict the spread of the virus. 
Collectins including mannose binding lectins (MBL), surfactant protein D (SP-D), and 
surfactant protein A (SP-A) which are present in the lung and play an essential role in 
inhibiting influenza virus replication (Whitsett, 2005; White et al., 2008)  
In this study, influenza infection, OVA challenge, and corticosteroid when given 
concurrently potentiated the protein content in the alveolar compartments. 
Corticosteroids have been reported to upregulate SP-D and SP-A in vivo and in vitro. 
DEX doubled total SP-A level in the rat lungs (Floros et al., 1989). The expression of 
SP-D mRNA is also upregulated by corticosteroids in vivo and in vitro (Deterding et al., 
1994). Corticosteroids also do not inhibit the expression of defensin (van Wetering et 
al., 2002).  
As previously discussed, Schleimer (2004) argued that corticosteroid spare innate 
immune responses if not enhance their expression in response to infection. This could 
also explain why the protein content in BAL fluid from mice sensitised with OVA, 
infected with influenza, challenged with OVA, and treated with corticosteroids were 
significantly higher than any other groups. 
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V.5. THE EFFECTS OF CORTICOSTEROIDS ON VIRAL TITRE 
Corticosteroid intervention in the course of acute infection has been debated as there is 
a possibility that the immunosuppressive properties of corticosteroids might facilitate 
viral replication and increase viral titre which could harm the patient. In this study, 
treatment with corticosteroids did not significantly alter the viral titre in either OVA 
sensitised/OVA challenged mice or saline sensitised/non-challenged mice. 
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VI. CONCLUSION 
The series of studies demonstrated that systemically delivered DEX was able to reduce 
the influx of inflammatory cells in the airways when influenza infection was given 
concurrently with OVA challenge in OVA sensitised mice. The numbers of eosinophil 
and lymphocyte was reduced by DEX, but not the number of macrophages and 
neutrophils. Despite being able to reduce the augmented late phase responses, DEX 
did not reduce the baseline respiratory functions 19 hours after the OVA challenge. 
Airway hyperresponsiveness was also insensitive to DEX treatment. In mice sensitised 
with saline, infected with influenza but not receiving any allergen challenge, DEX did 
not significantly alter the number of total inflammatory cell recovered in BAL fluid as 
well as the airway hyperresposiveness. 
FP on other hand significantly reduced the number of inflammatory cells influx in the 
respiratory system with all individual subset of leucocytes’ numbers also significantly 
reduced. FP also reduced the late phase responses. Furthermore, the suppression of 
late phase reaction or the low bronchoconstriction was preserved 19 hours after the 
second OVA challenge when the last Penh reading was taken. Airway 
hyperresponsiveness though, was not significantly altered by FP. The FP effects in 
saline sensitised, influenza infected, unchallenged mice were quite similar to those of 
DEX. FP did not significantly alter both leukocytes influx in the airways and airway 
hyperresponsiveness. 
The treatment of DEX and FP significantly increased the level of protein in BALF but 
did not significantly change viral titre in the lungs. Therefore, taken together, the 
findings suggest that some features of asthma portrayed in this virus associated 
exacerbation model of airway allergic inflammation such as the airway 
hyperresponsiveness are selectively resistant to corticosteroid treatment. 
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I. THESIS AIMS 
Asthma is a major health problem affecting almost 300 million people worldwide. It is 
characterised by airway inflammation with inflammatory cells particularly eosinophils, T 
lymphocytes, and mast cells largely present in the airway and involved in the process 
of inflammation (Barnes, 1996; Tattersfield et al., 2002).  
Airway hyperresponsiveness or exaggerating airway response to stimuli that would not 
cause any response to people without asthma is also one of the important asthma 
features (Grootendorst and Rabe, 2004). In addition, airway remodelling which is 
defined as airway structural change due to sub-epithelial fibrosis, goblet cell 
hyperplasia, angiogenesis, and smooth muscle thickening is also observed in chronic 
asthma (Fish and Peters, 1999; Bousquet et al., 2000).  
In allergic asthma, the most common type of asthma, which affect two third of the 
asthmatic population (Temelkovski et al., 1998) the progression of the disease is 
started when the person is sensitised with allergen. Dendritic cells detect the allergen 
which is presented to T and B lymphocytes in the lymph nodes. This process initiates 
the production of allergen specific IgE by B cells. The allergen specific IgE would then 
bind to the high affinity receptor (FCεRI) on the surface of mast cells. Future allergen 
exposure will cause a cross linking with this IgE- FCεRI on the surface of mast cells 
and lead to mast cells degranulation with subsequent release of inflammatory 
mediators. The release of the mediators results in early asthmatic responses (EAR) 
with features including bronchoconstriction which starts immediately after allergen 
challenge. Some asthmatics are dual responders which mean they also experience late 
asthmatic responses (LAR) after the EAR which commonly resolves in 24 hours 
(Picado, 1992). This cascade is thought to contribute to the influx of inflammatory 
leukocytes, development of airway hyperresponsiveness, and further airway 
remodelling.  
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Asthma is generally present as a chronic inflammation with periodic exacerbation at 
some points of the stable disease. Virus infection is the most common cause of acute 
asthma exacerbations. Rhinovirus, respiratory syncytial virus, and parainfluenza virus 
are the most frequently identified virus in the case of virus associated asthma 
exacerbation. Influenza is also a significant cause of asthma exacerbation particularly 
during the H1N1 2009 pandemic (Jain et al., 2009). 
With regard to treatment, corticosteroid based therapy remains the most effective 
treatment for asthma at the moment. However, the use of corticosteroid in virus 
associated asthma exacerbation is still controversial. In theory, corticosteroid should be 
able to effectively reduce the inflammation due to viral infection, but some evidence 
shows that the administration of corticosteroid alone is only partially effective in virus 
associated asthma exacerbation (Tattersfield et al., 1999; FitzGerald et al., 2004; 
Harrison et al., 2004). 
This thesis sought to establish the role of acute viral infection when combined with 
allergen exposure in allergen-sensitised host. The thesis also determined if there is any 
alteration of corticosteroid effectiveness in the exacerbations or worsening of allergic 
airway inflammation associated with viral respiratory infection. The study was carried 
out using a mouse ovalbumin (OVA) model of allergic airway inflammation. The murine 
ovalbumin model was subsequently developed by combining allergen (OVA) and virus 
infection to further evaluate the interaction between the two. The developed models 
were then used to study the role of either systemically delivered (dexamethasone/DEX) 
or topically delivered (fluticasone propionate/FP) corticosteroid. 
The endpoints evaluated and assessed were inflammatory cells influx, early and late 
phase asthmatic responses (EAR and LAR), airway hyperresponsiveness (AHR), 
bronchoalveolar lavage protein content, viral titre in the lungs, and histopahological 
features. 
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Most asthma studies using murine models do not include the important endpoints such 
as EAR and LAR as part of their assessments. AHR is probably the most measured 
physiological function by investigators in murine models of allergic inflammation 
studies. However, measuring AHR only would not completely portray what really 
happens in the clinic, whereas the animal model should be developed as closely as 
possible to resemble the disease (in human). The physiological endpoints such as EAR 
and LAR are more important to be a part of assessments when studying the efficacy of 
a treatment or the role of viral infection in the murine model of allergic inflammation to 
get a more complete reflection of the clinical implications resulting from the 
interventions. 
II. OUTCOMES 
II.1. IN VITRO ANTIVIRAL STUDIES 
The series of studies was started with in vitro assays to assess whether corticosteroids 
(budesonide, dexamethasone, fluticasone propionate, and prednisolone) that would be 
used in the studies had any inhibitory effects on the viral targets (parainfluenza virus 
type 3 and influenza A /H1N1/PR8). A cell based system using the viral plaque 
reduction assay and RT-PCR assay was used to assess the antiviral activity of 
corticosteroids against parainfluenza virus type 3. Ribavirin was used as a positive 
control. DEX had an inhibitory effect against the virus, but not the other corticosteroids. 
Gao et al’s study (2000) showed that HPIV3 infection upregulate the ICAM-1 
expression in epithelial cells which has been thought to facilitate viral entry into the cell 
target (Gao et al., 2000). Studies to evaluate the effect of corticosteroids on ICAM-1 
expression were carried out but the inhibitory effect of corticosteroids on HPIV3 
infection had no correlation with the level of ICAM-1 expression. For this reason, DEX 
might not inhibit HPIV3 replication via ICAM-1 pathway. 
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The antiviral activity of corticosteroids against influenza infection was examined using a 
cell based plaque reduction assay with zanamivir as a positive control. Again, DEX was 
the only corticosteroid to have the inhibitory effect against virus infection among all 
corticosteroids tested. 
The antiviral effects might be mediated by the NF-kB pathways, as corticosteroids 
reduce or inhibit the NF-kB activity (Barnes and Adcock, 2003) and some influenza 
virus is known to upregulate the NF-kB (Flory et al., 2000; Hiscott et al., 2006; Kumar 
et al., 2008)  for its own benefits. However, reducing the NF-kB activity is not the only 
mechanism that might underlie the antiviral properties of DEX as other corticosteroids 
tested too are known to inhibit NF-kB pathway. Solubility in media might also influence 
the higher antiviral activity of the DEX compared to other corticosteroids tested as DEX 
is the only water soluble corticosteroid among others which are quite liphophilic.   
 
II.2. IN VIVO INFECTION STUDIES 
Respiratory viral infection is the major culprit to cause asthma exacerbations. The 
following studies to be conducted after in vitro assay were in vivo screening of 
respiratory infective agents. The first candidate was human parainfluenza virus type 3. 
HPIV3 has been proven to cause a profound allergic airway inflammation exacerbation 
in guinea pigs in our laboratory (Ford et al., 2013). However, despite being given in 
either anaesthetised or un-anaesthetised mice, HPIV3 did not seem to infect mice as 
there was no virus detected in the lungs of HPIV3 infected mice when the lung samples 
were analysed with either cell plaque assay or RT-PCR. 
The unsuccessful infection by HPIV3 in mice led to the screening of another candidate 
which is poly (I:C), a synthetic dsRNA and TLR3 ligand. The study was successful, a 
high dose (100µg/50µl) of poly (I:C) instillation in mice was able to induce lung 
inflammation with neutrophilia accompanied by significant AHR.  
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Considering that poly (I:C) is a synthetic agent which therefore will not activate the 
murine immune system as complete as the real virus would, the screening for a 
respiratory infective agent was continued and led to the pilot in vivo infection of mouse 
adapted influenza A/H1N1/PR8. The influenza virus infected the mice effectively in 10 
pfu/mouse dose. The infection successfully caused cellular airway inflammation with 
neutrophilia, lymphopenia, and marked airway hyperresponsiveness. The dose given 
was relatively mild in order to more reflect the common influenza virus infection and not 
severe pneumonia.  
The influenza A /H1N1/PR8 is known to induce marked lung cell inflammation and AHR 
(Brown et al., 2004).  The development of AHR in influenza infection is thought to 
involve the IL-33 – NH cells - IL-13 axis (Oboki et al., 2011). IL-33 level in the lung is 
significantly increased during influenza infection (Le Goffic et al., 2011). The source of 
IL-33 upregulation which peaked on day 5 post infection is largely originated from 
macrophages but could be from infected epithelial cells. The IL-33 subsequently 
induces NH cells to produce IL-13 which play an important role in AHR (Oboki et al., 
2011). A defect of M2 receptors is also known to contribute to the increase of AHR in 
influenza infection (Folkerts et al., 1998).  
This influenza A virus was chosen to be used in subsequent study to evaluate the 
interaction between viral infection and allergen challenge in murine ovalbumin model of 
allergic airway inflammation.  Four days after infection was chosen as the time point for 
OVA challenge, and five days after infection as the analysis day.  
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II.3. STUDIES OF THE INTERACTION BETWEEN INFLUENZA VIRUS 
INFECTION AND ALLERGEN CHALLENGE IN MURINE MODEL OF 
OVALBUMIN INDUCED ALLERGIC AIRWAY INFLAMMATION 
The ovalbumin model of allergic airway inflammation was established by sensitising the 
mice twice intraperitoneally with OVA and giving them the OVA challenge twice 4 hours 
apart. The murine model showed the important hallmarks of asthma including 
eosinophilic airway inflammation, biphasic broncoconstrictions responses (LAR and 
EAR), and airway hyperresponsiveness (Fernandez-Rodriguez et al., 2008).  
The intervention of influenza infection was introduced in the developed OVA murine  
model 4 days before the OVA challenge. The last procedure and analysis were 
conducted on day 5 after influenza infection. This is coinciding with the maximum 
inflammatory responses to influenza alone in the previous studies. Therefore, in the 
chosen time points, it was expected that the dynamic inflammatory responses would be 
best reflected in the model. 
Allergen challenge in the acute course of influenza infection in OVA sensitised mice 
exaggerated the inflammatory response demonstrated by a significant increase of 
inflammatory cells influx in the airways, the profoundly augmented and prolonged the 
LAR bronchoconstriction, and significant increase in the airway hyperresponsiveness 
compared to the negative control group which were sham (allantoic fluid) instilled mice.  
In contrast to OVA sensitised and OVA challenged mice; OVA sensitised, influenza 
infected, and saline challenged mice did not develop airway eosinophilia which 
indicates that OVA challenge is more important than influenza infection to induce 
eosinophilia. OVA sensitised, influenza infected, and saline challenged group also had 
significant increase in AHR which was largely due to influenza infection. 
The results are in agreement with Marsland et al (2004) studies, where influenza 
infection was given concomitantly with OVA challenge in OVA sensitised mice, the 
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maximum eosinophilic response was observed when the OVA challenge was given on 
day 4 after influenza infection. They also observed a significant increase of AHR due to 
viral infection. Marsland et al (2004) conclude that the increasing number of allergen 
carrying dendritic cells in the lung draining lymph nodes and the migration of allergen 
specific T lymphocytes underlie the exaggerated immune responses (Marsland et al., 
2004).   
Kabata et al. (2013) who studied the addition of IL-33 in the OVA murine model of 
allergic airway inflammation also found a marked increase in AHR and airway 
eosinophilia compared to the group of mice which only being given IL-33 (Kabata et al., 
2013). This might explain the exaggerated inflammation demonstrated in the present 
model. 
II.4. STUDIES ON CORTICOSTEROIDS 
A good animal model of asthma has to best reflect the features of human asthma. The 
animal model has also to be sensitive to the mainstay treatment of human asthma, 
corticosteroid. Dexamethasone (DEX) which is commonly systemically delivered and 
fluticasone propionate (FP) which is topically (inhaled) delivered in human asthma were 
used to examine the corticosteroid sensitivity of developed murine model of OVA 
induced allergic airway inflammation. 
Corticosteroids are well documented to effectively reduce the airway cellular 
inflammation, particularly eosinophilic inflammation in human and animals (Birrell et al., 
2003). T lymphocytes play an important role in the airway eosinophilic inflammation by 
releasing Th2 cytokines including IL-4, IL-5, and IL-13 and some chemokines 
(Giembycz and Lindsay, 1999). The presence of eosinophil and the Th2 cytokines lead 
to the development of late asthmatic responses (LAR) and airway 
hyperresponsiveness (AHR). Corticosteroid acts to reduce the upregulation of the Th2 
cytokines and chemokines, as well as induce eosinophil apoptosis, and increase the 
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clearance of eosinophil into the airway lumen (Belvisi, 2004) which in turn also reduces 
the LAR and AHR. 
The therapeutic benefit of corticosteroids in virus-associated exacerbation of asthma 
remains controversial. Furthermore there is some evidence showing the lack of efficacy 
of corticosteroid in exacerbations (Tattersfield et al., 1999; FitzGerald et al., 2004; 
Harrison et al., 2004). 
This thesis aimed to investigate the role of corticosteroid in the developed model of 
virus associated asthma exacerbation model; whether there is an alteration of 
corticosteroid efficacy/sensitivity when influenza infection was introduced in allergic 
airway inflammation. 
 
II.4.1. DEXAMETHASONE  
The model was confirmed to be sensitive to DEX which attenuated airway cellular 
inflammation, reduced eosinophilic inflammation, abrogated late phase 
bronchoconstriction, and reduced airway hyperresponsiveness in a dose dependent 
manner. The experiments confirmed the effective dose of DEX which attenuated the 
airway allergic inflammatory responses i.e. 6 mg/kg DEX. 
The augmentation of cellular airway inflammation when inf luenza infection was 
combined with OVA (sensitisation and challenge) was sensitive to DEX. In both non 
infected and infected OVA allergic airway inflammation models, DEX effectively 
reduced the numbers of eosinophil and lymphocytes. Even though when influenza virus 
was given superimposed on the OVA induced lung inflammation model, the 
macrophages and neutrophils numbers which in the non-infected OVA model were 
sensitive to DEX (fig 7.5), becoming resistant (fig 8.5).  
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DEX treatment in mice with influenza infection alone did not affect the increasing 
number of inflammatory cells influx due to influenza infection. The number of 
macrophages, neutrophils, and lymphocytes were also unchanged by DEX.  
The late phase bronchoconstriction in both uninfected and influenza infected OVA 
models was also responsive to DEX. In the OVA only group, DEX returned the airway 
functions to baseline 19 hours after the second OVA challenge (24 hours after the first 
OVA challenge). When influenza was given concurrently with OVA though, DEX was 
failed to restore the airway function to a baseline level (fig 8.3).  
There was an obvious change of DEX sensitivity in the increase of airway 
hyperresponsiveness when influenza was superimposed in the OVA model. Airway 
hyperresponsiveness in all influenza infected groups were refractory to DEX, 
contrasting with the effectiveness of DEX in reducing the airway hyperresponsiveness 
in OVA only groups. 
 
II.4.2. FLUTICASONE PROPIONATE  
The OVA induced allergic lung inflammation was also sensitive to inhaled FP in a dose 
related manner. The higher dose of FP (0.5 mg/ml) reduced the inflammation features 
of asthma reflected in the OVA model of mice and was therefore chosen to be 
subsequently evaluated in the combined influenza and OVA model.  
In both OVA allergic lung inflammation groups with and without influenza infection, FP 
effectively reduced total inflammatory cells recovered in BALF. Regarding the individual 
subsets of leukocyte numbers, different from DEX, all individual cell type i.e. 
macrophages, eosinophils, lymphocytes, and neutrophils were sensitive to the 
treatment of FP in both virus infected and non infected OVA groups.   
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FP similar to DEX did not change the airway cells inflammation when the mice were 
given influenza infection alone. The number of lymphocytes though was sensitive to 
FP. 
The effectiveness of FP in attenuating the late phase bronchoconstriction was also 
unchanged by influenza infection. On either virus infected or uninfected OVA sensitised 
and OVA challenged animals, FP significantly reduced the late phase 
bronchoconstrictions, and the respiratory baseline functions at 19 hours after the 
second OVA challenge (fig 8.13). 
Influenza infection however changed the efficacy of FP in reducing the airway 
hyperresponsiveness when influenza infection was given simultaneously with OVA 
challenge.  FP reduced the increased airway hyperresponsiveness in OVA induced 
allergic airway inflammation but the airway hyperresponsiveness became refractory to 
FP when influenza infection was given to the animals. 
DEX and FP did not change the increase in protein content in BAL fluid in OVA only 
group, but significantly increased the level of protein in BALF in mice infected with 
influenza and challenged with OVA.  The corticosteroids also did not significantly 
change the virus titre in the lungs.  
The measurement of Th1 and Th2 cytokines and chemokines could possibly help 
explain the alteration in corticosteroid efficacy even further. However, some 
suggestions can be proposed. Firstly, corticosteroids while effective by suppressing the 
adaptive immune response seem to spare or enhace the innate immune response to 
the viral infection (Schleimer, 2004). In the case of influenza infection, macrophages 
and and neutrophils are effector cells of the innate immune response which are 
responsible for viral elimination (Watanabe et al., 2005) hence both types of leukocytes 
are significantly upregulated in the influenza infection groups. Corticosteroid increases 
the activation of both macrophages and neutrophils, induce the survival of neutrophils 
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but increase the apoptosis of dendritic cells (Schleimer, 2004). The induction of 
dendritic cells apoptosis by corticosteroid might counteract the increasing activity and 
number of dendritic cells when influenza infection is given concurrently in with OVA 
challenge in OVA sensitised mice (Marsland et al., 2004) and further contribute to the 
reduction of exaggerated inflammatory cells accumulation in the airways, including 
reducing the number of lymphocytes and eosinophils which regulated by the cytokines 
released from the activated lymphocytes. The number of macrophages and neutrophils 
though are preserved in the course of corticosteroid treatment. 
Both DEX and FP have a quite similar pattern in altering the proportion of leucocytes 
subtype recruitments into the airway in the influenza combined with OVA groups i.e. 
the portion of macrophages was significantly increased; the percentage of eosinophils 
was decreased; and the neutrophils portion was unchanged from the uninfected OVA 
allergic lung inflammation groups. The difference in DEX and FP’s potencies to 
downregulate chemoattractants and adhesion molecules which are responsible for the 
accumulation of the inflammatory cells in the airways could be suggested to underlie 
their distinct effect in reducing total and individual inflammatory cells when influenza 
infection was given to the OVA model. FP seems to be more potent than DEX in 
inhibiting the chemokines and adhesion molecules. 
The corticosteroid resistant accumulating macrophages and neutrophils might be 
involved in the development of persistent airway bronchoconstriction as they are 
capable of releasing the inflammatory mediators involve in bronchoconstrictions 
(Folkerts et al., 1998; Liu et al., 1999) which might explain why unlike FP, DEX failed to 
significantly reduce the respiratory function 19 hours after OVA challenge.  
The second proposed mechanism is based on IL-33 – NH cells – IL-13 axis. In the 
presence of TSLP (thymic stromal lymphopoietin), which upregulated in asthma, NH 
cells which release IL-5 and large proportion of IL-13 in response to IL-33 (which 
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increased upon influenza infection) are refractory to corticosteroid. The release of IL-13 
which is uninhibited by corticosteroid contributes to the refractory airway 
hyperresponsiveness (Kabata et al., 2013).  
The third proposed mechanism is the increase of nervous sensitivity to methacholine 
due to epithelial shedding.  The loss of barrier function of the shed epithelium leads to 
the increasing exposure of smooth muscle cells and nervous system to methacholine 
chloride provocation causing an elevation in airway hyperresponsiveness. 
III. EXPERIMENTAL LIMITATIONS 
The mouse model of asthma is not the most reliable animal model to predict human 
asthma (Zosky and Sly, 2007). Mouse furthermore does not spontaneously develop 
asthma. So it has to be induced, generally by sensitisation with allergen and 
subsequent challenge with the same allergen to obtain the allergic response. The use 
of ovalbumin (OVA) as specific protein antigen to induce asthma in mice has also been 
criticised to have a lack of relationship with common allergen causing human asthma, 
such as house dust mites. 
Nevertheless the OVA model of asthma is still popular for modelling allergic response 
as BALB/c mice genetically have a Th2 biased immune response. The OVA model 
displays most essential features of human asthma such as upregulation of OVA 
specific IgE expression, eosinophilic airway inflammation, EAR and LAR, and AHR as 
well as being sensitive to the basic therapies of asthma (Stevenson and Birrell, 2011).  
The acute OVA model used in these studies might also raise another caveat of the 
thesis.  Asthma is a chronic disease which is characterised by airway remodelling. The 
current acute OVA model lacks this chronic feature. Nonetheless, this model does 
resemble most of the essential acute allergic airway inflammatory features in asthma.   
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The term exacerbation in this current study of a murine model of allergic airway 
inflammation might also raise a concern as the virus infection was given in sensitised 
mice before antigen challenge hence the infection is administered before the allergic 
response. However, the term exacerbation in this model is defined as the exaggerated 
airway allergic inflammatory responses and the worsening of respiratory functions as 
seen in the exacerbation of asthma in atopic individuals (Busse and Lemanske Jr., 
2007). As in any other animal model the mouse asthma or asthma exacerbation model 
does not fully replicate human asthma. Several models and design of studies using 
different species of animals have been applied to model human asthma which 
demonstrated that there is no generally validated model of human asthma 
(INTRODUCTION to CHAPTER 5). Nonetheless, the model of virus-associated 
exacerbation of allergic airway inflammation developed in this thesis demonstrated 
characteristics of human asthma exacerbation i.e worsening symptoms of human 
asthma. These includes exaggerated cellular inflammation with neutrophilia, significant 
peribronchial inflammation as shown in histopathological analysis, worsening of 
respiratory functions, significant increase in airway hyperresponsiveness, and plasma 
leakage in broncho-alveolar lavage fluid (CHAPTER 6). The aggravated airway 
inflammation and respiratory functions were significantly worse compared to those in 
animals without respiratory viral infection which is also seen in human asthma 
(Message et al., 2008). 
Airway function was determined using non invasive whole-body unrestrained 
plethysmography. Penh (enhanced pause) is a dimensionless index based on airflow 
patterns of expiration and inspiration as the animal breathes which changes the box 
signal. The bronchoconstriction will also alter the enhanced pause. Penh has been 
criticised to have a limited physiological outcome and does not actually determine 
airway mechanics/resistance (Lunblad et al., 2002). However, Lomask (2006) has 
argued and showed that Penh has the effect of resistance in flow whole-body 
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plethysmoghraphy waveform from which Penh is mathematically derived (Lomask, 
2006). Furthermore, Hamelmann et al. (1997) have experimentally proven that Penh in 
methacholine dose response curve measurements observed in BALB/c OVA allergic 
airway inflammation model is correlated to airway resistance (Hamelmann et al., 1997).  
Whole-body plethysmography also offers some advantage over the more invasive 
methods as the airway function observation can be repeated and conducted overtime 
allowing the long period measurement such as the assessment of EAR/LAR and the 
evaluation of methacholine provoked airway responsiveness before and after 
treatment.  
The findings in these current studies might not be applicable to be generalised to other 
respiratory infection. The difference in the nature of inflammation of respiratory synctial 
virus (RSV) and influenza A infection superimposed on house dust mite (HDM) model 
has been noted in a recent study. The same study also revealed that the sensitivity of 
corticosteroid (Prednisolone) was also different between the RSV/HDM and 
influenza/HDM. Influenza/HDM features was more sensitive to prednisolone than 
RSV/HDM (Mori et al., 2013).  
Nevertheless an animal model of asthma is only a tool to effectively investigate the 
pathophysiological mechanism of the disease and needs a very judicious approach to 
extrapolate to human asthma as it only portrays a snapshot of a very complex and 
heterogeneous nature of the disease. 
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IV. FUTURE WORKS 
There are several studies that can be addressed in the future to complete the current 
work in the thesis. Firstly, the investigation of several key cytokines (IL-4, IL-5, IL-9, IL-
13, IL-33, IFN-γ, TNF-α, and TSLP) and chemokines (IL-8, or KC in mouse) and 
inflammatory mediators produced by inflammatory cells would be useful to further 
characterise the number of mechanism/pathways involved in the alteration of 
corticosteroid efficacy when influenza infection is given superimposed on the OVA 
induced allergic lung inflammation. The study of NH cells sensitivity to corticosteroid in 
the current model using fluorescence-activated cell sorting (FACS) would also be 
interesting to be conducted.  
Second proposed further works is to develop a chronic murine OVA allergic lung 
inflammation model to study the interaction between influenza infection and repeated 
allergen challenge. The model can then be used to study the role of corticosteroid 
which will be more closely resembles the human asthma. 
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V. GENERAL CONCLUSION  
In this series of experiments, a murine model of allergic airway inflammation 
exacerbation using respiratory virus infection has been developed. Influenza infection 
acted additively with OVA challenge in OVA-sensitised mice resulting in profoundly 
augmented inflammatory cell influx in the airways, late phase bronchocnstriction, and 
airway hyperresponsiveness. Mouse-adapted influenza A/H1N1/PR8 acutely induced 
airway inflammation with profound AHR. The low dose infection (10 pfu/mice) was able 
to provoke sufficient inflammation without pneumonia which was suitable to be 
incorporated with the established OVA induced allergic airway inflammation in mice.  
The effectiveness of corticosteroids (DEX or FP) in these models has also been 
established.  The OVA lung allergic inflammation model reflected most of the essential 
features of human asthma including airway cellular inflammation with eosinophilia, 
early and late phase bronchoconstrictions, and airway hyperresponsiveness which all 
were sensitive to corticosteroid treatment except the early phase bronchoconstriction. 
Unlike the OVA only model, the influenza-OVA model was only partially responsive to 
corticosteroid treatment which suggests there are some components in the model 
which are refractory or not regulated by corticosteroid.  
These models offer a way to understand the immunopathological mechanisms 
underlying the alteration of corticosteroid effectiveness in viral-associated asthma 
exacerbation in man and also will meet the need in the process of novel drug 
discovery, development and evaluation. This animal model of viral-associated 
exacerbation of allergic airway inflammation and evaluation of the roles of 
corticosteroid sensitivity in this model will provide invaluable insight to address 
unresolved questions regarding the interplay of respiratory virus infections, allergen, 
asthma, and corticosteroids.  
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APPENDIX 1 
1. EQUIPMENT 
Amicon Ultracel® 100K tube – Merck Millipore, USA 
Blotting cassettes – Fisher Scientific, UK 
Cannula - Bio-Med healthcare, India 
Capillary tube - Roche, Switzerland 
Cell culture flasks - Fisher Scientific UK, Loughborough, UK. 
Centrifuge (Mistral 3000) - Mistral, UK. 
Cold Plate - Fisher Scientific UK, Loughborough, UK. 
CO2 Incubator – Hera Cells, Thermo Scientific, UK 
Coverslip - Fisher Scientific UK, Loughborough, UK. 
Digital Camera (Leica DC500) - Leica Microsystems, Germany 
Egg Incubator – Maino, Italy 
Exposure Chamber - Buxco Research Systems, Winchester, UK. 
Glass Slides - Surgipath Europe Ltd, Peterborough, UK. 
Histology Cassettes - Surgipath Europe Ltd, Peterborough, UK. 
Microscope (Olympia BH-2) - Olympus, London, UK. 
Microscope (Leica DMRAZ) - Leica Microsystems, Germany 
Microtome - Mistral, UK. 
Mouse Isolator – Harlan, UK 
Neubauer Haemocytometer - Superior, Marienfeld, Germany. 
Nuclease free tubes - Invitrogen, USA 
Polysine slides - Thermo Scientific, UK 
Cyclegene thermo cycler - Technene, Staffordshire, UK 
Thermo light cycler - Roche, Switzerland 
Tissue homogeniser - Precellys, UK 
Tissue homogeniser tubes - Precellys, UK 
Wax Dispenser - Fisher Scientific UK, Loughborough, UK. 
Well plate (6, 24, 96) - Fisher Scientific UK, Loughborough, UK. 
Western Blot system – GE Healthcare Lifesciences 
Whole Body Plethysmograph (complete set up) - Buxco Research Systems, 
Winchester, UK. 
Wright Nebuliser (Pulmostar) - Sunrise Medical Ltd., Wollaston, UK. 
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2. MATERIALS 
Acetic acid - Sigma, Poole, UK. 
Acrylamide - Sigma, Poole, UK. 
ACTB antibody – Abcam, UK 
Aluminium hydroxide - Sigma, Poole, UK. 
Antimouse IgG HRP antibody – Vector Laboratories, USA  
Antirabbit IgG HRP antibody– Vector Laboratories, USA 
Aprotinin - Sigma, Poole, UK. 
Aqueous acetic acid - Sigma, Poole, UK. 
Avicel – FMC Biopolymer, USA 
Avidin-Biotin-Peroxidase Complex – Vector Laboratories, USA 
BCA protein assay Kit - Pierce protein biology, Thermo Scientific, UK 
Beta-Mercaptoethanol – Invitrogen, USA 
Bovine Serum Albumins - Sigma, Poole, UK  
Bromophenol blue - Sigma, Poole UK 
BSC-1 cells - European collection animal cell culture (ECACC) 
Budesonide – Sigma, Poole UK 
cDNA primers - Primer design Ltd 
Chloroform - Sigma, Poole, UK. 
Chloral hydrate - Fisher Scientific UK, Loughborough, UK. 
Cloning supplement – Invitrogen, USA 
Crystal Violet - Sigma, Poole, UK. 
Dexamethasone 21-phosphate salt - Sigma, Poole, UK. 
Dimethyl sulfoxide - Sigma, Poole, UK. 
DMEM - Invitrogen, USA 
DPBS – Sigma, Gibco, UK 
ECL developing media – Amersham, UK 
EGTA disodium salt - Sigma, Poole, UK. 
Embryonated chicken egg (Dekalb white) – Henry Stewart Co., UK 
Eosin - Surgipath Europe Ltd, Peterborough, UK. 
Ethanol - Sigma, Poole, UK. 
Fluticasone propionate - Sigma, Poole, UK. 
Foetal bovine serum - Sigma, Poole, UK. 
Formaldehyde - Fisher Scientific UK, Loughborough, UK. 
GAPDH primary antibody – Abcam, UK  
Glutamine - Sigma, Poole, UK. 
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Haematoxylin - Fisher scientific, UK 
Histoclear - Fisher scientific, UK 
Histomount - Fisher scientific, UK 
Human Parainfluenza Virus Type 3 - National Collection of Pathogenic Viruses, UK 
Hydrochloric acid - Sigma, Poole, UK. 
Hybridoma cells - Given by Dr. Awen Gallimore and Dr. Sarah Lauder (Cardiff 
University) 
Hyperfilm – Amersham Biosciences, UK 
IL-6 – Peprotech, UK 
IMDM – Invitrogen, USA 
Influenza A (H1N1/PR8) - Given by Dr. Awen Gallimore and Dr. Sarah Lauder (Cardiff 
University) 
Insulin transferrine selenium – Invitrogen, USA 
Leishman’s Powder - Sigma, Poole, UK. 
Leupeptin - Sigma, Poole, UK. 
Light cycler TaqMan master kit (contains master mix) - Roche, Switzerland 
MAb Trap Kit™ - GE Healthcare Lifesciences, USA 
Magnesium sulphate - Fisher Scientific UK, Loughborough, UK. 
Mayer’s haematoxylin - Surgipath Europe Ltd, Peterborough, UK. 
MDCK cells – Given by Dr. Awen Gallimore and Dr. Sarah Lauder (Cardiff University)  
Methacholine Chloride - Sigma, Poole, UK. 
Methanol - Fisher Scientific UK, Loughborough, UK. 
Mice (BALB/c) - Harlan, UK  
Milk (Powdered, non-fat) – Shop bought. 
Monoclonal Mouse HPIV3 antibody – AbD Serotec, UK 
Monkey ICAM-1 monoclonal antibody – Abcam, UK 
MTS cell proliferation assay reagent – Promega, UK 
Nitrocellulose membrane – Amersham Biosciences, UK 
Non-essential amino acids - Sigma, Poole, UK. 
Ovalbumin - VWR International Ltd., Leicestershire, UK. 
Paraffin wax - Surgipath Europe Ltd, Peterborough, UK. 
Penicillin/streptomycin – Invitrogen, USA 
Peptone primatone – Sigma, Poole UK 
Periodic acid - Surgipath Europe Ltd, Peterborough, UK. 
PMSF - Sigma, Poole, UK. 
Phenylarsine oxide - Sigma, Poole, UK. 
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Picric acid - Sigma, Poole, UK. 
Poly (I:C) – Invitrogen, USA 
Potassium alum - Fisher Scientific UK, Loughborough, UK.  
Prednisolone – Sigma, Poole UK 
Ribavirin – Sigma, Poole UK 
Saline tablets - Fisher Scientific UK, Loughborough, UK. 
Sodium bicarbonate - Fisher Scientific UK, Loughborough, UK. 
Sodium chloride - Sigma, Poole, UK. 
Sodium dodecyl sulfate- Sigma, Poole, UK. 
Sodium Fluoride - Sigma, Poole, UK. 
Sodium iodate - Fisher Scientific UK, Loughborough, UK. 
Sodium molybdate - Sigma, Poole, UK. 
Sodium pentobarbitone (Euthatal) - Cardiff University, UK 
NaVO4 - Sigma, Poole, UK. 
Sulphuric acid - Sigma, Poole, UK. 
Superscript first-strand synthesis system kit - Invitrogen, USA 
TEMED (N,N,N′,N′-Tetramethylethylenediamine) - Sigma, Poole, UK 
Triton X - Sigma, Poole, UK. 
Trizma base - Sigma, Poole, UK. 
Trypsin-EDTA – Invitrogen USA 
Tween 20 - Sigma, Poole, UK. 
Viral ribonucleic acid isolation kit - Roche, Switzerland 
Contains: Proteinase K - (reconstituted in 5ml Elution buffer) 
Poly A - (reconstituted in 500μl Elution buffer)  
Binding buffer - premade 
Inhibitor removal buffer - (reconstituted in 20ml ethanol) 
Wash buffer - (reconstituted in 40ml ethanol) 
Elution buffer - (Nuclease-free, sterile, double distilled water). 
Zanamivir – Given by GSK, Stevenage UK 
 
3. COMPUTER PROGRAMS 
Data acquisition - Fine point software, Buxco 
GraphPad Prism 5 - GraphPad software, Inc., La Jolla, CA, USA. 
ImageJ - National Institute of Health - http://rsbweb.nih.gov/ij/index.html 
Leica QWin software - Leica Microsystems, Germany 
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APPENDIX 2 
 
Figure A. displays a typical waveform of a flow whole body plethysmography. The 
index assessed is Penh (enhanced pause) which correlate to the airway resistance. In 
a single breath in the case of bronchoconstriction (following administration of 
bronchoconstritor) the slowing of late expiration correlates to Penh. PIP is peak 
inspiratory pressure, while PEP is peak expiratory pressure. Ti defined as the 
inspiratory time from the start to the end of inspiration, Te is expiration time from the 
end of inspiration to the end of expiration, and Tr is an early relaxation phase of 
expiration when pressure decays to 36% from the total expiratory pressure signal 
(Lomask, 2006). Therefore Pause is  
Pause = (Te-Tr)/Tr 
And Penh is calculated as follow 
Penh (Enhanced pause) = (PEP/PIP) x Pause 
 
 
 
Figure A: A diagram with some parameters which Penh is derived (Hamelmann et al., 1997).  
